var title_f27_33_28176="Circulating hot water ablation 2";
var content_f27_33_28176=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circulating hot water endometrial ablation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 419px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The closed loop system ablates the lining of the endometrium under hysteroscopic visualization by recirculating heated saline within the uterus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Brooks, PG. Hydro ThermAblator (HTA) System: Global treatment, direct visualization. OBG Management 2005. Copyright &copy; 2005 Dowden Health Media.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_33_28176=[""].join("\n");
var outline_f27_33_28176=null;
var title_f27_33_28177="LV Doppler flow patterns";
var content_f27_33_28177=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal left ventricular Doppler flow patterns",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With the Doppler beam directed from apex to base, a variety of Doppler flow velocity patterns within the left ventricle (LV) can be obtained. The position of the sample volume for recording each of these patterns is shown in the diagram of an apical \"five-chamber\" view. Pattern #1 is flow within the left ventricular (or mitral valve) inflow tract (LVIT) as recorded from the tip of the mitral valve on its left ventricular side. The M-shaped inflow pattern is nearly identical to the M-mode image of mitral leaflet motion. The initial velocity peak represents the highest velocity achieved during the passive or rapid filling (RF) phase; the lower peak velocity represents the atrial (A) inflow phase. Although there is similarity in the appearance between the mitral M-mode motion and Doppler flow signals, there is very little predictive value of one for the other. Pattern #3 is flow within the left ventricular outflow tract (LVOT), representing systolic flow leaving the LV; this systolic signal demonstrates flow away from the transducer or away from the apex. Pattern #2 (LVIT/LVOT) is a hybrid mixture of #1 and #3 and gives inaccurate information about either. It is important to sample the Doppler flow signal axial to its flow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_33_28177=[""].join("\n");
var outline_f27_33_28177=null;
var title_f27_33_28178="Illustrative cases of intensive insulin therapy in special situations";
var content_f27_33_28178=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Illustrative cases of intensive insulin therapy in special situations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/33/28178/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28178/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/33/28178/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28178/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/33/28178/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28178/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/33/28178/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic patients who are motivated and well educated can often keep their blood glucose concentrations in the normal or near-normal range on routine days. They may, however, need advice for more unusual events. Although it is not possible to cover all eventualities, some general guidelines can be given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EATING OUT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance of strict glycemic control with intensive insulin therapy requires relative constancy in the quantity and timing of carbohydrate intake. These may be difficult to anticipate when going to a restaurant or eating at a friend's house. It is helpful to keep a carbohydrate supply on hand, to check blood glucose frequently, and to learn to estimate (visually or by asking the chef) the carbohydrate content in the meal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Case 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 41-year-old man, whose diabetes is usually very well controlled, takes 8 units of regular and 18 units of NPH before breakfast, 4 units of regular before lunch, 8 units of regular before his evening meal, and 10 units of NPH before bedtime. One evening, after a busy day at work, he is invited to dinner with friends. Dinner will not be served until about 8:30 PM, although he usually eats his evening meal at about 5:45 PM. His blood glucose values for that day were 106",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    before breakfast, 112",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    before lunch, and 68",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    at 5:30 PM.",
"   </p>",
"   <p>",
"    Because of the relatively low blood glucose values, he eats a snack, ingesting the same amount of food as his usual bedtime snack (30 g). At 8:15 PM, after arriving at the party, his blood glucose is 137",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.6",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    This seems to be a reasonable value and he decides to take his usual pre-evening meal dose of insulin (8 units of regular). When he gets home at 11 PM, having eaten more than usual, his blood glucose is 362",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (20.1",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    He wonders what to do now.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient has done quite well so far. He should take his usual dose of NPH (10 units) plus an extra dose of regular (perhaps 4 units) to correct the hyperglycemia. With the advantage of hindsight, he should have taken more than his usual dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    before the meal or eaten less. Depending upon how well he knew the hosts, he might have asked what was going to be served so that he could have made a better guess as to the appropriate insulin dose. If the patient is taught detailed carbohydrate counting, including carbohydrate-to-insulin ratios, his ability to estimate how much extra regular insulin to take would improve. The use of insulin pens and rapid-acting analogs (such as lispro insulin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10920?source=see_link\">",
"     insulin aspart",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/9/1176?source=see_link\">",
"     insulin glulisine",
"    </a>",
"    ) have made eating out more convenient. It is possible to take the rapid-acting analog immediately after finishing the meal, basing the dose on the pre-meal blood glucose level plus the amount of carbohydrate that has been eaten. Another method is to select carbohydrate-containing foods in the usual amounts and only increase the intake of other foods. This allows more food to be ingested without adversely affecting glycemic control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ELECTIVE MINOR SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some minor surgery is performed in the fasting state. This is a potential problem for patients receiving intensive insulin therapy in whom fasting will predispose to intraoperative hypoglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Case 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 20-year-old man with type 1 diabetes requires elective oral surgery for extraction of wisdom teeth at 8 AM the next day. He has been told to come in fasting, and the procedure will be done under local anesthesia. His usual insulin regimen consists of 4 units of regular and 8 units of NPH before breakfast, 4 units of regular before lunch, 7 units of regular before the evening meal, and 10 units of NPH before bedtime. He asks for advice on how to prepare for surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preoperative recommendation depends upon the morning blood glucose concentration. If the patient feels well and the blood glucose value is 180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (10",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or above, he should take some insulin, using the following calculation. Add up the usual amount of prebreakfast insulin (12 units in this case), divide by two, and give this amount as medium-acting insulin (",
"    <strong>",
"     6 units of NPH",
"    </strong>",
"    ). He should then check his blood glucose after the procedure. If he is able to eat at that time, he should take his usual morning dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    and then eat. The meal can consist of liquids or soft food, but must supply the same amount of carbohydrate as his usual breakfast.",
"   </p>",
"   <p>",
"    If, on the other hand, his preoperative blood glucose value is 90",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or lower, then he should take no insulin and check his blood glucose after the procedure. Although he has been told to fast, he should carry fast-acting carbohydrate (such as glucose tablets or hard candies) with him in case his blood glucose drops to hypoglycemic levels before the procedure begins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     IMPENDING DIABETIC KETOACIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild infections (such as a cold, sore throat, or urinary tract infection) can, via the release of stress hormones, cause persistent hyperglycemia and some ketonuria. The clinician can often manage this problem over the telephone if the patient is reliable and well educated, with frequent monitoring of blood glucose and urine ketones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Case 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 24-year-old woman, who has had type 1 diabetes for nine years, has sudden deterioration of her diabetic control in association with an intercurrent flu-like illness. Her usual regimen is 6 units of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10920?source=see_link\">",
"     insulin aspart",
"    </a>",
"    and 12 units of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    before breakfast, 6 units of aspart before the evening meal, and 10 units of glargine at bedtime. She awakens with a blood glucose value of 375",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (20.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and trace ketones in the urine. She has some myalgias, a slight cough, and a temperature of 99.6&ordm;F. She does not feel hungry, but is not nauseated. She decides to stay home from work. Over the telephone, the diabetic nurse specialist tells her to take an extra 8 units of insulin aspart (14 units in all) and to drink at least two to three cups of water or diet soft drink every hour.",
"   </p>",
"   <p>",
"    She checks her blood glucose and tests her urine for ketones every hour; she also contacts a member of the diabetes team every one to two hours. She is told that, even though her blood glucose is high, she should take in some carbohydrate (perhaps 150 grams) during the day. This can be achieved by drinking fruit juice in addition to sipping plain water or diet soft drinks. However, her blood glucose remains above 300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (16.7",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    all morning, she develops moderate ketonuria, and she is unable to maintain her fluid intake because of uncontrolled nausea and vomiting. As a result, prompt arrangements are made for her to come to the emergency department.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although ultimately unsuccessful in this patient, it is often possible to manage mild \"pre-DKA\" with the patient at home and calling in frequently. A reasonable general guideline is to add up the total units of insulin for a typical day (34 units in this case), divide this value by four, and give this quantity of regular, or rapid-acting insulin every four to six hours",
"    <strong>",
"     in addition",
"    </strong>",
"    to the patient's usual insulin regimen. This approach is worth trying with reliable, motivated patients, especially if there is someone at home to help. Success is also dependent upon the patient being able to maintain an adequate fluid intake. An antiemetic (such as a Compazine&reg; suppository) may be helpful in patients with nausea and vomiting. If oral intake is still limited, the patient should be brought to the emergency department or doctor's office for intravenous fluid replacement and further evaluation.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1804 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_33_28178=[""].join("\n");
var outline_f27_33_28178=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EATING OUT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Case 1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ELECTIVE MINOR SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Case 2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      IMPENDING DIABETIC KETOACIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Case 3",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Interpretation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_33_28179="Plasmapheresis with hemodialysis equipment";
var content_f27_33_28179=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Plasmapheresis with hemodialysis equipment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/33/28179/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28179/contributors\">",
"     Andre A Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/33/28179/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28179/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/33/28179/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28179/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/33/28179/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditionally, therapeutic plasma exchange (TPE, plasmapheresis) was performed with centrifugation devices used in blood blanking procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=see_link\">",
"     \"Prescription and technique of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These devices permit selective cell removal (cytapheresis) but have been associated with posttreatment thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28179/abstract/1\">",
"     1",
"    </a>",
"    ] and require a dedicated centrifuge device. An increasingly popular and often more efficient alternative is to perform plasma exchange by membrane plasma separation (MPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28179/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MPS utilizes a highly permeable membrane and a standard dialysis machine used in its ultrafiltration mode, dialysis-bypass mode (similar to the technique in hemoperfusion). Therapeutic plasma exchange is also possible using NxStage dialysis machines and Prismaflex Continuous Renal Replacement Therapy (CRRT) machines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27940?source=see_link\">",
"     \"Short daily home hemodialysis: The low dialysate volume approach\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20935?source=see_link\">",
"     \"Continuous venovenous hemodialysis: Technical considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For many years, the most commonly used membrane in the United States was the Plasmaflo AP-05H from Asahi Medical. This filter has been replaced with a slightly more porous filter, the OP-05W [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28179/abstract/6\">",
"     6",
"    </a>",
"    ]. This filter can be used with most dialysis machines, but the Cobe 3 and Hospal machines are incompatible with the filter's tubing.",
"   </p>",
"   <p>",
"    The published American experience with MPS is very limited even though thousands of treatments are performed in the United States each year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28179/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNICAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Plasmaflo filter should be operated with a very modest transmembrane pressure (recommended TMP &lt;75 mmHg, although the maximum TMP for the OP-05W is listed as 100 mmHg) and blood flow (50 to 150",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    in order to minimize the tendency to hemolysis and filter clotting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28179/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]. Limiting TMP can be most easily achieved by limiting blood flow and by regulating filtrate output via use of a double roller pump on the filtrate output of the filter. This double pump also regulates the infusion of replacement fluid (such as albumin or fresh frozen plasma), matching its rate of return to the volume of plasma removed, thereby eliminating the risk of hypotension or fluid overload.",
"   </p>",
"   <p>",
"    It is important to appreciate that rapid removal and infusion of protein-containing solutions produce volume changes that are essentially limited to the intravascular compartment. Thus, even small mismatches in net plasma removal rate will have a far greater effect on systemic blood pressure than would be produced by an equivalent water shift during standard hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28179/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The protein permeable membranes, such as the Plasmaflo, are very susceptible to concentration polarization, a phenomenon whereby protein layering on the inner surface of the membrane rapidly limits the maximum achievable filtration rate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28179/abstract/3\">",
"     3",
"    </a>",
"    ]. As a result, inappropriately high transmembrane pressures will not yield higher filtration rates but will increase the tendency for the filter to clog (",
"    <a class=\"graphic graphic_figure graphicRef52183 \" href=\"UTD.htm?22/30/23021\">",
"     figure 1",
"    </a>",
"    ). Dialysis nursing issues have been the subject of several reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28179/abstract/9,11,12\">",
"     9,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6472987\">",
"    <span class=\"h2\">",
"     Biocompatibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing of the OP-05W reveals a potential for increased bradykinin levels and it would be wise to discontinue ace-inhibitors in any patient who is to be treated with this membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28179/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most TPE treatments performed with standard centrifugal devices use citrate anticoagulation. Although this technique can be modified for use with an MPS system [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28179/abstract/13\">",
"     13",
"    </a>",
"    ], most MPS treatments are performed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . Initial recommendations are to start with a heparin dose of 5000 units [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28179/abstract/7\">",
"     7",
"    </a>",
"    ] or 40 to 60",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28179/abstract/9\">",
"     9",
"    </a>",
"    ] followed by a maintenance dose approximately 1000 units per hour. The heparin dose should be increased when the hematocrit is reduced. In this setting, there is a relative increase in plasma volume removal (since more of the blood is composed of plasma), leading to enhanced removal of heparin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28179/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients in whom fresh frozen plasma is used as the replacement fluid can develop further anticoagulation and citrate toxicity, since fresh frozen plasma is 14 percent citrate by volume. Citrate toxicity is most likely to occur when citrate clearance is diminished due to hepatic or renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28179/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Vascular access",
"    </span>",
"    &nbsp;&mdash;&nbsp;TPE can be performed with any vascular access compatible with standard hemodialysis, since the blood flow requirements are modest. Standard TPE with centrifugal devices can often be performed with bilateral antecubital vein catheters. This approach is less likely to be successful with an MPS system, in which the blood flow rate is frequently between 100 and 150",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    However, removal of a larger catheter, such as a large bore, double lumen catheter, is potentially hazardous after an intensive run of TPE due to a substantial \"depletion\" coagulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28179/abstract/10,16\">",
"     10,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6646?source=see_link\">",
"     \"Complications of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H764476899\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Therapeutic plasma exchange (TPE, plasmapheresis) may be performed by membrane plasma separation (MPS), which uses a standard dialysis machine in dialysis-bypass mode. Therapeutic plasma exchange is also possible using NxSTage dialysis machines and Prismaflex Continuous Renal Replacement Therapy (CRRT) machines. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The membrane most commonly used for this purpose in the United States is the Plasmaflo filter. The Plasmaflo filter should be operated with a very modest transmembrane pressure (TMP &lt;75 mmHg) and blood flow (50 to 150",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      in order to minimize the tendency to hemolysis and filter clotting. Limiting TMP can be achieved by limiting blood flow, usually via use of a double roller pump on the filtrate output of the filter. This double pump also regulates the infusion of replacement fluid, which eliminates the risk of hypotension or fluid overload. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Technical considerations'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      Most MPS treatments are performed with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      . Initial recommendations are to start with a heparin dose of 5000 units or 40 to 60",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      followed by a maintenance dose approximately 1000 units per hour. The heparin dose should be increased when the hematocrit is reduced since there is increased heparin removal in this setting. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If fresh frozen plasma is used as the replacement fluid, patients may develop further anticoagulation and citrate toxicity. This is toxicity is most likely to occur when citrate clearance is diminished due to hepatic or renal disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TPE can be performed with any vascular access compatible with standard hemodialysis. Removal of a larger catheter, such as a large bore, double lumen catheter, is potentially hazardous after an intensive run of TPE due to a substantial \"depletion\" coagulopathy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Vascular access'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Sowada, K, Malchesky, PS, Nose, Y. Available removal systems: State of the art. In: Therapeutic Hemapheresis in the 1990s, Nydegger, UE (Ed), Curr Stud Hematol Blood Transf, Karger, Basel, 1990, No 57, pp. 51-113.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28179/abstract/2\">",
"      Gurland HJ, Lysaght MJ, Samtleben W, Schmidt B. A comparison of centrifugal and membrane-based apheresis formats. Int J Artif Organs 1984; 7:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28179/abstract/3\">",
"      Gurland HJ, Lysaght MJ, Samtleben W, Schmidt B. Comparative evaluation of filters used in membrane plasmapheresis. Nephron 1984; 36:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28179/abstract/4\">",
"      Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis 2008; 52:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28179/abstract/5\">",
"      Kaplan, AA. Why nephrologists should do therapeutic plasma exchange. Dial Transplant 2009; 38:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28179/abstract/6\">",
"      Nagano T, Nakazono K, Iwamoto H, et al. Comparative study of polyethylene plasma separator sterilized by ethylene oxide and gamma rays. Jpn J Aspheresis 1997; 16:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28179/abstract/7\">",
"      Gerhardt RE, Ntoso KA, Koethe JD, et al. Acute plasma separation with hemodialysis equipment. J Am Soc Nephrol 1992; 2:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28179/abstract/8\">",
"      Howard, RL, Tatum, K, Chan, L, Shapiro, JI. Performance of plasmapheresis by nephrologists: A survey. Dial Transplant 1990; 19:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28179/abstract/9\">",
"      Price CA. Therapeutic plasma exchange in a dialysis unit. ANNA J 1987; 14:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28179/abstract/10\">",
"      Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am J Kidney Dis 1994; 23:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28179/abstract/11\">",
"      Price CA, McCarley PB. Technical considerations of therapeutic plasma exchange as a nephrology nursing procedure. ANNA J 1993; 20:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28179/abstract/12\">",
"      Price CA, McCarley PB. Physical assessment for patients receiving therapeutic plasma exchange. ANNA J 1994; 21:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28179/abstract/13\">",
"      Ilamathi, E, Kirsch, M, Moore, B, Finger, M. Citrate anticoagulation during plasmapheresis using standard hemodialysis equipment. Semin Dial 1993; 6:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28179/abstract/14\">",
"      Frasc&agrave; GM, Buscaroli A, Borgnino LC, Vangelista A. Optimization of heparin anticoagulation during membrane plasma separation. Int J Artif Organs 1988; 11:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28179/abstract/15\">",
"      Pearl RG, Rosenthal MH. Metabolic alkalosis due to plasmapheresis. Am J Med 1985; 79:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28179/abstract/16\">",
"      Kaplan AA, Halley SE. Plasma exchange with a rotating filter. Kidney Int 1990; 38:160.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1864 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-B6CE745EC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_33_28179=[""].join("\n");
var outline_f27_33_28179=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H764476899\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNICAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6472987\">",
"      Biocompatibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Vascular access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H764476899\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1864\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1864|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/30/23021\" title=\"figure 1\">",
"      Relationship between transmembrane pressure and filtration",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6646?source=related_link\">",
"      Complications of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20935?source=related_link\">",
"      Continuous venovenous hemodialysis: Technical considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38420?source=related_link\">",
"      Prescription and technique of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27940?source=related_link\">",
"      Short daily home hemodialysis: The low dialysate volume approach",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_33_28180="Silent myocardial ischemia: Diagnosis";
var content_f27_33_28180=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Silent myocardial ischemia: Diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/33/28180/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28180/contributors\">",
"     Prakash C Deedwania, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/33/28180/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28180/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/33/28180/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28180/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/33/28180/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Silent (asymptomatic) myocardial ischemia is the most common manifestation of coronary heart disease (CHD), accounting for more than 75 percent of ischemic episodes during daily life [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28180/abstract/1\">",
"     1",
"    </a>",
"    ]. Furthermore, most silent ischemic episodes occur during minimal or no physical exertion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42135?source=see_link\">",
"     \"Silent myocardial ischemia: Epidemiology and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic approach to silent ischemia and the possible role of screening asymptomatic individuals for this disorder will be reviewed here. The rationale for identifying patients with this disorder is that silent ischemia is associated with an increase in coronary risk that may be reversible with appropriate therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=see_link\">",
"     \"Silent myocardial ischemia: Prognosis and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exercise treadmill test (ETT) and ambulatory (Holter) monitoring are the most readily available and frequently used tests to identify silent ischemia in clinical practice (",
"    <a class=\"graphic graphic_table graphicRef74785 \" href=\"UTD.htm?0/62/1003\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Exercise testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise testing appears to be the most readily available laboratory diagnostic test to document silent myocardial ischemia in asymptomatic individuals (ie, patients with no history of CHD) and in those with a history of CHD or exertional angina (",
"    <a class=\"graphic graphic_table graphicRef74054 graphicRef52995 graphicRef61603 \" href=\"UTD.htm?34/51/35646\">",
"     table 2A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28180/abstract/2\">",
"     2",
"    </a>",
"    ]. Exercise testing is frequently used to screen high risk, asymptomatic persons to identify those with asymptomatic CHD.",
"   </p>",
"   <p>",
"    Conventional ST segment analysis during ETT is moderately sensitive in detecting CHD. However, it has low specificity because of an unacceptably high rate (10 to 35 percent) of false positive responses, particularly in asymptomatic persons and especially in women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28180/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=see_link\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\"",
"    </a>",
"    .)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28180/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, the diagnosis of myocardial ischemia by ETT in asymptomatic individuals must be confirmed by radionuclide imaging techniques (eg, thallium perfusion scintigraphy or exercise ventriculography) before the subject is labeled as having silent ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28180/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Holter monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Holter monitoring is the second most frequently used diagnostic test for silent ischemia. It has the advantage of providing long-term ECG recording of ischemic and arrhythmic events while patients are engaged in routine daily activities out of the hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28180/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=see_link\">",
"     \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Episodes of transient ischemia during Holter monitoring are diagnosed by a sequence of ECG changes that include a flat or downsloping ST depression of at least 1 mm, with a gradual onset and offset that lasts for at least one minute [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28180/abstract/1,6,7\">",
"     1,6,7",
"    </a>",
"    ]. Although ST segment depression during Holter monitoring has not always been accepted as unequivocal evidence of myocardial ischemia, subsequent studies showed an excellent correlation between ST depression recorded during Holter monitoring, and other simultaneous objective evidence of ischemia by perfusion scintigraphy, radionuclide cardioangiography, and hemodynamic monitoring.",
"   </p>",
"   <p>",
"    One potential limitation to the use of outpatient Holter monitoring, especially for the evaluation of therapeutic interventions, is the marked day to day variability in the frequency and duration of ST depression and ischemic episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28180/abstract/8\">",
"     8",
"    </a>",
"    ]. In one study, for example, 45 percent of patients had variability in frequency of ST depression while 42 percent showed variability in the duration of ischemia.",
"   </p>",
"   <p>",
"    Although Holter monitoring is useful in further stratification of patients with a positive exercise test, exercise testing remains the preferred diagnostic modality for initial identification of patients with silent ischemia. In this context it is also important to note that only a small fraction of patients with negative findings on exercise testing will demonstrate evidence of ischemia on Holter monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nuclear and echocardiographic imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tests other than routine ETT and ambulatory monitoring may be necessary in certain circumstances. As an example, nuclear imaging tests such as stress thallium scintigraphy or exercise radionuclide ventriculography are recommended for the evaluation of silent myocardial ischemia in patients who have an abnormal baseline ECG (eg, left ventricular hypertrophy or strain, bundle branch block, preexcitation syndrome), and those receiving digitalis, phenothiazines, or other drugs that produce repolarization changes (",
"    <a class=\"graphic graphic_table graphicRef52995 \" href=\"UTD.htm?17/42/18093\">",
"     table 2B",
"    </a>",
"    ). Pharmacologic stress tests with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    or adenosine plus thallium scintigraphy, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    stress echocardiography, can be utilized in those patients who are unable to ambulate or exercise (eg, due to advanced peripheral vascular disease) (",
"    <a class=\"graphic graphic_table graphicRef61603 graphicRef77242 \" href=\"UTD.htm?14/51/15165\">",
"     table 2C-D",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=see_link\">",
"     \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, all of these tests are costly and have limitations. It is therefore essential at the outset to critically evaluate the need for these tests and predetermine the steps to be taken based upon the results of the given test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Electron beam computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of coronary artery calcification (CAC) on electron beam computed tomography (EBCT), as determined by a calcium score, can identify asymptomatic patients at high risk for coronary heart disease. However, it is not certain if this translates into identification of asymptomatic patients who have silent ischemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link&amp;anchor=H9#H9\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\", section on 'CAC and myocardial ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of CAC scanning for identifying asymptomatic patients with myocardial ischemia was evaluated in a study of 411 patients who had a exercise stress test with radionuclide myocardial perfusion imaging within a close time period of the EBCT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28180/abstract/9\">",
"     9",
"    </a>",
"    ]. Although most subjects (78 percent) with coronary calcium on EBCT did not have inducible ischemia with exercise testing, the likelihood of ischemia increased with calcium score, regardless of age or sex. No subject with a score &lt;10 had ischemia, while 2.6 percent of those with a score of 11 to 100, 11.3 percent with a score of 101 to 399, and 46 percent of those with a score &ge;400 had ischemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SCREENING FOR CHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced obstructive coronary heart disease (CHD) may exist with minimal or no symptoms and can progress rapidly to an abrupt closure of the artery, possibly resulting in myocardial infarction or sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28180/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The rationale for early detection of CHD is that detection during the subclinical stages of disease might permit the reliable identification of subjects at increased risk of an adverse cardiac event and that appropriate therapy (eg, lipid lowering) might improve the prognosis of those at high risk.",
"   </p>",
"   <p>",
"    The data and recommendations regarding screening for CHD in patients with and without diabetes mellitus are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=see_link\">",
"     \"Screening for coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18761?source=see_link\">",
"     \"Screening for coronary heart disease in patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1984213\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Silent (asymptomatic) myocardial ischemia is the most common manifestation of coronary heart disease (CHD), accounting for more than 75 percent of ischemic episodes during daily life.",
"     </li>",
"     <li>",
"      The exercise treadmill test (ETT) and ambulatory (Holter) monitoring are the most readily available and frequently used tests to identify silent ischemia in clinical practice (",
"      <a class=\"graphic graphic_table graphicRef74785 \" href=\"UTD.htm?0/62/1003\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The ETT is easy to perform with widespread availability and moderate sensitivity for obstructive CHD. However, due to a reduced specificity of an abnormal electrocardiogram (ECG) response for obstructive CHD, a positive ETT often requires additional testing to confirm the diagnosis of silent myocardial ischemia.",
"     </li>",
"     <li>",
"      Holter monitoring has the advantage of providing long-term ECG recording of ischemic and arrhythmic events while patients are engaged in routine daily activities out of the hospital. However, one potential limitation to Holter monitoring is the marked day to day variability in the frequency and duration of ST depression and ischemic episodes, with variations of 40 to 45 percent reported in some studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening for CHD is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=see_link\">",
"       \"Screening for coronary heart disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18761?source=see_link\">",
"       \"Screening for coronary heart disease in patients with diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28180/abstract/1\">",
"      Deedwania PC, Carbajal EV. Silent myocardial ischemia. A clinical perspective. Arch Intern Med 1991; 151:2373.",
"     </a>",
"    </li>",
"    <li>",
"     Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28180/abstract/3\">",
"      Yeung AC, Vekshtein VI, Krantz DS, et al. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med 1991; 325:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28180/abstract/4\">",
"      Deedwania PC. Should asymptomatic subjects with silent ischemia undergo further evaluation and follow-up? Int J Cardiol 1994; 44:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28180/abstract/5\">",
"      Deedwania PC. The need for a cost-effective strategy to detect ambulatory silent ischemia. Am J Cardiol 1994; 74:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28180/abstract/6\">",
"      Deedwania PC, Carbajal EV. Silent ischemia during daily life is an independent predictor of mortality in stable angina. Circulation 1990; 81:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28180/abstract/7\">",
"      Sajadieh A, Nielsen OW, Rasmussen V, et al. Prevalence and prognostic significance of daily-life silent myocardial ischaemia in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J 2005; 26:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28180/abstract/8\">",
"      Patel DJ, Mulcahy D, Norrie J, et al. Natural variability of transient myocardial ischaemia during daily life: an obstacle when assessing efficacy of anti-ischaemic agents? Heart 1996; 76:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28180/abstract/9\">",
"      He ZX, Hedrick TD, Pratt CM, et al. Severity of coronary artery calcification by electron beam computed tomography predicts silent myocardial ischemia. Circulation 2000; 101:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28180/abstract/10\">",
"      Warnes CA, Roberts WC. Sudden coronary death: relation of amount and distribution of coronary narrowing at necropsy to previous symptoms of myocardial ischemia, left ventricular scarring and heart weight. Am J Cardiol 1984; 54:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28180/abstract/11\">",
"      Gordon T, Kannel WB. Premature mortality from coronary heart disease. The Framingham study. JAMA 1971; 215:1617.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1486 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-8BB6C55152-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_33_28180=[""].join("\n");
var outline_f27_33_28180=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1984213\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Exercise testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Holter monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nuclear and echocardiographic imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Electron beam computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SCREENING FOR CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1984213\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1486\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1486|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/62/1003\" title=\"table 1\">",
"      Detection silent ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/59/24508\" title=\"table 2A\">",
"      ACC AHA ETT diagnosis CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/42/18093\" title=\"table 2B\">",
"      ACC AHA choice imaging CHD diagnosis able to exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/22/21868\" title=\"table 2C\">",
"      ACC AHA choice imaging CHD diagnosis unable to exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/13/28891\" title=\"table 2D\">",
"      Stress echo v stress MPI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=related_link\">",
"      Ambulatory monitoring in the assessment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=related_link\">",
"      Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/50/26409?source=related_link\">",
"      Screening for coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18761?source=related_link\">",
"      Screening for coronary heart disease in patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42135?source=related_link\">",
"      Silent myocardial ischemia: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=related_link\">",
"      Silent myocardial ischemia: Prognosis and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=related_link\">",
"      Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=related_link\">",
"      Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_33_28181="Squamous cell carcinoma esophagus Light";
var content_f27_33_28181=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histologic appearance of a squamous cell carcinoma of the esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 269px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a mucosal biopsy specimen demonstrating squamous cell carcinoma. The invasive portion of the tumor in the lamina propria shows squamous differentiation with cells having eosinophilic cytoplasm and keratinization (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Donald Antonioli, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_33_28181=[""].join("\n");
var outline_f27_33_28181=null;
var title_f27_33_28182="Nadolol: Pediatric drug information";
var content_f27_33_28182=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nadolol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"    see \"Nadolol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/37/31317?source=see_link\">",
"    see \"Nadolol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F198894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Corgard&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F198895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alti-Nadolol;",
"     </li>",
"     <li>",
"      Apo-Nadol&reg;;",
"     </li>",
"     <li>",
"      Corgard&reg;;",
"     </li>",
"     <li>",
"      Novo-Nadolol;",
"     </li>",
"     <li>",
"      Teva-Nadolol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1054212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antianginal Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiarrhythmic Agent, Class II",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimigraine Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Beta-Adrenergic Blocker",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"      see \"Nadolol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Migraine, prophylaxis:",
"     </b>",
"     Children &gt;6 years and Adolescents: Limited data available: Oral: 0.25-1 mg/kg once or twice daily; begin at low end of range and slowly titrate upwards every 1-2 weeks (Linder, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      SVT:",
"     </b>",
"     Limited data available: Oral: Initial: 0.5-1 mg/kg once daily; increase dose gradually to a maximum of 2.5 mg/kg/day; dosing based on a trial of 26 pedatric patients (age range: 3 months to 15 years) which showed SVT was well controlled  with a median dose of 1 mg/kg/day (Mehta, 1992)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Angina:",
"     </b>",
"     Oral: Initial: 40 mg/day, increase dosage gradually by 40-80 mg increments at 3- to 7-day intervals until optimum clinical response is obtained with profound slowing of heart rate; doses up to 160-240 mg/day in angina",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 40 mg once daily; increase dosage gradually by 40-80 mg increments until optimum blood pressure reduction achieved; doses as high as 640 mg/day have been used; usual dosage range (JNC 7): 40-120 mg once daily; doses up to 240-320 mg/day in hypertension may be necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment for renal impairment:",
"     </b>",
"     Adults: Manufacturer&rsquo;s recommendation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     31-50 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 24-36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 24-48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Administer every 40-60 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dosage adjustments for dialysis are not provided in the manufacturer&rsquo;s labeling; however, the following guidelines have been used by some clinicians (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     ESRD requiring hemodialysis: Administer dose postdialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Peritoneal dialysis: Administer every 40-60 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment for hepatic impairment:.",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer&rsquo;s labeling",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F198871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 20 mg, 40 mg, 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Corgard&reg;: 20 mg, 40 mg, 80 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F198858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1054216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer without regard to meals",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F9549805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature in tightly closed bottle; avoid excessive heat; protect from light",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1054215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension, alone or in combination with other agents (FDA approved in adults); treatment of angina pectoris (FDA approved in adults); has also been used for supraventricular tachycardia (SVT), prophylaxis of migraine headaches",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F198936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Corgard&reg; may be confused with Cognex&reg;, Coreg&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nadolol may be confused with Mandol brand name for cefamandole [Belgium, Netherlands, New Zealand, Russia]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F198934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, CHF, edema, palpitation, reduced peripheral circulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Drowsiness, insomnia, mental depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Decreased sexual ability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, constipation, nausea, stomach discomfort vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Cold extremities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Arrhythmias, chest pain, confusion (especially in the elderly), depression, dyspnea, hallucinations, leukopenia, orthostatic hypotension, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1054220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nadolol or any component; overt cardiac failure, cardiogenic shock, sinus bradycardia, greater than first degree conduction block, bronchial asthma",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment; dosage adjustment required. Use with caution in patients on concurrent verapamil, diltiazem, or digoxin; bradycardia or heart block can occur. Use with caution in patients with peripheral vascular disease (beta-blockers may aggravate arterial insufficiency). Patients receiving beta-blockers who have a history of anaphylactic reactions may be more reactive to a repeated allergen challenge and may not be responsive to the usual epinephrine doses used to treat an allergic reaction.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6006933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May depress myocardial activity and precipitate or worsen heart failure; use with caution and monitor closely, especially in patients with compensated heart failure and during upwards titration of dose; if heart failure worsens, may need to increase diuretics and not advance the dose of nadolol; a reduction in dose or discontinuation of nadolol may be needed. Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered over 1-2 weeks to avoid acute tachycardia, hypertension, and/or ischemia",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Severe exacerbation of angina, ventricular arrhythmias, and MI have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency. Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery. Beta-blockers should generally be avoided in patients with bronchospastic disease (nonallergic bronchospasm, chronic bronchitis, emphysema), as bronchospasm may occur; nadolol is contraindicated for patients with asthma.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Nadolol  may block hypoglycemia-induced tachycardia and blood pressure changes; use with caution in patients with diabetes mellitus. Nadolol decreases the ability of the heart to respond to reflex adrenergic stimuli and may increase the risk of general anesthesia and surgical procedures. May mask clinical signs of hyperthyroidism (exacerbation of symptoms of hyperthyroidism, including thyroid storm, may occur following abrupt discontinuation). In patients with pheochromocytoma, adequate alpha-blockade is required prior to use of any beta-blocker. Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9838219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F198867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1054222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid natural licorice (causes sodium and water retention and increases potassium loss)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F198868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F198880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies; therefore, the manufacturer classifies nadolol as pregnancy category C. Nadolol crosses the placenta and is measurable in infant serum after birth. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother. Nadolol is indicated for the treatment of hypertension, but due to its long half-life and potential effects to the fetus, other agents may be more appropriate for use during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1054211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, fluid intake and output, weight",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitively blocks response to beta-adrenergic stimulation; nonselective beta-blocker",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1054218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Duration: 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1054219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 30% to 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Concentration in human breast milk is 4.6 times higher than serum",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein-binding: 28%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Increased half-life with decreased renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Infants 3-22 months (n=3): 3.2-4.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 10 years (n=1): 15.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &sim;15 years (n=1): 7.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 10-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Moderately dialyzable (20% to 50%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1054210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/37/31317?source=see_link\">",
"      see \"Nadolol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit alcohol; do not abruptly discontinue; may mask symptoms of hypoglycemia, but sweating may still occur",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brauchli YB, Jick SS, Curtin F, et al, \"Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,\"",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2008, 158(6):1299-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/33/28182/abstract-text/18410416/pubmed\" id=\"18410416\" target=\"_blank\">",
"        18410416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/33/28182/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Devlin RG and Duchin KL, &ldquo;Nadolol in Human Serum and Breast Milk,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1981, 12(3):393-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/33/28182/abstract-text/6117304/pubmed\" id=\"6117304\" target=\"_blank\">",
"        6117304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gold MH, Holy AK, and Roenigk HH Jr, \"Beta-Blocking Drugs and Psoriasis. A Review of Cutaneous Side Effects and Retrospective Analysis of Their Effects on Psoriasis,\"",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 1988, 19(5 Pt 1):837-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/33/28182/abstract-text/2903871/pubmed\" id=\"2903871\" target=\"_blank\">",
"        2903871",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Linder SL and Winner P, \"Pediatric Headache,\"",
"      <i>",
"       Med Clin North Am",
"      </i>",
"      , 2001, 85(4):1037-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/33/28182/abstract-text/11480257/pubmed\" id=\"11480257\" target=\"_blank\">",
"        11480257",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mehta AV and Chidambaram B, &ldquo;Efficacy and Safety of Intravenous and Oral Nadolol for Supraventricular Tachycardia in Children,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1992, 19(3):630-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/33/28182/abstract-text/1538020/pubmed\" id=\"1538020\" target=\"_blank\">",
"        1538020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mehta AV and Chidambaram B, and Rice PJ, &ldquo;Pharmacokinetics of Nadolol in Children With Supraventricular Tachycardia,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1992, 32(1):1023-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/33/28182/abstract-text/1474163/pubmed\" id=\"1474163\" target=\"_blank\">",
"        1474163",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sch&ouml;n MP and Boehncke WH, \"Psoriasis,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(18):1899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/33/28182/abstract-text/15872205/pubmed\" id=\"15872205\" target=\"_blank\">",
"        15872205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12625 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-7D7969DF47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_33_28182=[""].join("\n");
var outline_f27_33_28182=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709161\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198894\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198895\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054212\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054206\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198871\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198858\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054216\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9549805\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054215\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198936\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198934\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054220\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054205\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6006933\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9838219\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198867\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054222\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198868\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198880\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054211\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054204\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054218\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054219\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054210\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12625\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12625|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=related_link\">",
"      Nadolol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/37/31317?source=related_link\">",
"      Nadolol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_33_28183="Rouleaux in myeloma";
var content_f27_33_28183=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74369&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rouleaux formation in multiple myeloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 226px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear from a patient with multiple myeloma shows red blood cell rouleaux (arrows), giving the appearance of stacked coins.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal peripheral blood smear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 257px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEBAYkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDuU8O+KXkMf9lhT03NKAv510nhbwR9lvo7/XJ47q6hb91bRf6uN/Uk/eI/Ku1YjHfHrnvSxH5wBj6Vw3tsdU8VOatscb418WXdnff2bopQT4zNORu2k/wj3ri44r/zDO17dGcnJfzDnNFoTPqV1I5JeSdyT9Ca7vS9NtZrQF9oc+/SjVHV7lCKVjI8OeL7zT7tLbXJWuLKVgomf78JPqe4r0dvl46+9eR+IYI1eRAAQMg16H4VuJLjwtpMs2S7QKCx744BpvVXObE04pKcdLmoXY7dqjGed3YetLnnPam5+b3xRk9ME1Byjs9M4I7Uue/600kY9jRuwTzz6etIQo6kDJFH0I644ppbkZy39KRm5weB1oGP4IPHTig4VSScCkHoKUkFSCAQe3rQA4gHkdOtVtSsLLVLYwajbR3ER5AYcr9D2qxyAQQAB0x6UhPGRTQJtao5M/D7Qd28m9EZ52eccD2re0jSdP0aAxaXarCCeX6sx9z1q5kdM9RnrTvupvkZUA/iJwKdzSVWclaTExkDP86OppI3jmyYpY5QBzsYGklkjt4pZp22xxIXc+wpWZmEm2JTJM6xxj+J2AFRWt5ZXRKWt7bzMD91JAa8j1HULnxFdtdXru0TH9zADhY17cetINI+QPHGUI6MmVI/GqstjtWDsvedmesa2JF0LUwmRL9mfb65wa8d0tlSzgwMqyKoP4V23gXxLOb1NG1Z/OWQEW8zD5iR1Rq5vxLpM3hfU5FCMdKlYtbyjomeqN6Y7UrGmHTpt05bnpljcaXDosbQyRraKm0pxknvkV5fqhjImIwqZYgHsO36VF9uTafnG3r97inaVp9z4mvltLEN9kyBc3OPljXuAe7EdBRYunS9leTZ6P4GLjwbo5kzu8njP93PH6Yqv4y8MHXdl5YukOqQjYpb7sq/3W/xroUSOGKKGEbIYlEaKOwAwBSjA/i56gZ60N6nnqo4z54njM0WqWEzR3um3iSA/wAKblJ9iOtXNO0HXNclCQ20tjb5+e6uBjA77V7mvXvMIHDnjtSbyTlmNCZ0PGytotTN0+203wxoIijdYdPtgXeWQ8s3die5Nc7cfEi0Rithptzcx/8APR8IGH0qh8U7h5dT03TM4tkia5Zf7z5wM/TNc7Bb7toXufz9qd7F0aEZx9pU1udIut+DdYmC6vpQspifvvHhf++hXX6ToukaUqy6TZWyBxlZl+YkeoNebXmi3MduGubd0jI6MOD71Z8Ga1LoOqRWFy7Npdy2xQxz5DnoR7Hpii9x1aV4/u5P0PTycnJPUUAcgdwKZcyR2sU01y4jghUu7noAO9ecan451PUGxoyCxtM/LI67pXHrjoKVjjpUZVfhPSmVghJBwPavNPi4u3XNEc58trd1X0zmqEPibxHayLIb1bll6LMnBHfpW9JcQ/ETQZ7Py1stdsT5sIJyM+oP909DVJHVToyoTU5bD/B0Vu9u5Z1VsDb6k0eK7aBNP3koJt2AB3FefW2o3OnXJhuVktLuM7Wjfgg+3rUmo680yk3M27PQdSTSOn6vJz5k9CzoW4eNNE8rcHNwPu+nevai5W4JGPvV4wv9o+D9DuPGFzpsk10q+VZ2zDiEN1mlxyB2wPUdOtd54D8Y2HjDSRdWZ8q5jwLi2Jy0Tf1U9j/XIrr+oV3hvrajeF7X7Pz7HBjMRTlW9knqkZPjDwRcz6jNqvh5o2eY7prRjgM395T2PtXO2+k+IN2x9GukI4J4r13JB4zThI5P3jkHHWuLcuGLnGPK9Tx7V0uYdZlju4Xhby0ZQ/8AdAx+Wa67SNDhk8NvIrB7x+SQeFHpTviZpVxc21tq1mrPJaArKg6mP1/Cua0HxBNawYhYNE3TJ6U7HTzSq004bkksEloSkqED17Vl6y2LcuOCrBh25BFa1/qzXEbI21c881n6LYv4i16CxiBa1hYTXcnZVB4H1JoS1NYtpc0j1qBy9nas+dzRKTntxS4Hq3506QhpDgfJjCjPQU3I9T+VTqeQ9S8qsxwoYkDdwtG1kYEggjnnivJ7i91e9cvdancluu1H2KPoBU2n+INa0tgVunu4R96C4O7I9j1FaWXc6PqkraMTxlpr6Lr01ysZGn3jeYkgGVR/4lPpzyKZbazti+V+PXNekaTqNlr+lefCivC3yTW8oyUbupFVf+ES8PtJ5h0uDPoM4/Kltoy1iVblqLVHnFra3PiTUBZWeck/vpf4Y07kn1x0FejeIta0/wALabbxlC7hBHa2sZ+ZgBjJ9B71r2Vrb2kawWUEdvET92MY/OvINduX1TxbqV05LLHMbeIHoEXjj8cn8aExxaxM9dIou3HjLxJcuWjnt7Re0cUQb9Tmrmn+O9Rs5ANahivLb+KWJNsij6dDj04qbQdCW/t5HeQRheBisvWdNFo7L/D2NHMaqNGT5LHp8N1b3NpHd20qSWsyhkkB4PoPrUw4HYfhXmnw2vDba6dMmIMUyPLb5P8Aq5ON2PqMV6QoCgY/L0pSVtjhrU/ZS5RScdcAUAhnKAgleo9PrQgJfgDd6+3vXCa/49dLt7Xw9DHMUOHu5RlCe4Ud6SVxU6UqjtE7tCG+dRwO5GDwcU4t279eK8ri8ZeJY33vc28w7o0IAPtXYeF/FcGuS/ZpY/seogZ8k8rKO5U/0p8vY0qYacFd7HSk8ctSHoc8UjNx056Usa73Cjj8ak5zI8Sa9DoNqjFPOvp8+TAO/wDtH0Fed373urS+fqlw8zE5CZwi+wFT6jeHWPEd5escxhzDD6CNTj/69dZo2kwNbrJMgckcKe4qz0IqNCKb3OE+xfZts9u7W8inCOjbTn2rstG1O58T+FNY0u6YHUooSu9RjzFI4P17Gm+KLCC3KtbjarDheuKzPAZaPxpmMkI1q3mY6Yzxn8acX0ZU2qlPn6rU5/QJA6wFlIwArDHQjgj8K9JjFuNLUMV27flx61g+LvDEkU8mq6LGzl23XFsnc92X+ormRrbxKYpi8TDjEgIIpBJe3SlFk2qSC21a0ngOHjuIypHruFeuXgR/MilRZI3yCjDIP1ry3wjpcmv6zFdyxyDTbRxK7sMea4+6g9eeTXp0h3uzEkZ60nsYYpq6XVGMfCXh5pPMbSbctnODnH5ZrYgjjghWG3jSOFeiIMAfhTh796TPHX3pHM5yluxRye/1pf8AOaY5WOIySMscS9WY4ArOXxHoZnMX9rW3mD34/OmlcSi3saoOOKTOBycf1oVlkiWSF1kibo6HI/OkIBIJGdvIOO/rSEcX8ULFmgs9XiUkWuYZ9o+6jd/wOKwdCu47W/triUB0VgzDrn3r1FlR4njmUPEylXQjIIPY155rfgy+sJWm0D/SrM8/ZmP7yP2U9xTO3D1YuPs5Ox1uoazp1zaMd6sGB+XqRXlPiKSPyJZEypU7wfcdKfLc3EBMU9ndRyZwVaM5zWloHhe+167il1GCS00mNg7mXh58HIUD0z1NB0U6caCcm9DpfiTqEi+FNMteQ+osglPT5QASPzxWL4V0+K/n8tyQoHQCun+Ielvq/h9p7dSbqwbzo0H8S9GX8q4nw1q/2WVJ4iSjDkdx7U27kUNaLUNzqdY8Pwx2BeBmMijkEVwjXMuk6vZ6jauUlilAYj+JScEH1rudV8TrJZyRQgfOMFj2HtXCmBtW1ew063JMtxMucc4QHLH8qS0NKHNyv2mx7HrGn6fqo2alZQXcZ+ZfMXJGR2PaqGm+HtF0ufzrDS7aKb/noRuYfTPStaQgSfIPkXCjnsOKIl8yVVPdsZ9qR5qnJKyehn69qenaVpsl1rsyJbSZj2MNzTE/whe/+c180Xd3ceE/FT+IfCcE1rYFz/o8xDgITyjY6qe3ccc5ANdp4o1KbxH4svLmQ/uLeRra2jPREU4JHuazNfTUrXTX/s/SFvomXDtndtHug5b8K93IsZVw+J9jBKUZ6SjJpJr56X7dfyLxWApfV+eo2pLVNdPu/E19Z+Non0O3lsdPFteNcRlgJQ2EUhnHTuPlz6N617NazRXVrBdWsnmwXEayxSDoysMg/lXxHICJGyuw5+76e3NfSn7PmtvqfgubTpW3zaZMEQk9I3BKj8w1fRcS8OUcBgo18MtpO/pLb7tF8zxMHjZVqrjPt+X+e56ip2jjBB6iuV1bwTY3s0ktrK9jcOxbMSjYc+q1u3+pWWnKZL2dExxgnms6w8R2F0s+yYArjaSeua+CUZbpHsQlKGsTnofhy0kh/tHWZHixykEYXd+PWuy02ws9LsltNMtkt7cHO1eSx9SepPvU1sy3EIdGVhjqDT3GRg1LKqVp1NJMb69Np9aOaXJJ56GjI9DSMjm9E8PpfWrSzy+WmSAAOSay9d0p7CVFIyvVW9a1fD2pmEmBziNj19KseK7i2kgiVHV3A6g8Yq3udinNVLPY5fwrftpXiq35P2a8PkTLnjJHyn654/GvUnGCQcZBrxqVTNqmnxpyz3UQXH+9nP5Zr1TxNevp1hPdRjcydBjINNq6ROKjeatuzRQnehPQd68U1C3fTvEep2lwPnW5aQE8ZVjkH8jXWeHPGF5f6nBb3cYKzEjAGCPpWn448MvrYivNPKpqkC7QGOFnTrtJ7EdjRKDg7MdB+wm4z0uZvhu+WOMwudq/Wm+KbiOWQKg4AwCO9cat9Lp0xg1CGWznQ4ZZVI/I9DTn1F76UQ2cct3MxwscKljn+X50tzq9hafMavgmMz+O7HYOIY5JnI7DGK9V4LEfjXN+BvD0mh2c0+obP7UvMGQKciFB0QH+fvXRFuPalLscOJmp1LrZHPfEO/l0/wAKXBt32y3Mi2qsDyobJb9Afzrz7SLIOIoogOcKBXefEa0e88JTvCA0lpKtxgd1HDfoa4jRLxY5IpVIO07hjmjodWG0pO250V34Xmjty6umQOR3/CuTv4ZtOmW4hbZdWreapzyCO35V3v8AaaSI8jPlm469BXFeIbhDHcugBLAhQOpJ4AoWj0LoSk3aR65Z3a32n2l6nC3ESyHHbI5qxER56gjrxnPSqGh2r2Gg6ZZyf6yGBVb2OMkVcIwep60O1zzJWTdjyCxU2k09rLw8MrowPrmuos9ceCAIFzitDxR4T/tO8OoaZMlvfsMSK4+SXHf2NYkXg7XWGJJrGEeoJbNFz0HUpVVeTKurar5m6WaQBVHU+ldB8PtOmt7S61W8jMct7hIUYYIiHQkds1Jo3gyzspo7jU5zqFyhyisMRL/wHv8AjXTuxYZbr2ouYVa0eXkgLyrAgnNMmiguHLXFvBM4HBkjBNScc+nSjFI5bhkbNgARBwFUYx9KQDBz69cUH889vWhhtUGQrGnZmYKM+lIQE4Bx09qIvnYLzzSR7JQTE8cgH9xg38qdEWWRMAA9OaYHl3ivU317WZotx/s+1cxRRg4DsDgsR35zist7SMrhY1I9NtV7RnjluI5BiVJ3Vw3UfMc12+g2dnPZN5qjcRjce1N7nrtqjFJbHM+H9WufDV6JYWd9Pc/v7c9Mf3lHY161CySW0MkUplR0DK56sD3OK81vtPXzSi/d3YJ9a7TwgPL0FIv4YXZAab2OTFKMkprc1mBbAGQfaoLy+srHJvb2C3I/hdwD+VYvjPXptJt0tNPA/tC4UnzDyIk/vY9fSuBtNL+0Ozy7p535aST5mY+pNKxFLD865pOyPUtP8QaXqMmyx1KCWQcBS20n6Zq3JvBPmEk+/NeP6hpSo2HTa45B6EfQ11vgPxBPdSNo2pyebcRrvt5Xzl0HVT6kdqLLoVUw3LHmg7o7JCY/u54HeuV1rwPaahcNdaTMdPuXOWUDdGx9cdq6maWGC3lnuZRFBChaR2/hArzrV/G2oXzMmjAWNn0WQjdK49eegpIihGo5Xpg/w/10uEa9sVi6mXDZH4YrqfDPhez8PCSWN2utQkGJLpxggf3VHYVwMGva/bSebFq9w7DqsuGU/ga7bwd4pGtl7G/jjg1ONdw2fdmX1A7H2p27HRXVbl1enkdGB8vPI9TUkBCzoT2NNHp6dRSNnjH60jhPDtWsZNF8UalZzArmdpoiejoxyCDWrBqKpAECqD9etekeItB0/wAQ2yR6jGwePPlTxnDp+PpXJN8NWDAJrbCM9N0ILCjzPThiqc4pTdmedeItNtdZnSL7GJ72Y7Igg+cn6jt9eKhkjPwp1aUaZqy3kt5aeVPEEwYnPIIIyGwfp1Ne3+GPC+neHhJPbq1zflCGuZzubHcL6CvlrxC0l3r2pTyy/N57A+wyele3gMwxKpTw7m3TatyvVfLt8jOGFw+MrqXLbl1vs3/wDa/4S+5uL0G7gkmP3jI7Z+b6ZqB9WvI2knifCORwT0rHtGjaRM8kDH1pZXJWUbj83ABqlFI9tUYR0SPQ/BPj+4sbqOG4lJicgcnIr36GT7RbxyqMiRQ2RyOa+PUs9tuJTKAxPAHUV9FfDHWZ9Z8CnYxE1rmPcepwK4sXSWkkeXmOGjFKpBHapLE7FY5UY+gYGn4P+TXk+hQ6vdeKBKkbgRN87tkDGa9P+2xf89F/KuOdPldlqebUp8ltTzS11FQu1mKyKMFX4YH3p95qUajLug9MmvUdR0nTNSOb+xhnbHLlcN+Y5qrY+HtEsZBLb6XbiTPDON5H0zSujo+tQ3tqcr4F0W4u9Si1q+jeK2gz9licYaVsYL47Adqu+PPFkOk25tfI84zddwwBXbPvIZ5CAo/iY4H61ia9oem+JbQW87wSMDndG6lv0qoNXTa0MfaxnUUqi0Od8Nvoll4euPEwim220byS7QXKKoyxVR1wMnjmt/wz4q0LxTZi48P6pa30QAJEMmWT/eU/Mp9iBV3TtHtNM0wafbQBYACrK4zuB65r4a8T+CdZ8LfE3XLHQxqEMOlE3wubLJlhtCy4kXDAsVDgHkdD0wcOyqN6mM5c0mz7vnSKddtxFFMo6eYgbH50QRxWylbWCKHPURoFrmPhtMlz4N0+4g8Qz+IoZV3C/mVFZuPu4UDGCOQ2WznJrpx655781k9BXdrC4BbJGaXAPGMfSkP3TjNKOQSOnqakQYHIKBlIKlSOCD1Feba74Mv9MuJJ9BjN3YOd3kA/vIfYeor0nI4OcA0cjlTz0zTua0q0qTujx1BqbtsTStQMh4x5RHNdR4U8I3Rv4tT8QIsQhbfb2YOTu7O/07Cu98x8feY/8Cphz1J5p3sbTxUpKyVhzsWbcevqRQB1xQOpFKBmkcg0AADnPvSHr16U4dBTJpEghlnnbZDEhkc+w5oAivLi3src3F/cR20I/ic4/CsB/G2g7yoku3UjG9YTt+tcRf3s/iHUDfXwJQ/6iHPyxL2GPX3q5b6ZLLGXihYqOuBVaHfHCxS996nouk6pp2rIzabdrMyjmM8MPwNXMdc15BcW8lvcLcWztBcxNlZE4ZT/AF+leleFNbXWtJN1cBUurbK3KjpkDOR7Gi19jGtQ5Pejqir4s8RroiJbWiLNqcy7lRuViX+839BXnd291qMzS6jczTysc/OSF/AelPiuJNU1G61GY7pLmUkZ7KDhR9K7e18MQ/YoZJ5AJXIY5GRt7j69KTutjpioYdK+5wqwyWhElpLJBKOQyMRivQPBXiFtage2vdq6lbKCSOBKv94e/rWZregR2tmbiFyUDYINYPh2RrTxjpTx/wDLSQwsPUMKa10YVFGtBtbo3PG3hq4kvX1fSIjM0mPtNun3iR/Gvr7iuVh1h7PdHJ5kJ7rIpBr2TG1vl4INMkjhuMGeCGUg8M6BiKVznp4nljyzVzyvSm1LXLpYtOt5GXPzzupVEHc5PWvT7C0jsbOO2iJKJwSf4j3NWC2Igq4VR0VQAPypvUYycjvRcyq1vabKyPNfGsp/4TK6iYnAijK554/wrQ8KRB74EkYUZ+pqX4laXIy2+tW0ZdoF8q5Cjny+zfga5vS9WNv+9gfORxjpTep2wXtKK5TrvG8MaQxSLgO3bviuH0yRrfxTpEseTILpUwO4PB/nVzUNTku/mmcs31qX4f6e2qeI11AjNlpxLb+zSkEBR9M5NJFwj7Ok+Y3virdtHb2Gmxk7LuRnmx/Eq9B+ZrnPDWnR6lqaQykiLGWxXSfFGzkn0uy1KNS32NyJQBk7Gxz+BrltB1H7BerOuGVvQ8EUyaH8D3dzs9T8N6fJbPHaxlGUHBz3rzt5n0nWLW6ibElrOMkdxnBH5V3eo+KYBZt9lX984xz0rhLe2l1nXbKwgUtJNKJJSP4UBySfQULQeH5rP2mx6VeeLdHtfGFt4curkw6pdwfabdHQqkq5I2qx4LcE4Fb2Bx/nFcn8UPDWieKPD80Wu3CWCWp8221HeI3s3HR1ckY6DIyM/kR87SfHHV7HxF4a0/Ub23vYNHvnS+v7RyY9QhKhFkx6hWc+hbB4pxhzbHmH1oec0nP4elNVw6q6MGRgCGByCPWuX8YeL4fDZjSSFpJH5yOwqYxcnZFRg5vljudXHjec4OQRmvlDxzpb6b4q1iFkIV5S68cYNfT2gapHq1hHeQgBHHFct4+8EJ4gt5riJgl3/D7/AFrow9T2UmpHXgqyoVfe9D5p08oSJWkO7jaOma1ruzUwecGVmK9V7VJrHhfWtPuXV7CcqGxvVCRWd5Woi3e3isLlucswQ16iknqmfQKcZaplXe3zBvlQDINfQvwJtprbwK8jxkedKSm7jcK8n8I+A9T1e+i/tXGm6bkGSW4O3I9BnvX0LpmqeHoEh0rTtUsx5QCou8Afn0zXHi6iceRHm5jWUo+zjqakYUEkALuHOO9V/sEXvV3yT5igYAPfrke1TeVH/eWvOTaPFuT5xxu5xWL4o1+PQbONlRZr644ghJ/Nm9hWyeSBnk15j4pm+2+NL9m+5bBbeMHtgZOKpGuHpqctdkZ919u1abzdVupbiQ/w7sIvsFHFMbSUQCSMFGB+VkOK6fw1Yrd3qrJ9wDcR6itjxQsIgjEcSIF+X5VobZ1utyy5EjnfDfiu60uaO11mWS6sJGCrNIcyQk8cnuv8q7s6ZZx6rLqKQRm9mhSBpwOXjUsyr9Mux/GvKNVRTE6noQf5V2a69Lpfw207UGw1/JCsNuG7seA34AZp/ErmWIoptOC3OU/sCH4dePDf6HqlvaeH9S3yahoZBZklx8skCjhcnGQcDHrwF6dfiDYeZhtNvVi/v5BP1xXF6VplxfXLN8893KcySvyzE+pre1DwtdWMW8skigZYxnpQ2upaw9KHuyep3Gj6rp+swvLptx5m378bDDr9RV/Gc5xj0NeNWF5Jo+tWl9AdpSRVkHTejHBBr2aUYkbHTr+FJpbo5sRS9lJW2YDryccUHgeh9BSDrnj2pVG0YFSYCAY6CmMvUg4FSfQ+1HY0BcQD160452nBwe2RScZ/zxSmmAgBxg9fWsbxmrv4Q1ZYgd3kHp6Z5/StnoMn8KGVGVkkUOjqVZT3B7UFRlyyTPItP2FUIPBwQa9O0uSI2cQhCiML81eb63pU/hm/MbgtpznNvP2A7IT6iprfVXSPEcpC+gPWmejVh7ZJxZqeKI4hfMYQAD1x61H8Odz6/q9r/DcWgJ+uSP61iahfrtaSaQAeua6/4daVNZ2l1ql4jRXF9gRxsMFIh0J9z1px01FU9yi0zhtLBs3ktpRtmt5GjZT2INdzaeIIzZRJMp8xOAaPF/hR9SuW1HSmSPUCMSxMcLMB0Oexrj2stZt38ubSr3eOPlQsD+IpXHeFdXvqdDrWuNeQrCgCx1S8E2baj4oW5IJttOBd27GQjCr9e/4U3TvC2tamwN0v9nWp+88n+s/4CtegaXp9ppNhHZWMeyFeST1du7E9zRcyqThTi4Q3Lmecjqe9L9Pxpo5wf5d6U4znipOAQ991JjNKOvPWlVSzBQM+1AxobgjGQRggjqK5bV/AGmXTNc2ssumSNy2wjZ/3yeBVTxT4wlhu5dO0HYZY/lmuyMhT/dT1PvXGXMNzdMz3dzdTs3JLyE/pVWtudlCjUXvJ2OvtvhzaSPmfWJ7uMdY4iq5+pHNdha28FjaR2tnAsNtGMLGowP8A9fvXixtZbSQS2k01vIpyrRuQQa9L8EeIH12ylgvsf2laY8wqMCRD0f8AoaT12KxNOoo8zldHQuVaN0kRXjddrKehHpXC6r4CbzjJoN2sMbc/ZpwSqn/ZPYe1d0eefbpSc0jmp1ZU3eJ5vb+BNbmfF1eWdrGD95Mu2PYV2fhzQbLw/bSR2W+SeXma4k+/J7ew9q1PTFFO5U686is9iG4gguoJLe6ijnhddrxyKGUj3B4IryTxt+z94R18yTaUkuhXjchrUboSfeI8fgpWvXLiUwwSSbQSqk4rzHUPGWow6gjSS7oS2AEHCj3rSlGUvhJp0pVHaJ0vhmDU/CHgPT7TXJor67sI/s6zQlsSxrwhII4O3aD15HWsJ5Lbx1qCW15bGF4+sinPFP8AE/i6VvDsc0UGY3O1jjNafw/jhvIY79IPLAXAbpk1oouEXJ7m8IOlDna1Oo0jTrfSdPisrRdsUfT396t8jPf0pw680gJxycmudu5zNtu7EwG+8ikehFYPizXbXw3BEltbQy6ld5MUZUBVA6u3tW+uSwxxk9TXlfjhpZvHl79oGPLjRYv9zH+NEe5th6aqTs9jMu1utUlaW/la4kY7iMYUfQdBVWfSkaPmMY69Oldx4ZtreSFnlABA6eopfEcMCtm3UKMZxjHNGrO9V7S5EhPhXrcsnnaBfM0ssMZlt5XOSV/un6VR8zWv+ep/75rN8JzfY/H+mSAE+YWibHoRXsH9kw/3V/OrUrHJieWnO6W4pwDkdjxXnPja1ax8S/a+fs2oKCrjtIOCM9q9EmjSRNrhtpHVTgis+80e1vrB7O+aWeBuRu+8h9QfWouYUaipyuzjdEv/ALBOHXp/EP51f1rV1vShChAP7tZd94U1rT2P2NRqVsD8pUhZB/vCqyaXr852Jo1wD0zIQoH409zs5acnzpoy9YcrC4UEu3yIo7k8AV03xDsZdP8AC/hqFgGjsysUxHRW2AA/mDWl4Y8JNY3ceo6zJHPeJ/qYY+Y4T/eJ7tXTX9pDf2ctnfx+bbzjbID/ADHoaOaysZzxEVONtUjznwxqK2V0pcAxng+1dhqOs2sdlJtdZC6njvyK4jUPCWuaXKRZxf2lZ5xHJEf3gHYMKht9F8Q3z+XDpk0J7yXJ2ItG5rOnTm+fmIbOxk1nX7OwhGPMkEspHRI1OST/ACr1+cq824joflPoOn8qxfC2gQ+H7SUGQXF9Pgz3BGAfRV/2RUPijxKmhutrbQi51KQbgjH5Yl7Fv8KHroc1aTrTUYdDoINzru8twASPmHocfr1p2CPY15TJrWv3D75NVnQk5CxYVR+Are8M+JNQS5MOryfarXqZSuHi9/cUWXRilhZxVzuVVmYhBkn24FUrnVdLtX2XGo20bjqBJnH5VxPivX5tVn+zadK8elp/y0UlTOfUn+7WCsEaDG0AevWiyW5UMK2rydj1y2nhvIvNs547iMfxRtux9cVJzn39q8lh8/Tp1udOmaCdeQV6N7EdxXpOjajFrejpdBSjPlJowfuOOoosnqjKtQdPXdGjyF6Yo44H4UikYGB9BTj79OlSYjZUjmheGeNJYWHzI4yDXN3XgjRZpS8S3FsT1WGX5fyOa6X8STQRwf50IuFSUPhZhaX4S0bTplmWB7idTlXuG37foOlbzMWYk5JpuQP8aUdyeoouKU5Td5O4dM8cU4O237xAHBwaaMnHfPanCJscLx+WaCRPmJOevrQBj8KcUZeGUgetNGNxwfamA7HPfPamHnj9AaD3OD6c0h3H2buKQgB9ME1m+KL6TTvDGp3kPE0cRCn0JOM/rWhg479fSq+qWCappN7YSEKLmMru64PY/nTWhcbKSvseSaPAirHHnPqfU9zXoNjpluloC0W4sMkntXm8Rm066ksb9DDeQnaytxn0I9Qa6O01yaOER7tyjgD0oZ6leEpaxJPFNrDBODCAAw5FUfh87p43VU+69tIJPoMEfrVHWdVDZkmfBPAHc/QV2Hw20KawgudW1VTBcXSYSN+DFCOct7n+goRNR+zotS6nVXVxb2tq1zezxwW6cM8jbR9B61zzeOvD6uQJrllH8awnH1rhNb1WfxLqTXc2RZIxFrCeip2Yj1PWnx6VcvCZUtpGjHUhaeiMoYSKX7x6nqenX1lqlsZtNuY7lF+8FPK/UdqsHOeeteMQ3F1od7Hf6exjmiILp0Ei91I717DZXcV/Y217b58q5QOo9M9RSa7GNeh7LVapkhG7IPIIII9a4/U/BNpLdSS3dzHb20hyodguPzq3438SvoSRWWnKrapcLv3NyIU/vEevpXm8kE19N519cS3UxPLStk/hVRk463NMPRm1zp2R6pb2OhzaWumQXVlMiDGwSqWNalnZx6fbR28SBI0GFXFeLS6Ui8hMHswGMV1/gHxFOl4uh6nK8iyDNpKxyQRzsP1ApN3HVw0lFyUrnoGcGkPHWk5BPc0E/rUnEGcc1wnxP02b7Rba5bIZIo08q4CjJUdm+ldznpj/ABpykjKsAVIwwI4IoTsaU6jpyUkeR6fqu2IGJwQffNP1DWAYy0j7VAOdxrtdV8EaHfymVIpLKU8lrZtoP4dKNN8D6Fp9wtw0Ut3Kv3ftL7lHvinc7frFF+91MH4baXLc6hJr9zCUt0XZabxy5PVx7e9d9vb1P51If4cKAFGFA4A9hRkUrnHVqOpLmZYzgjpjpikV1LsgOWA3EdwPWuR8TeMRp1y9jpUSXF7Gdss0nMUZ7gDua5p/FHiSXH+niPk/chUE/p0quXuXDC1Jq+x6ptGfl7H16UoYnvn8a4XQfHMn2lLXxBGgU4UXcY24PbePT3Fd2wwccH6H9aTi0Y1KcqbtJCY9DxSDA6HGaXg4x09ar3t1DY2dxeXbbbe3Qu574Hb8elIhK+hY+6hcsEQfxE4H51Wi1GwuJfKi1G2ll/uCYE15Bq2qX3iS5NxfsVg/5Y2w+5GvbI7n3qqbCIqAI14PHFVZI7o4LT3panuqJ+/VWHfPNeLLM95qt/dzktNLcPuJPQA4A/ACug8D+JZ9N1GDTtTmaWxlbZE7nLQt2GfQ1m+LNKn8Pa3cPIrHT7mUyQzfwqW6qfQ5oatsXh6bpTcJbvYfbReY3tWhrNk1j4YknDANOwUkHsTWJb3wAGCCPrWhY3UmtC60aPdJJKFaArkqCBk7j0HPrUpG0000+gujrF/ZpaVcpG4ArotLl0e4tZILyJUk5Kv3+lchveyZtPuFMdxA37xT6+v0qbdnGMc9fpTZE4c3UluFVJZUjOUB+XJre+HDNu1mMH92rRuBnuQf8K5e7u44IWdyFA/X2ru/BGly6bogku1aO8vJPPkTuoxhVP4c/WiJGIaVOz6m+pz60AEZy3f9PSjPOf60ue5oPOF47Hj3pD6nijPTmk4xnBpAIcD24pC2KCfTtSoN8gUdCe9AjC8VeIjo0cdvaqJNSnBZQ3SJf7x/oK4O6kvr1/MvL+5lkPXDlR+AFT+IZ2u/F2qSc/u5BCPYKP8A69bfhrSI9Qd2uHKQxjJA6k1Wq2PThGNGCk9zG07WNV0eQPb3Mk8Q5aCdtysPqeRXpGj6lb6xpyXtoSFb5XQ9Y27g1y/iDRIbOLzbc7ojwVYZ5qv8OJXh8RXdjyYbiHzSPRlI5/Wq+LRmVWMKkOeO6Or1/WbPQ7RZr0l3k4igj+/Ifp6e9cPd+M9buWJtVgsouwVd7fiTWXq13JrHiG+u5zkLI0MQ7IinAA+vX8a2tM8O3N5ZG6UKkPQEnlsUm7aIuFGnTinPcpQ+MPEFs4Lzw3K5zsljxn8R0rs/DPiK18QQv5afZ72HmW3Y5wP7w9RXE6jp7Wxw469Kz9CuW07xZpc8f8cwgYD+JW4IpXvoy6lCE4txVmeo6tpGn6zCE1O1SYqPlfo6/Q1zcvw6sI8OdWu4Ic52uV/LNafjXxEPDtskNuqy6nck+Sp6Io6ua8vuFn1CUzajPLdTk8tI2fyHQUl5mWHhVcbqVkeqaL4W0WwkFxYQx3dynSaWQSFT7DoK0ddSWTQtVWPPnNbSAeudprxhbJraRZrZpIJU5R4mKn/69eheAfFUuoTHS9XYPeKpaGYgDzlHVT74p+gq1CcffvzWOM8OCGT7MHA2YXivV9PuEYYjZFhReV4xivMfEmkT+GdQkZY5G0qRi0MqgsI8n7remPWoF19RBgXKAeoakbVaft0pRZZ8UvF9tumjx5eSc+ldr8PkZPBekLLn5lLD/dJ4rgdJ0q78V3IjtldNP3j7RdsMLt7qvqx6V61GkcEccEChIYlCIg/hA6UzPEyUYKn1PJfFxaTxzrBl+8roq57KF4xW94MsYb25kEiqzou5VPen/EfRJzcrr1jG0g2BLuNRlgB0cD+dctYalsAeGTg4OVNJm8X7SilE9E160sVtDhESXpha86hUt4o0ZbXPmfbEA9cA8n8s1LqGsfL5k8uADnLV0/wx0WaW+Ou6jE0QIMdnG4wxB6uR29BQSl7Cm3Jmn418Wpod39h0+FLjUmG9ix+SFT0J9SfSuSg8b+I4pS87Wlymc+W0e3j69qxXlkv9U1C8ueZpbh9x+hwB+QroU8NXr6eLvYNjLkL3x61TdtBxo0qcUprU7Hw1r9t4htmeBDBdRHE1ux5HuPUe9bGCRycV45aXcmia3aX8ZICuEmXsyE4Oa9lJUkNGdyMAyn2NS0cmIpKm/d2Y3HFKRzQQAMAD2pCRuwPrmpOYXimYHqfzpx4BOCfpT9p/vfqaAPG9HtxtDPlpH5dickk967OHw2z6clyGXcwztrjNOmeCY29wpjuISUkQ9mFdPba1IluYlkwh/KrPVrc9/dMTUrJQrI6gqRg16H4FmmvvCtm1wS8kRaEk/wB1Txn8K5Yz262s9/dDMUX8Pqew/EmsN7/Ub6wkRpZILd23eRCdq/j3NNbWZFSDrRS7HsQjZvu4b/dIOK5X4m+Z/wAITeFBx5sXmf7u7/HFed26TWrCSzurmCQcgpIf69a7Dw34l/tUPoHifbNDeKYo7jGCx/ut7+hoUU9jL6tKi1PdI5XS1jd0D42EjJ6cV6Pq82kTaK6RpCo2ARhRgg15rrOl3vhe9a2v0drMNiC6Ayrr2yR0PsaiOsxiP/XLjr1otodNSl7VqUWN1jCQOw4ZSCpHqDxXtW1brT4kvYlkSWFDJHIMgkqM5rzPwj4dutbvoL6+hkg0iFhIN4w1yw5AA/u+pr1JmLMSR16/0pPRWOTGTV1Fbo5tvBPh0yeZ/Z5UddqykKfwrbsrK1063MGn28VtEeojXr9T3qbBNKoI69vakcsqk5K0ncx9f8P2GubXug0VygwtxEcPj0PqK54+BJgx8vWiFz1aLnFdyfXHOehrmvE3i610WdrS3i+3aj1aMNhIv94+vsKErm1KpV+GBJovhLTtNuFuZWlvrpOVkuPuofVV9a6Ikk5bkmvNT471wPu+y6ft67drc/jXT+GfFtrrUi2c8P2LUT91CcpJj+6f6Gna+w6tKtbmnqdFjFKAM0pznHp3xR1x6dKk5g9aCe/el/zxTTx+PcmmA0jknH40LkfXrUGo31npsHnalcxW8bDjeeW+g6mseLxnoBn2i7lXPG9omC/ypqLKUJS1SOW8aWn9n+LJZcYgv1EqN2LgYYfyq7oOoi1b5ydp64rrr+x0/wASaQ0TSrPak7o5oWBMbeo9DXE3HhLXLJ8WqxX0P8LBtjY9we9HqdtOpGpDkm7NGtrmspcQCKEfL0yar/DmFpvEV7fDiC3i8o+7MQcfkKqWfhHXLxwLxobCA/eYtvfHsBxXd6VYWuk2EVnYoVhQkkscs7HqxPrVJ21JqThTg4Rd2zyrULWTR/EN7Y3O4bpWliY9HRmJGPzxXQ2PiB4LH7KCNnUH0Peuu1zSbHW7cQX8RJX/AFcqnDxn1BrjpfAV6jFbTV4XTsJoyGH5VNylWp1YpT0ZnapqJuBlu38qq+DbGTV/FNvcRx7rOwbzZpOgL/wqD3Pet+08AF3DatqjSx94rdduR7sa6+ztbewtI7SxhS3t4/uog/U+p96kdSvCMeWGp5h48uXu/Hd4smQLaNIYx7EZJ/OtbwlZ2s8xa4AYpyAelTfEbQ5JJhrlihcqgS6jUZOB0cD271zmkakIiHhkHI60bmsffopQOv8AE9tD5G6NFwDngVxNu7W3iHSp4SfMW6jCgd8nB/Qmte/1oNa7XcYxyTVjwNokt/qEevXwEGl2hLwGQ7fNbGN3+6PX1qkhR/d03zno8nEjrgFCSCp5BrPOj6SJzKul2ZkJ6+WKybrxv4fhkdUnnuTnLPDESue/PetfSNX0/WYmfTLlZSn34yNrr9QaHFnn8tSCvZpF0YWMKiqka9FUYA+gphUBmYDDHv60/sQO3pQdoVnkZY41BLsxwAKRAgYqTn8R61z2peD9Av5Wmk0/yZWOS0DbPxrM1Xxy/nGPQraKSJTj7RcA4f8A3R1x7mqtr461GGTOpWNvcQHqYPlYD2B607HTCjWj70dDe0zwdoOmyiWKxM86nKyXDb9vuAa6KOQmVXOMjgD0qpYXlrqljDe2MnmW7nIPdW9CPUVYxyAcY71JhOUpP33qeSX9t/ZvifULWThFmMq+hVuR+HNehWupWc2mBpJUBC/d71R8e6DLqltHqGnpuv7VdpjHWWP0+orz631AEFS5RhwyNwV9sVW53qKxEE76of4idJEunAAU5xXq2gMX0HTJH4ZrdCffivJYrWXXNQh0zT8u8h/euOREnck17LHGkEMUEX+rhQIv0ApMnFtKMY9R27BAPQ0Z7ZoIP4Vj+JvElj4dRBOrXN7KMx20f3iPVv7o96SVzijFydo7mx9en86Xc/v+dec/8LF1AS7hpFp5P93zTu/OrX/CyV/6AMv/AH+FVymrwtX+U6PxH4T0/XJvtTM9pf4wZ4v4/wDeHeucHgXVVbEeqWTL0DGNgfyzXog6enc4piryeOnFStBQxNSKsmcNrvh5NI8HXTz3b3Mkboz7V2qPmA6fjWPpbQyxlMrg8DFem3dvDd2c1rdJvgmjKSD2P9f8K8n1bR9R8M3GydHmsc/urtBkFfRvQ07nTh6ntE4t6mrd6dbrbs5cbh/nFcxqW5IfMT/WI6shH94MMVak1hJodu8v/uAmtnwx4XutXvYLzUoZLXS4nEiq/D3DA5AA7L3JoSs7nTzezjebPTJf3sCLcKrB41Low3Akjng1Qj0jS47kSxaZYrKv3XEK5BrQlJdi2cHuPSm4yecD6UPV3PHUmtmK0hbknNA+bt+dKB6dKUdDj1pCDvzRwfSjOT1GO3vRjkA/5NAirqd5/Z2lX97gF7aB5QP9oDj9a8c0yAyAySsXllJkkc9WY8k17JqlmNR0u9ssgG5heIH0JHH6149pkrw7oJ1Mc8LeXIjdVYcGn0PQwduWVtzopdCuBYpciImL1Fc5qMLRjzIWKTxnejLwVYdK6weIJjYi2JBQDArltYuljgkc/XHcmls9DopObdpHrmj3w1PSLG/GB9ohVyB696t//rrB0+a38KeDNMXVpPLaKEL5Y5d3PO1RXOXPjrVZ5D9gs7e1i7CQb3x71bWp5yoSm3yLQ9Czz1+lVdWvotL0y6v5+Y7dN23+8ew/OuN0/wAe3ULhdZs0khP3pbcYZffbWt8QJI73wFPdWUgmtneOUOvOV3DNCj1D2EozUZrc4KWW41O7a+1F/MuZOcE8IP7qjsBUiafJIh8uF2QdSF4FNsmBYEkV6Jpep2qacYE2o20jBH3qW56FWo6SXKjz3SdQufD18LuyyYSf38GflkXv+Poa9ctbmG7tLe6tWLQToHQn0I/nXlWu+Ws0mBgEZNdx8P8AengrTvNz8xdkH+yXOKe6OfFxUoqp1Oiz78fypjbsjBAGefp7U2TO3KpuORgZp5HBHqCKk4TLOoWM2ppAL2RJYiR5aybUY/7QHWtFsK2euRXml54Q1h9XJhA8tnLGXfjjOa9Kt0KQxxk7nVQCRzmrnGKtys1qQjFKzuIx96QHnjtUjQvj7pxUYXn6etZmYZK9DXO6j4O0W+maYwy20rHJNs+wE+pHSujI4H0pjdAD245oKjOUHeLsc9p3grQ7eUF7eW9cnj7S+4D8Olcv461uXV9Vl0m2YppVkRGyJwJXA5z/ALI6Yr0uAkPwOQpx+VeKaWSxkduXaVyxzzksapOyudmGbqSc5u9i3Bp7uhMULOFHJUdKrK01hcx32nSmK5hOVYDGfVT7V6b4ceKLRo1jVeQd/vXC6+EW5nKY2bifSlexvTrc8nFo9K0jUY9W0m01CNdonTLIv8L9GH51znxLunS1sNNjOBdkvOR1KL0H0zVv4bxOng2zLA/vZZZFH+yW4/lUHj3S5bnVNOuBLEgSJozvbGOc0ddDipxjGvbornIwxDbgDr27VYurRVt1yxDnBypwa0f7Gu4bU3PlrLAvV4zu21nXLg85yD0xSO5S5noaHw6umttevNMB/c3UZmVeyuvUj6ivQMZxXnnw/tzc+KJ71f8AUWcJTce7t2r0PoBkD8KbOLFW9poAOGJDEY7Vnajo+k6jJ51/p9vPL3cr8x/LrWgT8wBP4UKD0JJ5Jyf5UjCLcdUV7GxtdOj8nT7WC2iblhGuCan9iKd3IzzSZ59qQNtu7HwAeYAxOME8968NuLmTVdYv9RuDmSaZsZ7KDgAfhXuUBAkBIyM14rqVidI8R3+nSAqElMkRI+8jHINUtjswNuaXc0LTQ7q6tWmii3IBmq39l3P/ADzaus8Oa2sFmYGAVau/2jB6foKEjV1qik1Yn8F+JJNaV7DUgv8AaEK7g6fKJl9cdj61038Rzn2FeU+HZGt/GekNH/HIY2x3UqcivVgCJJCzlwTlQQBtHoMdfxpy6M48TTVOfu7McBz3oJ+VlP3SMMpGQfwoAx1ye1L6kCoOchgt4LY5t7a2h7/u4lWpXJLElix69aT0znFQ39ytlZ3V3IAwtomlx64HApj1kzL8ReIrHQh5c+Z75wGS1jPzY9WPRRXJyeO9Ydi0FnZQx9gVZj+ea5uz8y8le9vHaS5uD5rsfU9B9K67TfCk11aiZ5lhL/cUrkkepqr2PQ9jSpL39WWtI8dxySrDrlqLbcQBcQnKZ/2h1A967TaOMMCG5DDoR6ivIdSsHgllguUwynawPf8A+tXafDe+ku9CntZ3LyWMvlqSf4COB/OnpJGOIoRjHnhsdSgCoAAAoGABwB9KMHDbjuycjjGB6UDrTu/86g4xpz26+tcz4q8JW+tzfbLWYWeo4w0gXKSD/aHr710pyH2gHpn2xTs5yccUFwnKm+aLPLJPB/iSOTy0itJVPRxOAv1wea6Lwz4HSzvIb3WZku7tG3RQIP3UZ9Tn7x/lXYd/1p8OBKrds800bTxdSStseTeKL99b8T3MrNm2tGMEA7ADq31JrQ0XQrjUg32fYiL1dzgVgLC9nql9azDEsU7gg+5yDXY+HNaSygaKQblznHvT3Z2VLwglTMHVdOlsZnhuFG5e4rT+HF3/AKRqGg3SCSynjaZEbt2YfjUPiLUf7QuTITwOAPak+HVu03iq7ulB8m1tyjN/tMeBn6U46Cm26LcjJ1zRL3w3dOGjebTc5huEBbav91vQiqcWtQopInUfQ17QTxtwCCMEHvVQWFksvmLZWiyE/e8petK5isYmvfWp5bo+j3/ie5CxpJBp5P766kUj5e6rnqTXrUMUcUUUFsgSCNBHGg7KBgCnDc5AyMDj0Arz3xJ4wuLmeSz0FjBbIxR7offkI67fQe/enuQ3PEyslZI9GELn+E/nTCpU4OQR614xtvJDva8u2c87jKx/rWzpHi7U9IZUvne/sQcOr8yKPVT3+hpWT2Y5YOaWjuemgZLfMFGMsSeAO9efeIfGNzdTNa+H28i0QlWusfPKf9n0Hv3re8bamkfgqW50+UPHebIo5FPO1+v6AiuN8P6b9ru7e1jO3cMZPYUbDw9KNnUmVUu9UjYOmp3wf1MpP6V1fhTxZNNdx6drhVpJTthuVGNx/ut/jWhH4W0yUGBZ5fOHR93euD1q3aFZ0Y4kiJww7EdKOZvc2/d17xSPXXUqxBB4puOMiotNuDd6VY3LHJlgVmb1OKsdDUs856OwkfyOG9PWvKPFOlvoGuzsVP8AZ905lhkH3VJ6ofTmvViOeM0y4ihuYHguYo5oG4aNxlTQa0KvsnfoeX2mqvBAUST5SPWqdlZXXifUfsWn5MWf9Iuf4Il789z7V3b+CPDxl3m0kUZz5azMFPtjNb9lBBp1k8VlBHBDGjMI41wM4/U0XOmWKhHWC1ON8VeIG01o/D/hwiJbWJYpbgcmMY4Rf9rHJPvXKiz+0Ltnkkmk67pHLH9aj0vM0RuJG3SzEyOx6liSa6LS4rY2MjScSgnnvjtTu9kbqKpR03Mazn1HQiW0+ZkU/ehb5o3+orVXS7vxHEt1oqR26SHZN5h4ibvgd6qO5kXrkfTmtDwBfSW3iKfTWb9xdRmQr0Cuvcfgad7iqXUXOK1Oy0PS7fRNKjsLY7gpLPIcZkc9TV7OPbnB+tCkMMggg9x6UvoRzz1zUnmNuTuxhyWwenXNKoJOMZ4yPWmzzQ21tNdXb7LeFSzk9sV53qPjDVtRkP8AZ7f2daZ+UKAZGHqT2+lFjSnSlU+E9Gwfujg9aoaprWmaQQupXqQykZ8oAs/5CuItvFWtWFpKXuY7iSQiONpUBZff3xWFDaPdTySys0lzId7u55c07Jbm8MI7++9D1LTNf0jU32WOoRNKeBG/yN+APWqvjDw1H4hgjZZBa6lb58mYjIIPVW9v5V5rd2KuCJF2svQjgg+xrvPAWuyalbTadftuvrQBlkPWVPU+4o06DqUHR/eU3scPc2WtaXKYL3TrnI43wqZEb6EU3zNT/wCgXff9+mr2NXcZwSB9aPNb++3/AH1RcPrj6xOI+H2jS3GoLrl4my2iUi1VxhpGPWTHoBwK78qzA9h1LHpUOo3kVhazXl4VS1t49zY6j0UD3ryfVNW1DxDcNLdyPDbH/V2yMQiL2zjqfrVPUzUZ4mTlsj1xJYZHxHcQSP8A3RIKlZSvUEV4l/ZyKMom09dynkV0nhvxTc6VMlrqkj3GnOQu9zl4c989xSST2HPCNK8Xc9HwPeq2o2wvdNvbUfenhZBnuccfrVsgHaVYFSPlIPBHY0hzweh9qg5E7O54ppMm2LyZhsliPlup6qQeld/pfiS3WBBdKxdAApXoab4r8Irqtyb/AEyVLa/P+tVh8kvufQ+9cufDniRG2f2ajHoWWdcVdz0pOnXV27D9fvxd3s1xjAc+vb3rf+F1s8elajeuD5d7OPLLdWVRgn6c8VS0zwPdXDrJ4gnSK3B5toG3NJ7M3YfSu7iSOGNIoUWOGMBURRhUA7UXsZV6sVD2cdSTgEAnnHWsTxF4p0zQm8m4MlxeEZ+zwcso/wBo9vxqz4i1M6NoN9qKgGSGPEYP98nC8fU5rx20iknkM07mWWVi8zvyzk0aLVkYbDqreUtjtv8AhY7+Z82i/u/+u3zYrpvD3ifTNecw2zPBeAZNtMMMcf3T3/CvN1s/lztwB7Vn3sUsOyeAmK4ibfGyNyrD3oUk9GjplhKclaOjPcjjqetB/Oqeh3/9q6HYX5GDcRBmH+0OD+tW0JIOV2nNJq2h5jVnZnKeM/DEuqSrqWllV1FF2yRtwJ1HTns1cNPJd2Hy3tjd27ZCndGcEk4Az7nAr2Ue30pHYsArDcuQcEAgY5BoudNPFOC5Wro8qsdE1vVjtt7JrSHo090NoX6DqTXomg6Tb6FpiWVoS+CXllf70rnqxrSLE43Enjuc0nXrjNFyKteVTTZCYyMmkZc5yB1zTj35/GgYbPPI6UjAyfFc8lr4X1eeE4kWBgpHbPBNeWaXCqogXoFwB7V6/qNouo6ZeWUh2i4iaPJ7Ejg146nm6deNY36GK7h+VlbjOOhHqD1qulj0cG1ytdTtbHRFuLPzQRnGcCuc1S3WJnXuM81etdZlgtnjV8gnIFZrm61i9Wx0tTLcOcFh92Md2Y9hSsawU025bGnY20l78J7kLHvNndPJF7or5OPzNUdEvvJlhuIn6YwR6V6bpGnw6TpltYW43QwpsJI4kJ+8T9TmuE8ReEbvT7mS50OM3Ni+WMCn54j6D1FNsypVozcovqzUl8QQ/ZZViiZJpEKCRGwyZ7g9j3rxGXxhqlneXVprCpdursjyfcYn144Pr0rv4k1CV1ii029eXpgxEfqa4/4reE9Q0hbTV71Il+1ExSJGd3lsB8uT3JAP/fNcmKcox54PY+n4ap4SeIeExMU1Pa+912e6uv0PVPBvxC8OajptlZrei0uY4liMNz+7yQOzfdPPvmu4DDaCCCD0x6V8m+GbXS4tasx4rjvIdOnUOHj+XIJ4Y8ZK8EHHNfUuiWGn6dpMEGjJGlhtDRCNiwIPcHnOc9aWHrSqJ8xx8T5NhssqR9g5e93ScflLuu1vmXmHHbilIJFNVdvQAZ6+9P7fMa6T5QidAylWUEHqDT4gBIA3CEbT7jGKC3HI/Ok4zkCgDyaS0bStTutOlGGhkPl5/ijJypH4H9KmDhQFzndxiu68S6DBrsEbiTyL+HiKcDII/usO4rhr/R9bsG2z6e8wzxJbneD/AFFM9OnVjUWr1JzpF9JbiYyRQRsfk38bvxq74N0mWPxY89wdy2kLDI6Et/8Aqptpbanq1tDZajp9xHBE2cnj6V2Wk2QsLZlwRI5BYk5PA4qmkloZVa0opxfUtgcYXA9h0FLn35FIy7lK5ZQ3dTz+FLnHPSpOE5H4n3LLpmnWGcLcymST3Ve35muTiTIHQGun+KUDCDSb1cmOKRonPpu6VzFu3QjrTfQ9PDfwlYn1WzePR7G86wiZo2PoSOD+lJFKFSMKvIxhs10NvPZ3mhXOlXhEayjdFJj7jjoa4/z3tWWK8Xy3Bwd3Q+4PpQ0aU25XT6GnqbI90xTnKj8/pS+DWZPHNoseP3kTiT/drGudTt1Y/vVZuwU5JNdl8P8ASX09LzxBrK/ZyYiIo34ZY+7Eds0rahVahTdztVUuPlGR60mE/wCekH/fYry/XvEOp+IJHWzM1rpgHyxRnDSD1Y9fwrn/AOyx/wA8pf8Avo1Vkt2csMHJq8nY9M+KMjLolhbA4We6G/3AGcVzOm2wfaAAK3PFF23iH4f2WsxxkS20oklQc4x8rfrWFp15HEEkYnyyM5xkAe9Nq2jNaKapWW+p0lx4daO280n5gM4rlb+3GGVhg45z6V2UniHzLbYVByuN2a5W+kUknP3jz3zUWsOg5/aOy+HuoPfaE8MxLTWcvlEnk7MfL/Wujx9K474XREWGqXOCIpZ1RCO+0cn9a7IkHJyPSqlucNdJVGkMOOW7e4pO+c49acSTnI74pepxUmJFEm2NFyTtGCWO4n6nvUgBxxSkdOevU0vcjOP60Ac747sZtR8I6jDApaZAs6qOrbTkj8s15jpE6PGjxng8ivbwSrZ4yP8AOK4bxF4DM95LeaBPHbSSHdJbSAhC3qp7Z9KZ3YWvGKcJaGZHfIttsUA5HesDV7hI4JJMHjge57ACtX/hEvFBYr9itwP7xnXFdH4c8EpZ3cV9rU6Xl1Ed0UEY/dRt6n+8RQkdDq06et7m94UsX0zwzplnMCJo4d0g9C3OP1rU5xwOe1DZYk5GSc0uMcdT/Ohu7ueVJ8zuwAIwTjdjnHSjA6elLjGc/p2oIOKQho6jmlUZJ/PJ6AUc46fjXN/ES9ey8MvHA5SW8kWAMD0U/e/SmlcqEXOSiupl6x47C3D2+gwRzhCVa5lPy5/2R3HvWUnjTX423yfZZk6lGi2j8xWfpViJnSGNQM4AA9K2tT8PS2duJGKt6gdqrmtsej7OjD3WjpvDPiK216JkCfZr5FzJbk5yPVT3FXNW0jTtYiCanaRz7ejdHX6Ec15OZJ9Ovor61JSe3fcuO47j6GvZLa4jvLSC7h4iuI1lX2yM0PXVHNXp+xkpQejOYHgPQhJnbeFM8oZjg10On2Nrptt5On28dvEeoQcn6nvUtxNDa20tzdyrDbxDc8jngCuKufiApnP9maW00A4Ekz7N/uF7UKNyF7WtpqztznHp6cfpSjIIxkenNcro3jeyvJ0t9Rtzp8rnakhbdGx9M9vxrq3BBwelJxsZzhKDtJWAuefmwawvF+hR+JfDl3pk7hGmXKOR9xwcqfzH5ZrcAz70lS4pqzKo1p0KkatN2lFpr1Ry3ibwRpWueHLfS5oxEbWIR2s6j5ocAAfUcDI7/XBry/wt4l1T4b60fD/iaNn0wvlJBlvLB/jjPdT3HUc98g+8MAeScrjmsnxF4e0zxHax2+rWyzxxuHU5IKkdQCOcHoawqUbvnhoz28uzmNOEsJjk50Za26xfePn/AF3vowXEdxBHNbypJDKodHQ5UqRwQakYgjINRwwJBEkUMaxxIoRUUYUAdAB2p4z+NbWPCla/u7DSOevvTl4PPXsDQMnrigdcdf6UEjMnpzjNOUtnr9KaR0JBFPA7nrQA/cxHU1GRzk/rThkjofpSHBIB+tMQiKWcqoOQAay77xFollOYbjUo/OU4YIC2D74rL+IGqz2sFrpdnKY5roF5ZFOCsY7D0Jrio7aGGMIAo79OTVWS3Oujh+ePNJ2PTGOl+KNKubGC8injlXB2H5kPY49q8puobzRL5rHVo/KmX7j/AMEq+qmleBoJ1ntJHgnTlZYzhl/xru/DurW3i6yk03X7SCe+txu+YYEq/wB5fQ+op6W0N1F4e7WsfxRxEl/GkRZ3UKPU11vw80154LnUtSgBhm+S3imXPy/3sHpWxa+EtAtJRLFpqtIOR5jFgPwrcJJK9MAYwBxUmdXExlHlgUrbS9MtpfOttPtYpT/GsYyKzPiFJIng+7KEne6I59ATW8cYA+tQX9vFf6dcWVw+1LhSmcd+2PeknZ3OeM/eUpa2Ob8LWdv/AGK0ioC4XPrzVXd/vf8AfNYtvqF/4Vu5NOvuDj5D/DIvqDUn/CSp/wA8Y/8AvurSOx05OTktUztfAdg1p4Pto7yI5ut00kb/AN1+gI+mOK5HW/C2oaNes+jxS3enOC6og+eH2z39q9PlLsTtfbnoAo6elRqjI+RI5QdQ75I9CDSerucsMRKMnLv0PGn1N0fZJDcJJn7jRtkfhitTSdD1XXpQGhlsrHP7y5nXaSPRAeSfrXq5OWyVQN67cmkJLEFuSvP0ouayxmnuxsyCxs7fTrG3tLKMx2sK7VA6+5Puam79T+NIzKiPIzBIlGWdiAFHc5rktQ8e2EU7RabayX23rKDsTPt60WctTmjCdR6K51hzk5+71AHrSqe/4VxcHjzobnSGCdzE+SPwrqNK1Ky1aFp9On8wLw6HhkPuKHFhOlOHxIu9x1pefwpFyBz0FPzgnnn2pGQ3kH2Pagrkd8E08HjNIcg8dO1ADGwckdaULngfTApWPPTv3rm/HOszaXp0FvYtsvL0lRJ/zzQdSPfnAppXLhBzkoos634l0vR5DDcSvPdA4NvbgMw+vYVjnx7Hv+XSJinr5oz+VcvpelmVwsSs7sc5JyWPqTXSP4XlSFmZl3gdBTul0Oz2NGGkndm5ofifTdXnFvGZLW6P3Yp8Df8AQ9623DKCAMnsGPFeP39ptypyjqcqw6qfWvSfCOpyat4ctrmY5uEJhlY92Xv+VNpNXRlXoKC5o7GsAOoJPFcn8TYC/h23uR0tblXf/dPGa6zOOnTpUN7aw3tnPaXK7oJ0KOPr3qUY0p8k1I820KZY7mJ852nr1rrdRuYvsUnO4sO54FcDd2t14evTZaiGCg/uZ8fLKvY59asPqBaLaX6ds0z0Z0udqSKupY2P24P416N4KJbwdo/mDnyjjPpuOP0rzSC3n17Ul06wy0kh/eSD7sKd2Jr2GCGO1toLW2GIII1iT6KMUdDLGSSio9Tz74l6i1zq0GkRFjBbKJZlzgM56Z9cCqOhaWL6UoSQqjJPel8coYvHF7vPySxROpxzjbg1peFdQt7USCc4Vv4sUM1V4UVyFDxDoaW8bL1Qrgg11ngHUX1Dw4qXDl7iyc27Me4/hP5Vz3iPUobnKW/3f7xrU+F8BXQ7266Jd3R2D1CjGaa2aMq15Uby3OvxnGe1Hv2HFBA9ePY/1oyDx2qDgGgYHCge1NwM9OcdakxTW3EHadreuM/pSAjuI/NiKbim7GSvX6U4nOTwAe1LgYwQM0v+7QMTtjvikxwfT6YpTj3J7U2Vo4oDNcypFAgyXdsAUAIfu4HUD60IfmrnrrxlpSsUtluZyON6phTUtl4q0iecQyzPbO3CmZcKT9arldzT2U7XszfB4OOgpT9KCpU56jqpHeg+h79KRkcF8Romj1+xuOqTW5jGfVTkiszTfJa+ha7XMS8lfX2rvfE2kjW9Ha2VlS5jPmW7n+Fx2Psa86sIbo3b281tJHdRnDoeMH/CnuehQmpU7dUb3iWys22TWSBFI+YDp+Vc7oUklr4u0h4eGklER91bgiurn0mddKSUvGS3/LMcEVjeGdKnvvFlvKY2S3sW853Pdh0Ao2KhNcjTdz0dgA7qMjBoUAEcdaU8sT1ye1Gdoyeg5wKlnnDMHuMe1RscduDUud0YZWBB5BB4x7UxlwDz1pDKd9ZWepQmDULWK4iByBIPu/Q9RWR/whnhz/oGn/v+/wDjXQquDnvSZ/zii5aqSjpFiprWkSSiNNVtC+eAJBzWhj5QykMh53L0IrxVrNMYKLkDGBWt4U16bQr+OCWRn0yU7ZI258sn+JfT6Vsop6I3ng7K8Hc9TA2nGc496Cchv5U+RdpPTBqIg5yexrI4jz74j6lLPqUWiwuVtooxLcAH77H7qn2GM1jafpz3DLFEmXPQAVc8dQNbeM5JW5juYVKk+oyCPyrU8KXUFtcF5cD5cA96rdHqp+zpJxMi906eywLiMpu6AmqtreyaLqcGoQHGxgsgH8aE8g/0roPFeqR3syLHxHGMA965uztZNa1e302AE73DSkDiOMEFmPpxwPrTjdMqL5oXmexPgkFeVPPPvSjtn17VXiu0mvJbZYZV8pAd7r8pHbHvVkDr+nFJ7nkPQRRgDB4xxinEHvnNGMHpS47dc0hDSB+NcJ8SonTUNIuT/qtrw+wbOf5V3pGODWdr2kwa1pUtlOSgJDJIBko46EU1obUJqE02cj4WnhguR5pIB711Mt9ZxI7NcAsvGByQfSvPL6x1TRJNl9bM8WcLcQjcrD146VU/tMSNhFlkOeioST+lP0OyVD2j5ky7qsyyTyOOASWOOwrsPh3btD4XSRxxczPMoP8Ad6D+Vc1o3hjUNbmD6hFJZad1bdxJKP7oH8I9zXpMUMcMUcUMaxxRqERFGAoHansjPE1Eo+zQhHHU59aQDPHH4U9umQMEd65/xvq8mj6Hm1YLe3T+TE393+834CkldnJCLm1FEniDVtBtUaz1qaGbd1g272Hvx0rl7K18BahOix+ZA78hJXdFPtk8frXO2lgvLHLO3JY8lj6k+tTzachGGTIx0p3iuh6UaCgrKTPU7DTbPTLbyNPtoraE84jH3vqepqZ/72TgAkqO4/z/ADrgPBmuTaXfw6XeymSwnbZEznJic9AD6GvRGBVjkjA4HalJdUcFaEoStLU5TxzoDazYx3Voyrf2inZnpIndT/SvNftbW5C3MckMnoymvctjc+WMjrj0qLyY0lc7I9rHOCBgUrm9HFezjytXPINJ02/8R3K29nFJHbZ/fXLqQqL3x6t6CvXLK2hsrKC0tIylvAgSNfYd/wAasbvlALKAOw6YrP1/VYdD0t72VfMcnZFFn/WOeg+lNa6Izq1pV2opF1gI4g0hSGNe7EKKZDJDOSIJ4ZfZHBryi+mu9Wm+0apO0zk5CZwieyiofsiROHh/dyDlWQ7SD9RR7pqsG7ay1PYGBBOc0hznHvXKeCfEU9/O+l6mwe5RN8Ex4MgHVT7iusGCcAjNS1Y5pwdOXLIac7fxxSE4xx+FUb7WdIsXMd7qNvG46qDuI+uKlsb6x1DJsb2C4I/hVvmx9KOV72FZ2vYtLjBaTCoo3MT2A5ry/XdXl8RXzSMSNOjbbbw54I/vn1Ndz4ume18JatJGxDiHbx1AJAP9a8807bHFGFHCqBTWiOvCwWs2SQwFiFAyeuBRdWeUZZI/lPUEV3Ph6C1TS45vKXzWyX3nJFZPiaS3kkDRbQcc4FKxrGvedrB8PNTlMtxo125cRr5tszHJC91/Cu05615p4Q58cWgTosErPjsMf416SCO5P5VT1OXFRSnp1HjaAzudqKNzMTgAetefa/4pGqThNIQwqvy/a2X5nHsPT3ra+I928PhuO2iYhr2dYif9jqw/KuJghAQBVGOBgelGkUaYaimueQ0tqMLGT+0p9w7ls5/DpXZeEPE0F7Kml3UK296QWR14SfH8j7Vyzw7TtYHjtis2/EkEkE9ru+0RSK6bRzkGi99GdM6UaiseyYA4yeeKcODgUrBm2yFG+dQxwO9Jnkc/jipPLGkYYlBgdce9NOFx608cZI5x+tIw4x6+gpWAiY8kYox/tindCQV47UZP92SkO5k+I9I0+10ORxGkDxcrL3PrmvNNSCm2Zt3ylchh3FbmoaxPdBVmlLYHGTxVHSNNk8Q6ullGMQD57iQdET6+p6CtlHU9OipU4tzZ6vppeTSNOaVm3tbxlvc7atYzjnpSnbuAUAAcADsO1ARuPkPPpUvV3R5Lepm67o9rrmnm1vFPBzHKv3o27EVwr+D/ABBbybbeS2uoxwsm/YfxBr00qeAQeKMDIOAB2pLQ2p4idNWWx5vb+CtZupB9vvLe0hz8wQ+Y5Ht2rs9D0Sy0S1aCxQ5fHmSu2XkPuf6VemkitonmuJEigjXc0jngVyreO7MTN5Gn3MluOkmQCw9QtUk2W51a6slodb1IBJxQq8c7hg561V0jU7PV7czWEhOw4dHGGQ+4q6Oec5HbFJqz1OZpp2YAAHgnHbJp2OOM/nQuTnIxzxnvQTjJPA96QgOBSY5zj3FOIz0HtxWBr/iW30ydrW2j+1X4HK5wseem4/0qkrlRi5u0Texnt9RimiNVO5I41PchQDXnsviPXZX3faoYv9lI+B+ZrT0fxfKtwsGtxxhWOEuY1IVSf7w7D3pqKexrLD1Iq515QE5bBPqTSFVHYY6VKVA9CD0NUdaupLTSLye2QSzRISiep7UktTBJt2RZAAxg/jXFfFGI/ZdIuMfJFOyMfTcOK2vB2pXGq6Ubi7iMbhtuMcHir2u6bHrWj3FjK20SDKP3Vh0NNx5XZm1N+yqLm6Hn2lJGZU3rxkZz9a7bWLOzk0p3WONSi5Ur3rzqGWWwu3s9QUw3kRwwPAb3X1FaU2pO8YUyNtAwFzxj/GlY7alOUpJpmLrYEcDup2lcMCOxHevUNc1uLSNHgvrlPMnmRVjgHV3Iz+AHevOtLsm8Q63DYwqTbxsJLmTsiA5xn1PTFbPxEmM/ie2gP+qgtgyr6Ficn8gKpKy1CrFVJxgzMu/EGu37l3vWt1z8scA2gfj3qfTfFGs6cVF04v7YfeSQfPj2ap9D0z7fcCIsAMZLH0q7rOgLaQF4X3xgd+1LmY26V+RpHW6XfW2qWUd5ZPuibgg9UPcEdjXF/EuUtrGlWx5iSFpsdtxOM034eztb+JbmyDHy7m3MmPRlI5+uDWl8SNLkuLO11O2QySWeVlVRyYz1OPanZGEIKlXSexz+k2y3d1FC7bQTya6LW/D9ra2vmRZXb1J71yFjdj5HifnqGFaN3q9xcQbZZCyAdzxUWOicZuSs9DMgf7N4h0qeFf3gukAA7gnBH5V13xG1uXT1i0rT3MdzdAvLKOqRZxx7k8fTNYngrTm1bXk1B1P2CxbcrkcSS9gPYdc0zx4jHxvIXBw1tGV+nIP65prQJKM6qT6Iw7ewQR8Lg7sk9SfrSSWZjkEsDNFMpyjocMDXVeGrSG5uVSc4Qjuat+KNLgsyDDnaRyvWo13Lddc3Ix3hjWD4n0q+0TVio1DySokHAlXs31BxmuHtxNY3UljfKUuoG2Mp7+jD1Bq5pszWPijSriMEMZhG3urcEV6P4h8PafreFvkZZY+I54+HUeme49qbZk5RoSt9l/gcNBfvHEAshC+xqlf6gsUReaQKB09/wrdf4fzbsRaywjzj5oecU+70nQ/B0cV5f+bqmpyH/R4pMYJHfHQAepprXYpVKV/d1Zf+Hei3FpZz6peRFLu9A8uNuscQ5Gfc/wCFdcY32/dP868qvde13V5S8l5JbIfuxW/yhfqepqBLvWLVg0Gp3ilTkbn3D9aqy7mNTDzqS5pNI6r4npnRNPuRytvdANjsG4zXKW0mGQjkqc/Wt/RPEU+v3Z0PxClklvcRMnmgMHmfsB2Ujryee1ZWpeFdZ0aTEETahag4SSL7+P8AaX1+lKSsa0fcXs56M1v3GphQMRug+cj0HeuevNUMknlaXEsUG7HmkZd/f2q7pun6zdWt8ItPniDQkBpBsP05qroFpEzRm5kVDjAX0PvSXcuKUb3ew2a/1hZw0OqXiMvA+fIGPau08G+In1mOW01AKup243MV4Eyf3gPX1rn9U0W6sCXdA8LdHXoazNJnaz8WaRMhI3TeU2O4bqKd76MidOFSGiPVsdT6c0jDt2NSuNjsOeD0/Gm7SGJySD0GOlQebcj2569R3pu1vf8AOpipyMfoKPyoA4+1+HsQkJvNVnmjB5SJAh+hNddpenWulWn2XT7ZYIc9urn1J6k/Wr2MZwPfiopXEMEkrDCxoX/IZrQudadXSTOU8XeK20yY2Olokl6BmWVuVhz2x3b+Vce+o6vc5kl1O8Zuo2SlQPwFVNPDXebmUl5ZiZHY9yTmuq0bQ5b5WYYULxnsabdtjvUKdGOqKujeLtQ06RV1NmvLP+IsMyJ7g9/pXo0TxTwRT27h4ZFDK4PUHpXm+q6c1rI0bDkdMCt74bXDNp99Yu2RbTZjHorDOPzzT+NGGIpxcfaQM74j3TT3lnpSkiJV+0TAHhj0UH+dYkFsSoIXHvWn4tw3jW6B4xDEOe9b2hWCTQEn6c0maqapU0cnazXOjXyX1ocunEiE8SL6H+hr0+xuUvLG3u4sbZlDjBzj2zXF+ILFIJNqcjGfpWn8OZS2jXNselvOQvsDzj+dNe8vQxxCU4e0R046n0HvRIQiMx6DnAGacBliBycZx6U/bnpjNTZnEY3ifUzpGjT3MY/ftiKHI/jbgfl1rzq2VYoyxJdidzknJZj1JrsfiSrDSbFsMVW7XdgdMqwGfxNctZSC1u4bgqJPLYMUPQj0p26HoYdWp3IvtUWdpyG9CMUy4CTIy7cqeCa7xdT0C+Hm3EUSydxInNZd++lTzCO0QLuIAPQUcjRUa2uzNLwZemXwlBPeyqn2cMjyM3ACnqSfasu98dQ+Zs0uxa5izzNKdit9B1qjr2BaJpsfFsCJHA6O3v7VTsdN8x1VW6/KBVNrciNKDvORoDxrqMcgA021MPXarEH866Tw/wCIbHW9yW+6G7Ubngk4P1HrXL6noc9ihLEEDAIz2rCmeTT7qG+tn2zQMGVh3HcH2pKSk7Mp0KdSPubnp+r6NYavGE1G2SXb91+jL9D1rCXwHpAlJZ7x4uuwzHBHp611g/eIHUnDgNg9sgU7bjNTaxxRrTgrJlWwsrTT7Vbewt47eAfwoMZ9z/jXJfEfT3D2mrRqSkS+TcYHRc5Vvzz+ddttDKeDz+dOdBKjI6BkYbWUjIIoQ6dVwnzHlmiag1ncpcQkEjtngitvWteF5beXGgQY+YDv7Uan4EdZ5JNGuxCrHcYJhlVPse30qvaeB9QuHH9p38UUP8S2wJZvbJ6U/I7HKjJ87ZV+H0DXfiW5v0z9ntITCW7M7YOB64A/WvRcfxcdMH/Cs2STS/C2jxq222s4xhEHLO38ya5e48e3LSYstNRYs/KZn+Y/gKrlbMZqeIlzQWho6l4K0y9naa386xkbk+QcIx9StQ2ngLTUkDX1xdXajokjbVP1Ap+k+OLa5mEOq2/2N3O1ZFO5Cfc9q65h0PY/kahxsKVStT92TIIIIreBILeJIoFGFRAAAK5jx9os19bQajYp5l3Zgh0HWSLuB7jrXR6jeWunWrXF/OkMA7seT9PWuYk8f6ekmLeyvJkH8eAv5A0KLJoqpzc8Vc5PTb9AqvBIMexwR+FW7vUJJwfMYk4wMnNX2t/C/ii7ZreWXSdUkOChG3e306E/Sp4vh4TIVu9XmeIdVjTaT+NDi1udrqU07y0ZgeF7R9W8XWgVQ0Fk3nzSdhxwp9816s4JLe5zUGk6VZ6PZC206EQxdWPUufUnvVwL61LOKvWVSWmyI1QEgHua8n8RynU/FGoyyMGMD/Z1XP3Avb+teuYxgjH0rzrxxpUmnau+pRqTYXZBkYf8s5Pf2NNIvCSSm77kXhrTVu5sMOF569a6e/0KB7NiqBGFcjpN+9lOJYiPw71q6h4lnurcxbUGSDuHb1p8prVjUc7x2OT1u2CJIR8skZ3Iw42kdDXq+hXjX+iadeOT5k0CM3ucYNeUzxzatex6dYr5lzcHaxHIRe7H2r2CztUs7S3tYseXBGsY464GM0PYWLa5Yp7kquRJy2exH+NeQarZyaPr93ZzZAZzNAx6OhOePcdK9fA6nHSs/WtGstatPs9/GWCnMcinDxn1BpIww9ZU5a7M84fUJ5IBGZCVwB68D/JpvhKzbV/FduyKWtbD97K/bf2X610S/DmJn2tq140OeUCgH6ZrrNG0W10WyFpp8IjhzkknLO3qT3o3OqeIpxi+Tdk/3iT3PNB/XvUmwqMEdPWmyZCkKCT0ApWPOuRsMk+vvTtsnof++ahvrmLStMuby4YtFbxliW5JxXmH/CzdZ/58IfzNVGm5am1OjOr8CuevD/WH6n+dRXv/AB5Xf/XJv5GiikzKHxI8b0X/AI9k/wCuf9a9N8Jf8eR+h/nRRVyPQxfwmV4y/wBc3+6KZ8N/+PvV/rF/I0UUU9mS/wCAyh4s/wCR1l/64R10nh3/AFLfj/I0UUuhNb+GvRGd4o/1yUfDb/mN/wDXZP8A0E0UVcOoP+Azrb7/AI8H/GuY0H/kJv8AWiitY/CcXQvfET/kVLr/AHk/9CFcQn+q/CiisJHoYf8Ah/Mi/iH1p0X+sj/3v6UUU0avZmj4j/5CDf8AXOP+VS6T/rk/3x/SiikzN/Abvi37p+lcHrf/AB7H/eH8xRRUvdBhfhR7An/HvF/uj+VNf/ln/vCiiqluea9yRfv1Ff8A3RRRVw3BbD7P/UCnn+tFFE9xs89+Kn/H/o//AG0/pXLL1f60UUn09D1cN/CX9dSpqH/Hm/8AuCvZdF/5Aenf9cU/lRRUv4TLG/DH+uxw3xf/AOPnSPq1csOr/wCe9FFOWyN8N/Cj8/zKuo/8sf8Arsv8694P3V+g/lRRQ/h+f+Rz437PzEP3Kd/AaKKzPPFPb61neJv+Rd1H/ri1FFDKpfGjx3Sf9Qn4f0q1P/qB/un+VFFansvc3Pg//wAf2qf7gr0f+99f6Ciiol1POxn8T5Dz9wfSiTp+NFFSjlRIn+r/AA/pWKv+ub6iiitqewmbUvQfSo06j6Giis3uN7nOfEH/AJEfUf8AdH868xoopv4Uergfgfqf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view of a normal peripheral blood smear. Several platelets (black arrows) and a normal lymphocyte (blue arrow) can also be seen. The red cells are of relatively uniform size and shape. The diameter of the normal red cell should approximate that of the nucleus of the small lymphocyte; central pallor (red arrow) should equal one-third of its diameter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_33_28183=[""].join("\n");
var outline_f27_33_28183=null;
var title_f27_33_28184="Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection";
var content_f27_33_28184=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/33/28184/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28184/contributors\">",
"     Steven Flamm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28184/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/33/28184/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28184/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/33/28184/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28184/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/33/28184/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     Ribavirin",
"    </a>",
"    is a nucleoside analog which has a broad spectrum of antiviral activity. It inhibits the replication of RNA viruses in cell culture. Ribavirin appears to decrease hepatitis C virus infectivity in a dose-dependent manner [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/1\">",
"     1",
"    </a>",
"    ]. Its mode of action is not completely understood, but several mechanisms may be involved:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depletion of intracellular triphosphate pools through direct inhibition of inosine monophosphate dehydrogenase",
"     </li>",
"     <li>",
"      Inhibition of the 5'-cap structure of viral mRNA",
"     </li>",
"     <li>",
"      Inhibition of the viral-dependent RNA polymerases",
"     </li>",
"     <li>",
"      Altering the balance between proinflammatory (Th1-like) and antiinflammatory (Th2-like) cytokines [",
"      <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Inducing mutations into viral RNA [",
"      <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Potentiating interferon action [",
"      <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     Ribavirin",
"    </a>",
"    has been used clinically in treating RNA virus infections such as respiratory syncytial virus. Since it is an oral agent, is well-tolerated, and has activity against RNA viruses, investigators have evaluated the efficacy of ribavirin in the treatment of chronic hepatitis C virus (HCV) infection, both as monotherapy and in combination with interferon alfa. Combination therapy with peginterferon and ribavirin (and in patients with HCV genotype 1, a protease inhibitor) is standard of care for most patients with chronic hepatitis C who have compensated liver disease. Ribavirin should not be used in patients with renal insufficiency.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    in the treatment of chronic HCV infection will be reviewed here. A summary of recommendations and an overview of the treatment of HCV infection are presented separately. Alternatives to ribavirin that are under investigation are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=see_link&amp;anchor=H5#H5\">",
"     \"Investigational therapies for hepatitis C virus infection\", section on 'Ribavirin derivatives'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RIBAVIRIN MONOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several controlled trials have evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    monotherapy in the treatment of chronic HCV. A meta-analysis of 11 trials (with a total of 521 patients) concluded that ribavirin monotherapy had no significant effect on achieving a sustained virologic response [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/5\">",
"     5",
"    </a>",
"    ]. Ribavirin was associated with an end-of-treatment biochemical response and improvement in histology, but there was no observed benefit on liver-related morbidity or mortality.",
"   </p>",
"   <p>",
"    An illustrative study included 58 patients who were randomly assigned to placebo or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (600 mg twice daily) for 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/6\">",
"     6",
"    </a>",
"    ]: Ribavirin was associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A more frequent decrease in serum aminotransferase concentrations compared with controls (54 versus 5 percent)",
"     </li>",
"     <li>",
"      A higher incidence of normalization or near normalization of serum aminotransferase levels (35 versus 0 percent)",
"     </li>",
"     <li>",
"      Liver biopsy specimens showed improved histologic scores of hepatocellular necrosis and inflammation among",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      -treated patients whose serum aminotransferase levels became normal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, serum aminotransferase concentrations remained normal in only two patients (7 percent) after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    therapy was discontinued, and serum HCV RNA levels did not change during or after therapy.",
"   </p>",
"   <p>",
"    Overall, these data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    monotherapy is associated with a decline in serum aminotransferase levels during therapy and may lead to histologic improvement in those in whom the aminotransferases become normal. However, ribavirin is ineffective in eliminating HCV RNA, although it may reduce HCV RNA levels in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/7\">",
"     7",
"    </a>",
"    ]. Furthermore, aminotransferases rarely remain normal after therapy is discontinued, and histologic improvement associated with ribavirin among those who normalize serum aminotransferases is generally modest [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The absence of a virological response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    monotherapy suggests that it has a limited, if any, primary role in the treatment of chronic hepatitis C. Its use in specialized situations, as in liver and kidney transplantation, continues to be studied [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/9\">",
"     9",
"    </a>",
"    ]. A small controlled trial suggested that ribavirin monotherapy may sustain biochemical and histologic improvement in patients who failed to respond to combination therapy with interferon plus ribavirin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/10\">",
"     10",
"    </a>",
"    ]. Further studies are needed to determine the clinical significance of this observation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     COMBINATION THERAPY WITH INTERFERON ALFA",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     Ribavirin",
"    </a>",
"    improves the rate of sustained virologic clearance when given in combination with standard or peginterferon alfa [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The enhanced response to combination therapy was first demonstrated in two small uncontrolled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In both, the rate of sustained virologic clearance was higher in subjects treated with interferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    than those treated with interferon alone. Subsequently, the efficacy of combination therapy has been assessed in several trials involving patients who had never been treated, those who relapsed or did not respond to interferon monotherapy, and in patients who have recurrent disease after liver transplantation. The following sections will summarize the data regarded combination therapy using standard interferon. Combination therapy with peginterferon or peginterferon plus a protease inhibitor is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=see_link\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=see_link\">",
"     \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Interferon naive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have demonstrated that combination therapy with interferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    can improve the rate of sustained virologic clearance compared with interferon monotherapy in interferon naive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. Two large multicenter trials in the United States and Europe illustrate the findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States trial, 912 patients were randomized to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"       interferon alfa-2b",
"      </a>",
"      (3 million units three times per week) plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      (1000 to 1200 mg daily) or placebo for 24 or 48 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/16\">",
"       16",
"      </a>",
"      ]. Sustained virologic clearance (absence of detectable RNA 24 weeks after discontinuing treatment) was observed significantly more frequently in patients receiving ribavirin (31 versus 6 percent, and 38 versus 13 percent for the 24 and 48 week groups, respectively). Histologic improvement was also more common in patients treated with combination therapy.",
"     </li>",
"     <li>",
"      Similar results were observed in the European study, in which 832 patients were randomized to interferon plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      for 48 or 24 weeks or interferon plus placebo for 48 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/14\">",
"       14",
"      </a>",
"      ]. At the end of the study, sustained virologic clearance was observed significantly more often for both regimens containing ribavirin compared with interferon alone (43 and 35 versus 19 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A sustained virologic response occurred more often in patients treated with combination therapy compared with interferon monotherapy in all treatment groups. As an example, patients treated with 24 weeks of combination therapy were more likely to achieve a sustained virologic response than patients treated with 48 weeks of interferon monotherapy (31 versus 13 and 35 versus 19 in the United States and European trials, respectively). In the United States trial, an end of treatment response (absence of HCV RNA at the end of therapy) was also more common in patient receiving combination therapy (50 versus 24 percent for 48 weeks of treatment).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Variables associated with a virologic response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both studies evaluated variables that were associated with a response to therapy. Two of the most significant factors were the baseline HCV RNA titers and the viral genotype, which significantly influenced the benefit of 48 versus 24 weeks of combination therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The benefit of extending combination therapy for 48 weeks was greatest among patients who had relatively high HCV RNA titers (&gt;2 million",
"      <span class=\"nowrap\">",
"       copies/mL).",
"      </span>",
"      The sustained virologic response rates for 48 weeks of treatment were approximately the same as 24 weeks of treatment in both the United States and European studies (42 versus 43, and 47 versus 44 percent, respectively). By contrast, 48 weeks of treatment was associated with a higher sustained response rate in patients with higher HCV RNA titers (36 versus 27 and 40 versus 28 percent in the United States and European studies, respectively).",
"     </li>",
"     <li>",
"      Similarly, patients who were infected with genotype 1 (which is associated with a poor response to interferon monotherapy) had a higher sustained response rate after 48 compared with 24 weeks of combination therapy (28 versus 16 and 30 versus 18 percent in the United States and European trials, respectively). By contrast, the sustained response rates were similar for 24 and 48 weeks of treatment in patients who had other genotypes (69 versus 66 and 59 versus 58 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Combined analysis of treatment trials demonstrated that a sustained virological response was more likely in patients who remained on treatment for 80 percent of the planned duration (36 weeks) and who took at least 80 percent of the planned total exposure of interferon or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/17\">",
"       17",
"      </a>",
"      ]. Such patients had a significantly higher sustained virologic response rate compared with those who did not achieve these goals (48 versus 20 percent among all patients, 37 versus 8 percent among those with HCV-1 infection, and 100 versus 19 percent among those with HCV 2 or 3).",
"     </li>",
"     <li>",
"      Combination therapy appears to at least partially improve the poor responsiveness to interferon monotherapy that has been observed in black patients. This was illustrated in an analysis of a subgroup of 53 black patients who participated in two clinical trials comparing interferon monotherapy with combination therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/18\">",
"       18",
"      </a>",
"      ]. Among 13 black patients who received combination therapy for 48 weeks, a sustained virologic response rate was observed in 23 percent compared with 42 percent in whites, and 43 percent in Asians. The sustained virologic response rate among blacks who received interferon monotherapy was 0 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Histologic response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlled trials of combination therapy have demonstrated that a virologic response is associated with improvement in liver histology including fibrosis. The effect on fibrosis was emphasized in a combined report that included 1509 patients from three randomized controlled trials who underwent liver biopsies before and after therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/19\">",
"     19",
"    </a>",
"    ]. Three factors were independently associated with an improvement in fibrosis: a sustained virologic response, longer duration of treatment, and the presence of significant fibrosis at baseline. Another report from the same authors pooled the results of four trials of peginterferon given alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/20\">",
"     20",
"    </a>",
"    ]. The most striking finding was that treatment was associated with improvement in fibrosis including reversal of early cirrhosis in 75 patients (49 percent of cirrhotic patients included in the studies). Independent variables associated with fibrosis improvement included lower initial fibrosis scores, a sustained virological response, age &lt;40 years, a body mass index &lt;27",
"    <span class=\"nowrap\">",
"     kg/m(2),",
"    </span>",
"    no or minimal baseline histologic activity, and a viral load &lt;3.5 million copies per mL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=see_link\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse effects of combination therapy reflected the toxicity of the individual drugs, without apparent synergism. Approximately 20 percent of patients required dose reduction within the first 24 weeks in both studies. Discontinuation of therapy was similar for patients treated with combination therapy compared with interferon monotherapy (11 versus 8 and 8 versus 5 percent in the United States and European trials, respectively). A detailed discussion of the side-effects encountered during combination therapy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These results demonstrate that combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is superior to interferon monotherapy in interferon naive patients. Treatment for 24 weeks is comparable to 48 weeks in patients who have baseline HCV RNA titers &lt;2 million",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    and in patients who are not infected with genotype 1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Interferon relapsers and nonresponders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients treated with interferon monotherapy relapse after treatment is discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35768?source=see_link\">",
"     \"Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .) Several open-label and controlled trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    and interferon have focused on this group of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/15,21-24\">",
"     15,21-24",
"    </a>",
"    ]. A meta-analysis of 186 patients from four major European study groups found that patients treated with the combination of interferon alfa and ribavirin were ten times more likely to achieve a sustained virologic response compared with patients treated with interferon alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/15\">",
"     15",
"    </a>",
"    ]. When the analysis was stratified according to the patients&rsquo; previous exposure to interferon, the investigators found a sustained response rate of 52 percent for those who relapsed after previous interferon monotherapy, and 16 percent for patients who failed to respond previous interferon therapy. Because of geographic variations in genotype distribution, these results may not reflect the efficacy of combination therapy in specific populations.",
"   </p>",
"   <p>",
"    Two subsequent large trials, one in the United States (153 patients) and a multinational study conducted in Europe, Israel, Canada, and Australia (192 patients), led to the approval of combination therapy in patients who relapse following interferon monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/25\">",
"     25",
"    </a>",
"    ]. Both studies used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    (3 million units SQ three times per week) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (1200",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    or 1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for patients weighing &lt;75 kg). The proportion of patients with genotype 1 was 51 and 56 percent, respectively. The treatment duration was 24 weeks, followed by 24 weeks of follow-up.",
"   </p>",
"   <p>",
"    The results of the two trials were similar and were combined in the reported analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/25\">",
"     25",
"    </a>",
"    ]. A sustained virologic response was much more common with combination therapy (49 versus 5 percent). A sustained response in both treatment groups was more common in patients who had HCV RNA levels &lt;2 million",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"    Viral genotypes other than type 1 were associated with a sustained response only in the combination therapy group.",
"   </p>",
"   <p>",
"    Although combination therapy caused a predictable fall in the hemoglobin concentration, its overall safety profile was similar to that of interferon monotherapy. In other reports, the duration of therapy (rather than the dose of interferon) had a more important influence on the likelihood of a sustained virologic response [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data demonstrate that combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    leads to a sustained virologic response in a substantial proportion of patients who relapsed following treatment with interferon alone. Although the above studies were not designed to compare combination therapy in patients who relapsed versus patients who did not respond to interferon monotherapy, the preponderance of data suggests that patients who relapse after interferon monotherapy represent a select group with a favorable treatment profile. In addition, combination therapy may be of particular value in patients who relapsed following interferon monotherapy who have genotype 1 and in those with a relatively high viral load.",
"   </p>",
"   <p>",
"    The response to combination therapy in patients who did not respond virologically to interferon monotherapy is relatively poor compared with relapsers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. A meta-analysis that included nine controlled trials of six months of therapy found an overall sustained virologic response rate of approximately 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/28\">",
"     28",
"    </a>",
"    ]. The authors estimated that 14 patients would have to be treated with six months of therapy for one to have a sustained virologic response. The response rate appeared to be slightly higher with longer duration of therapy (48 weeks) and for those with non-type 1 genotypes. Similar results were found in another meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/29\">",
"     29",
"    </a>",
"    ]. The sustained response rate was slightly higher (14.5 percent) when the first meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/28\">",
"     28",
"    </a>",
"    ] included the results of a subsequent controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/28,30\">",
"     28,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possible benefit of longer duration therapy and higher doses of interferon were explored in another subsequent controlled trial from Italy that compared interferon (3 or 5 million units three times per week) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for 6 to 12 months in a total of 594 interferon nonresponders [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/31\">",
"     31",
"    </a>",
"    ]. The response rate was 23 percent among those treated with the higher dose of interferon for 12 months. The benefit of longer and higher-dose therapy appeared to be confined to those with genotype 1 infection.",
"   </p>",
"   <p>",
"    In summary, these data suggest that longer duration of combination therapy (12 months) is probably best for patients with genotype 1 infection who failed to respond to interferon therapy. Whether the higher dose of interferon used in the Italian study confers a significant benefit is uncertain since similar response rates have been reported using standard doses of interferon combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]. Furthermore, the optimal treatment of patients who relapsed may turn out to be peginterferon plus ribavirin based upon the improved efficacy of this combination in interferon naive patients. The results of these trials are eagerly awaited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Identification of nonresponders to combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients receiving interferon monotherapy, it has been generally recommended that treatment should be discontinued if there is no response by three months, since a sustained virologic response with continued therapy is unlikely [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35768?source=see_link\">",
"     \"Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .) By contrast, different cutoffs for stopping therapy in patients receiving combination therapy have been proposed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=see_link&amp;anchor=H32984769#H32984769\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'Changes in viral load during treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     After liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of combination therapy in liver transplant recipients with chronic hepatitis C is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16474?source=see_link\">",
"     \"Liver transplantation for hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS OF RIBAVIRIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed review of the adverse effects associated with combination therapy with interferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     Ribavirin",
"    </a>",
"    is generally well tolerated. The major adverse effects include hemolysis, and nonspecific fatigue, depression, insomnia, vertigo, anorexia, nausea, nasal congestion, and pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/6,8,33\">",
"     6,8,33",
"    </a>",
"    ]. Anemia (defined as a hemoglobin below 10",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    requiring dose reduction occurs in 10 to 15 percent or patients; the hemolysis is reversible after discontinuing the drug. Use of erythropoietic growth factors can help support the hemoglobin concentration and thereby permit continued use of higher doses of ribavirin",
"   </p>",
"   <p>",
"    Hemolysis typically becomes an issue only in patients who have preexisting anemia, renal insufficiency, or coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, chronic hemolysis induced by prolonged therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    can lead to increased deposition of iron in the liver. In one report, for example, the average rate of hepatic iron accumulation in six patients who had received ribavirin for 6 to 12 months was 1500",
"    <span class=\"nowrap\">",
"     mcg/year",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/35\">",
"     35",
"    </a>",
"    ]. The authors predicted that hepatic iron concentrations might enter the range clearly associated with hepatic fibrosis after approximately 15 years of continuous therapy. Other possible long term complications of hemolysis, including the development of gallstones, were not addressed.",
"   </p>",
"   <p>",
"    As a result of hemolysis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    treatment may be associated with a mild reversible increase in serum bilirubin and uric acid. Neither condition requires modification of treatment.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     Ribavirin",
"    </a>",
"    accumulates in gonadal tissues and can be detected for approximately six months after treatment is discontinued. The drug has proven to be",
"    <strong>",
"     teratogenic or embryocidal",
"    </strong>",
"    in all animal species tested. As a result, it is imperative that patients on ribavirin adhere to strict contraception.",
"   </p>",
"   <p>",
"    Combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    and interferon may be associated with an increased risk of side effects (such as nausea, rash, and dyspnea) compared with treatment with interferon alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/13,25\">",
"     13,25",
"    </a>",
"    ]. However, a meta-analysis and the large studies discussed above suggest that the incidence of serious side effects is not significantly different [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28184/abstract/15,16,25\">",
"     15,16,25",
"    </a>",
"    ]. Ribavirin is contraindicated in patients with renal failure, including those on dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/39/32370?source=see_link\">",
"       \"Patient information: Hepatitis C (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"       \"Patient information: Hepatitis C (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal treatment strategies for patients with hepatitis C are evolving. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"    </a>",
"    .) With respect to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      monotherapy has limited clinical benefit; it results in normalization of ALT and improvement in histologic activity in some patients during therapy, but does not induce eradication of viremia, and any improvements often disappear following cessation of therapy.",
"     </li>",
"     <li>",
"      Combination therapy with standard or peginterferon is superior to interferon monotherapy in patients who have never been treated. Combination therapy with peginterferon is preferred.",
"     </li>",
"     <li>",
"      Patients who relapse after an initial response to interferon alfa have a higher response to combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      plus interferon. Combination therapy with peginterferon should be the treatment of choice in these patients (with the addition of a protease inhibitor in patients with genotype 1). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=see_link\">",
"       \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link\">",
"       \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=see_link\">",
"       \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Combination therapy is less effective in patients who did not respond initially to interferon alfa monotherapy. However, it is reasonable to offer a trial of combination therapy with peginterferon to patients who otherwise tolerated interferon monotherapy.",
"     </li>",
"     <li>",
"      Combination therapy may be useful in patients who develop recurrent hepatitis C infection following liver transplantation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16474?source=see_link\">",
"       \"Liver transplantation for hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/1\">",
"      Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/2\">",
"      Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998; 160:3487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/3\">",
"      Crotty S, Maag D, Arnold JJ, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000; 6:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/4\">",
"      Thomas E, Feld JJ, Li Q, et al. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011; 53:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/5\">",
"      Brok J, Gluud LL, Gluud C. Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials. Am J Gastroenterol 2006; 101:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/6\">",
"      Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/7\">",
"      Pawlotsky JM, Dahari H, Neumann AU, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004; 126:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/8\">",
"      Bodenheimer HC Jr, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/9\">",
"      Fontaine H, Vallet-Pichard A, Equi-Andrade C, et al. Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation 2004; 78:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/10\">",
"      Hoofnagle JH, Ghany MG, Kleiner DE, et al. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology 2003; 38:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/11\">",
"      Chemello L, Cavalletto L, Bernardinello E, et al. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995; 23 Suppl 2:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/12\">",
"      Lai MY, Kao JH, Yang PM, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/13\">",
"      Reichard O, Norkrans G, Fryd&eacute;n A, et al. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/14\">",
"      Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/15\">",
"      Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997; 26:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/16\">",
"      McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/17\">",
"      McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/18\">",
"      McHutchison JG, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group. Gastroenterology 2000; 119:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/19\">",
"      Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/20\">",
"      Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/21\">",
"      Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/22\">",
"      Schvarcz R, Ando Y, S&ouml;nnerborg A, Weiland O. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J Hepatol 1995; 23 Suppl 2:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/23\">",
"      Bellobuono A, Mondazzi L, Tempini S, et al. Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial. J Viral Hepat 1997; 4:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/24\">",
"      Barbaro G, Di Lorenzo G, Soldini M, et al. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study. Am J Gastroenterol 1998; 93:2445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/25\">",
"      Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/26\">",
"      Saracco G, Olivero A, Ciancio A, et al. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. Hepatology 2002; 36:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/27\">",
"      Barbaro G, Di Lorenzo G, Belloni G, et al. Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial. Am J Med 1999; 107:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/28\">",
"      Cheng SJ, Bonis PA, Lau J, et al. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 2001; 33:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/29\">",
"      Cummings KJ, Lee SM, West ES, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. JAMA 2001; 285:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/30\">",
"      Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, et al. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon. Hepatology 2001; 33:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/31\">",
"      Saracco G, Ciancio A, Olivero A, et al. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Hepatology 2001; 34:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/32\">",
"      National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997; 26:2S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/33\">",
"      Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/34\">",
"      Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C: alpha interferon and ribavirin. Hepatology 1997; 26:108S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28184/abstract/35\">",
"      Di Bisceglie AM, Bacon BR, Kleiner DE, Hoofnagle JH. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol 1994; 21:1109.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3654 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-684EC2BD62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_33_28184=[""].join("\n");
var outline_f27_33_28184=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RIBAVIRIN MONOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      COMBINATION THERAPY WITH INTERFERON ALFA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Interferon naive patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Variables associated with a virologic response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Histologic response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Interferon relapsers and nonresponders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Identification of nonresponders to combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      After liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ADVERSE EFFECTS OF RIBAVIRIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=related_link\">",
"      Investigational therapies for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/5/16474?source=related_link\">",
"      Liver transplantation for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=related_link\">",
"      Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=related_link\">",
"      Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35768?source=related_link\">",
"      Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=related_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/39/32370?source=related_link\">",
"      Patient information: Hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=related_link\">",
"      Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15785?source=related_link\">",
"      Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_33_28185="Prevention and treatment of delirium and confusional states";
var content_f27_33_28185=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention and treatment of delirium and confusional states",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/33/28185/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28185/contributors\">",
"     Joseph Francis, Jr, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/33/28185/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28185/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28185/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/33/28185/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28185/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/33/28185/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H25688416\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delirium is an acute confusional state characterized by an alteration of consciousness with reduced ability to focus, sustain, or shift attention. This results in a cognitive or perceptual disturbance that is not better accounted for by a preexisting, established, or evolving dementia. Delirium develops over a short period of time (usually hours to days) and tends to fluctuate during the course of the day. Delirium is typically caused by a medical condition, substance intoxication, or medication side effect.",
"   </p>",
"   <p>",
"    Delirium is considered by some, but not all, experts to be a special type of confusional state that is characterized by increased vigilance along with psychomotor and autonomic overactivity; these features are reflected in clinical manifestations such as agitation, tremulousness, and hallucinations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis of delirium and confusional states\", section on 'Definition and terminology'",
"    </a>",
"    .) In this discussion, however, the term delirium will be used synonymously with acute confusional state. The additional elements of agitation, tremor, and hallucinations are allowed for but are not essential diagnostic features of delirium in this sense.",
"   </p>",
"   <p>",
"    Delirium is one of the most common mental disorders encountered in patients with medical illness, particularly among those who are elderly. It is associated with many complex underlying medical conditions and can be hard to recognize. Systematic studies and clinical trials are difficult to perform in patients with cognitive impairment. Thus, the management of delirium is based primarily upon expert consensus and observational studies, as there are few randomized, controlled trials.",
"   </p>",
"   <p>",
"    The prevention and treatment of delirium will be reviewed here. The definition, epidemiology, pathogenesis, clinical features, and diagnosis of delirium are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BASIC PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four basic principles of prevention and therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Avoiding factors known to cause or aggravate delirium",
"     </li>",
"     <li>",
"      Identifying and treating the underlying acute illness",
"     </li>",
"     <li>",
"      Providing supportive and restorative care to prevent further physical and cognitive decline",
"     </li>",
"     <li>",
"      Controlling dangerous and disruptive behaviors so the first three steps can be accomplished",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These principles are summarized in the Algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef59337 \" href=\"UTD.htm?9/29/9682\">",
"     algorithm 1",
"    </a>",
"    ). The algorithm includes two pathways that are followed simultaneously: one to manage the behavior disturbance; and another to find and treat the underlying medical disorder. The algorithm makes the assumption that more than one medical condition may underlie the disturbance, and that the symptoms of delirium can have a prolonged duration extending many weeks into the post-acute period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS AND CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delirium is a multifactorial disorder. Factors that increase the risk for delirium can be classified into those that increase baseline vulnerability and those that precipitate the disturbance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Age and neurodegenerative disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly identified risk factors are underlying brain diseases such as dementia, stroke, or Parkinson disease, particularly when associated with cognitive impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. These are present in nearly one-half of older patients with delirium. Other factors that increase vulnerability include advanced age and sensory impairment (hearing and vision loss). Elderly patients are at the highest risk for delirium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Polypharmacy and multiple medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that may precipitate delirium include polypharmacy (particularly psychoactive drugs), infection, metabolic disturbances, dehydration, immobility (including restraint use), malnutrition, and the use of bladder catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/4\">",
"     4",
"    </a>",
"    ]. Other factors that increased delirium risk in a prospective observational study included stay in an intensive care or long-term care unit, increased number of room changes, absence of a clock or watch, and absence of reading glasses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delirium is highly prevalent in the setting of advanced cancer. In one study, 42 percent of patients entering a palliative care program had delirium upon admission; preterminal delirium occurred in 88 percent of deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/7\">",
"     7",
"    </a>",
"    ]. Delirium was associated with opioid medication, hypoxic encephalopathy, metabolic disturbance, infection, and dehydration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Postoperative setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delirium is a common postoperative complication in older patients; for complex procedures such as cardiac surgery, hip fracture repair, or aortic surgery, the incidence of delirium many exceed 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/2,3,8-10\">",
"     2,3,8-10",
"    </a>",
"    ]. Risk factors for delirium in the postoperative setting are similar to those seen among medical inpatients: increased age, premorbid cognitive impairment or brain disease, psychiatric symptoms, and medical comorbidity. Other factors linked to postoperative delirium in one or more studies include a low preoperative hematocrit (&lt;30 percent), impaired mobility, abnormal serum albumin, and American Society of Anesthesiologists status of 3 or 4 (",
"    <a class=\"graphic graphic_table graphicRef56098 \" href=\"UTD.htm?8/33/8733\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/9,11\">",
"     9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The route of anesthesia (general versus regional) does not appear to influence the risk of delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/12\">",
"     12",
"    </a>",
"    ]. One study compared the incidence of postoperative delirium in patients randomly assigned to light versus heavy",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    sedation (titrated according to electroencephalography) in 114 older patients undergoing hip fracture repair under spinal anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/13\">",
"     13",
"    </a>",
"    ]. Postoperative delirium was 50 percent less common (19 versus 40 percent) in the light sedation group. Postoperative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    use has also been linked to delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/9\">",
"     9",
"    </a>",
"    ]. Other medications linked to delirium are shown in the Table (",
"    <a class=\"graphic graphic_table graphicRef70449 \" href=\"UTD.htm?1/11/1214\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the perioperative setting, untreated pain and inadequate analgesia are also strong risk factors for delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Among cognitively intact elderly patients with hip fracture in one study, severe pain increased the risk of delirium ninefold [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/16\">",
"     16",
"    </a>",
"    ]. Use of nursing protocols to better manage pain has been demonstrated to reduce the severity and duration, but not the incidence, of delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relationship between pain and delirium is complex. While undertreated or prolonged pain may cause agitation and confusion, opioid use for pain management itself can precipitate or prolong the duration of delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/7,18-22\">",
"     7,18-22",
"    </a>",
"    ]. Additionally, it has been suggested that \"crescendo pain\" may represent a form of delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/23\">",
"     23",
"    </a>",
"    ]. Clinicians therefore must balance the benefits of using opioids to treat significant pain with the potential for an opioid-related delirium. Certain classes of opioids are probably best avoided in older patients and others prone to delirium,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    in particular, which has been shown in multiple prospective studies to increase the risk for delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/16,24,25\">",
"     16,24,25",
"    </a>",
"    ]. Cancer patients with terminal delirium and pain may benefit from switching from shorter-acting opioids to long-acting agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREVENTION STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventions to reduce the risk of delirium by managing many of the modifiable risk factors are effective. In one study, for example, a multicomponent intervention used standardized protocols to screen and control for six risk factors for delirium in 852 hospitalized patients aged 70 or older: cognitive impairment, sleep deprivation, immobility, visual impairment, hearing impairment, and dehydration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/27\">",
"     27",
"    </a>",
"    ]. Interventions were targeted to the identified risk factors. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Orientation protocol and cognitive stimulation for patients with cognitive impairment",
"     </li>",
"     <li>",
"      Environmental modification and nonpharmacologic sleep aids for patients with insomnia",
"     </li>",
"     <li>",
"      Early mobilization and minimizing use of physical restraints for patients with limited mobility",
"     </li>",
"     <li>",
"      Visual and hearing aids for patients with these impairments",
"     </li>",
"     <li>",
"      Early volume repletion for patients with dehydration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This program resulted in a significant reduction in the number of delirium episodes compared with usual care (62 versus 90) and in the total number of days with delirium (105 versus 161), although there was no effect upon delirium severity or the rate of recurrence. The investigators have since reported that community hospitals were able to successfully implement this program when there was a commitment of resources by hospital leadership and appropriate adaptation of protocols to local needs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/28\">",
"     28",
"    </a>",
"    ]. A similar intervention program administered via a geriatric consultant team that emphasized avoiding medical complications achieved a similar reduction in the incidence of delirium among 126 elderly patients undergoing hip surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These studies also support the tenet that sensory deprivation can contribute to delirium. Older patients should be provided glasses, assistive hearing devices, orienting stimuli (eg, clocks, calenders, windows with outside views) and structured activities as feasible for their condition.",
"   </p>",
"   <p>",
"    The available evidence does not support the use of medications (cholinesterase inhibitors, sedatives, or antipsychotic agents) to prevent delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/30\">",
"     30",
"    </a>",
"    ]. Prophylactic use of cholinesterase inhibitors (e.g.,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/26/6567?source=see_link\">",
"     rivastigmine",
"    </a>",
"    ;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    ) has been proposed as a means to prevent delirium in selected patients and high risk settings (eg, older patients with or without dementia, postoperative and post-stroke settings) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. However, clinical trials have not demonstrated a reduction in the prevalence or incidence of delirium, and side effects have been greater in patients receiving these medications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. A few randomized studies have examined the prophylactic use of low doses of antipsychotic agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ) in the postoperative setting, and have reported inconsistent, but at best, modest benefits in reducing the incidence, severity, and duration of delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    , in one pilot study, appeared to reduce the incidence of postoperative delirium, perhaps by reducing pain and opioid administration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT OF THE UNDERLYING ACUTE ILLNESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually any medical condition can precipitate delirium in a susceptible host; multiple underlying conditions are often found [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/40\">",
"     40",
"    </a>",
"    ]. The conditions noted most commonly in prospective studies of the disorder include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fluid and electrolyte disturbances (dehydration,",
"      <span class=\"nowrap\">",
"       hyponatremia/hypernatremia)",
"      </span>",
"     </li>",
"     <li>",
"      Infections (urinary tract, respiratory tract, skin and soft-tissue)",
"     </li>",
"     <li>",
"      Drug toxicity",
"     </li>",
"     <li>",
"      Metabolic disorders (hypoglycemia, hypercalcemia, uremia, liver failure)",
"     </li>",
"     <li>",
"      Low perfusion states (shock, heart failure)",
"     </li>",
"     <li>",
"      Withdrawal from alcohol and sedatives.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of alcohol withdrawal is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug toxicity accounts for approximately 30 percent of all cases of delirium (",
"    <a class=\"graphic graphic_table graphicRef70449 \" href=\"UTD.htm?1/11/1214\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/41\">",
"     41",
"    </a>",
"    ]. Clinicians must be aware that delirium can occur even with \"therapeutic\" levels of such agents as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many older hospitalized patients have biochemical evidence of thiamine deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/42\">",
"     42",
"    </a>",
"    ]. In addition, chronic alcoholism is often difficult to detect in this population, and symptoms of persistent alcoholic delirium may be difficult to distinguish from those of Wernicke's encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/43\">",
"     43",
"    </a>",
"    ]. Thiamine supplementation is inexpensive and virtually risk-free; it should be provided to all hospitalized patients with evidence of nutritional deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10217?source=see_link\">",
"     \"Wernicke's encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the underlying acute illness responsible for delirium is identified, specific therapy is directed toward the medical condition rather than the delirium itself. One exception may be anticholinergic intoxication; specific treatment in these cases has a direct and immediate impact upon acute confusion. The slow intravenous administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40372?source=see_link\">",
"     physostigmine",
"    </a>",
"    can reverse anticholinergic effects. Patients receiving physostigmine should be carefully monitored for bradycardia, bronchospasm, and seizures; some believe that the risks of this drug outweigh the benefits. Anticholinergic toxicity and treatment with physostigmine are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=see_link\">",
"     \"Anticholinergic poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A second exception may be",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    , which causes mental clearing in some patients with hepatic encephalopathy by modulating the effects of toxins binding to GABA receptors in the CNS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/44\">",
"     44",
"    </a>",
"    ]. The response to therapy in these cases has been mixed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4346?source=see_link\">",
"     \"Hepatic encephalopathy in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The delirious patient is at risk for complications of immobility and confusion, leading to a high prevalence of irreversible functional decline.",
"   </p>",
"   <p>",
"    It has long been assumed that the outcome of delirium could be improved by earlier identification of the disorder and comprehensive intervention to treat underlying causes and prevent subsequent complications such as immobility, aspiration, and skin breakdown. Unfortunately, there are few controlled studies. One study found that early identification and comprehensive geriatric consultation for patients with established delirium had little impact on length of stay, functional outcome, or survival [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/45\">",
"     45",
"    </a>",
"    ]; another found that multicomponent interventions shortened the duration of delirium but had no impact on morality or nursing home use [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/46\">",
"     46",
"    </a>",
"    ].The focus of interdisciplinary efforts must therefore be on prevention, for which stronger evidence exists.",
"   </p>",
"   <p>",
"    An interdisciplinary approach to delirium should focus upon maintaining adequate hydration and nutrition, enhancing mobility and range of motion, treating pain and discomfort, preventing skin breakdown, ameliorating incontinence (seen in over half of delirious patients), and minimizing the risk of aspiration pneumonitis. This team approach should also include family or other caregivers who may feel frightened or exhausted; delirium can be the \"last straw\" for those who have been caring for the demented. Caregiver resources must be realistically assessed. Because delirium may require weeks or months to fully resolve, management often extends into subacute settings [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Transfers of care to new settings are periods of particular vulnerability for older patients, and it is important to effectively communicate information about mental status to the accepting treatment team [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGING BEHAVIORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Managing disruptive behavior, particularly agitation and combative behavior, is the most challenging aspect of delirium therapy. This hyperactive delirium is less common in older patients, and when it occurs, alternates with periods of hypoactive delirium, which may be less obvious to the clinical staff [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/50\">",
"     50",
"    </a>",
"    ]. Periods of disruptive and hyperactive behavior place the patient at risk for falls, wandering off, or inadvertently removing intravenous lines and feeding tubes.",
"   </p>",
"   <p>",
"    Physical restraints should be used only as a last resort, if at all, as they frequently increase agitation and create additional problems, such as loss of mobility, pressure ulcers, aspiration, and prolonged delirium. In one study, restraint-use among patients in a medical inpatient unit was associated with a three-fold increased odds of persistent delirium at time of hospital discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/3\">",
"     3",
"    </a>",
"    ]. Alternatives to restraint use, such as constant observation (preferably by someone familiar to the patient such as a family member), may be more effective.",
"   </p>",
"   <p>",
"    Mild confusion and agitation may respond to interpersonal and environmental manipulations. The hospital environment, characterized by high ambient noise, poor lighting, lack of windows, frequent room changes, and restraint use, often contributes to worsening confusion. Special units that address these concerns have improved the functional outcomes of hospitalization in such frail patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/51\">",
"     51",
"    </a>",
"    ]. Frequent reassurance, touch, and verbal orientation from familiar persons lessen disruptive behaviors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptom control is occasionally necessary to prevent harm or to allow evaluation and treatment. A cautious trial of psychotropic medication is warranted in these circumstances. Unfortunately, there are limited data to guide treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7363389\">",
"    <span class=\"h2\">",
"     Neuroleptic medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;While neuroleptic agents are the mainstay of therapy to treat agitation in the patient with delirium, there are very limited data to support their use, in part because effective alternatives are not available [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/52\">",
"     52",
"    </a>",
"    ]. In a randomized, placebo-controlled, study low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    was administered as prophylactic treatment to older hospitalized patients after hip surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/36\">",
"     36",
"    </a>",
"    ]. Treatment did not reduce the incidence of delirium, but did reduce the severity and duration of episodes. This suggests that the medication is effective as a symptomatic but not a preventive therapy.",
"   </p>",
"   <p>",
"    The newer atypical antipsychotic agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    have fewer ' side effects, and in small studies they appear to have similar efficacy to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. A meta-analysis of three small studies that compared haloperidol with risperidone and olanzapine found that the three agents were similarly effective in treating delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/55\">",
"     55",
"    </a>",
"    ]. A small clinical trial compared escalating doses of quetiapine to placebo as add-on treatment to as-needed haloperidol in 36 patients in the intensive care unit with delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/56\">",
"     56",
"    </a>",
"    ]. Quetiapine was associated with a shorter duration of delirium, reduced agitation, and higher rates of discharge to home after hospitalization. In contrast, a randomized trial comparing haloperidol, ziprasidone, and placebo found that active treatment did not improve outcomes in number of days alive without altered mental status or incidence of adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extrapyramidal side effects are higher in patients treated with high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    (&gt;4.5mg per day), but were similar among patients treated with low-dose haloperidol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/55\">",
"     55",
"    </a>",
"    ]. A systematic review of four trials reached similar conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/58\">",
"     58",
"    </a>",
"    ]. Sedation can also occur as a side effect of these medications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/56\">",
"     56",
"    </a>",
"    ]. Newer generation antipsychotics are more costly than haloperidol.",
"   </p>",
"   <p>",
"    Based on limited evidence, it is recommended that low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    (0.5 to 1.0 mg orally or intramuscularly) be used to control agitation or psychotic symptoms. Intravenous haloperidol has been associated with clinically significant QT prolongation requiring additional precautions regarding its use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link&amp;anchor=H4#H4\">",
"     \"Acquired long QT syndrome\", section on 'Drug-induced TdP'",
"    </a>",
"    .) The onset of action is 30 to 60 minutes after parenteral administration or longer with the oral route. An immediate response is not expected. Haloperidol is associated with a low frequency of sedation and hypotension and should be avoided in patients with underlying parkinsonism, for whom atypical antipsychotics are preferred. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21031?source=see_link\">",
"     \"Prognosis and treatment of dementia with Lewy bodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21784?source=see_link\">",
"     \"Management of comorbid problems associated with Parkinson disease\"",
"    </a>",
"    .) Short term use of antipsychotic agents is advised as these agents have been associated with a higher risk of mortality and possibly stroke when used in patients with dementia. [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/59\">",
"     59",
"    </a>",
"    ]. As a result, short-term use is advised. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link\">",
"     \"Treatment of behavioral symptoms related to dementia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7363396\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    0.5 to 1.0 mg) have a more rapid onset of action (five minutes after parenteral administration) than the antipsychotics, but they can worsen confusion and sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/60\">",
"     60",
"    </a>",
"    ]. As an example, in a prospective study of intensive care unit (ICU) patients, lorazepam was an independent risk factor for incident delirium, increasing the risk by approximately 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/61\">",
"     61",
"    </a>",
"    ]. In a randomized trial of sedative treatment in mechanically ventilated ICU patients, the benzodiazepine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    was associated with significantly more delirium compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/53/33622?source=see_link\">",
"     dexmedetomidine",
"    </a>",
"    treatment (77 versus 54 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/62\">",
"     62",
"    </a>",
"    ]. A systematic review of benzodiazepine use in delirium found two studies comparing benzodiazepine versus neuroleptic agents; one study found no advantage, the other decreased effectiveness of benzodiazepines compared with neuroleptics [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/63\">",
"     63",
"    </a>",
"    ]. Surveys of practicing clinicians suggest that benzodiazepines are overprescribed for patients with delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/64\">",
"     64",
"    </a>",
"    ]. Benzodiazepines have a limited role in the treatment of delirium; they are primarily indicated in cases of sedative drug and alcohol withdrawal or when neuroleptic drugs are contraindicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=see_link\">",
"     \"Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7363403\">",
"    <span class=\"h2\">",
"     Cholinesterase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized clinical trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/26/6567?source=see_link\">",
"     rivastigmine",
"    </a>",
"    to placebo in 104 hospitalized intensive care patients with delirium who were also prescribed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    . The trial was stopped early because of higher mortality in the rivastigmine group (22 versus 8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/65\">",
"     65",
"    </a>",
"    ]. Median duration of delirium was also longer in the rivastigmine group (5 versus 3 days, p = 0.06). Cholinesterase inhibitors do not have a role in the treatment or symptom management of delirium. Cholinesterase inhibitors are also not helpful in the prevention of delirium. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Prevention strategies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ETHICAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of patients with delirium is complicated by the critical nature of their illness and their impaired capacity to make decisions. The doctrine of \"implied consent\" allows the emergency treatment of patients with delirium in order to stabilize a life-threatening process [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/66\">",
"     66",
"    </a>",
"    ], but it is important to document the assessment of cognitive abilities and decision-making capacity. Current practice leaves considerable room for improvement. As an example, in a prospective study of 173 medical and surgical procedures performed in patients with delirium at a university hospital, investigators found no documented assessments of competency or decision capacity, and cognitive assessments in only 4 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/67\">",
"     67",
"    </a>",
"    ]. No informed consent was documented in 19 percent of procedures, and surrogates were used in only 20 percent.",
"   </p>",
"   <p>",
"    Relying upon implied consent or substituted judgment in cases of delirium introduces other difficulties since clinicians and proxies do not always make the same decisions as patients. Every effort should be made to determine what the patient&rsquo;s own treatment preferences are, and not assume that decision-making capacity is &ldquo;all or none&rdquo;. In some cases, for example, psychopharmacological treatment of delirium may restore sufficient mental capacity to allow a discussion of treatment preferences [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/68\">",
"     68",
"    </a>",
"    ]. In addition, since delirium typically fluctuates in severity, there may also be periods of lucidity in which a discussion of treatment preferences may take place.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delirium has an enormous impact upon the health of older persons. Patients with delirium experience prolonged hospitalizations, functional and cognitive decline, higher mortality and higher risk for institutionalization, even after adjusting for baseline differences in age, comorbid illness, or dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/8,69-72\">",
"     8,69-72",
"    </a>",
"    ]. Signs of delirium may persist for 12 months or longer, particularly in those with underlying dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/73\">",
"     73",
"    </a>",
"    ]. One long-term follow-up study found that after two years, only one-third of patients who had experienced delirium still lived independently in the community [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/74\">",
"     74",
"    </a>",
"    ]. Thus, although delirium is considered potentially reversible, it is often the harbinger of future problems for frail, elderly persons.",
"   </p>",
"   <p>",
"    Mortality associated with delirium is high. This was illustrated in a report of pooled results from several studies, which estimated the one and six month mortality to be 14 and 22 percent, respectively, approximately twice that of patients without delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/75\">",
"     75",
"    </a>",
"    ]. These findings were likely due in part to the presence of concomitant dementia and severe physical illness (eg, sepsis). However, prospective observational studies that adjusted for dementia and other potential confounding factors still found that delirium was an independent marker for mortality at 6 or 12 months after hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/8,76-79\">",
"     8,76-79",
"    </a>",
"    ]. In one study, protracted delirium (ie, persistent symptoms of confusion at six months) was associated with increased one-year mortality compared with those whose symptoms had resolved more quickly, regardless of whether or not patients also had underlying dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/79\">",
"     79",
"    </a>",
"    ]. Other studies have also found a relationship between the duration of delirium and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/80,81\">",
"     80,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Episodes of delirium may adversely affect the course of the disease in patients with Alzheimer disease. In a prospective follow-up study of patients with AD, a significantly faster rate of cognitive decline was observed in 72 patients who experienced an episode of delirium compared to the rate of cognitive decline in 336 patients with AD who did not experience delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/82\">",
"     82",
"    </a>",
"    ]. Other studies have found that patients with delirium are more likely to have long-term cognitive problems than hospitalized patients who did not suffer from delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28185/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/54/8034?source=see_link\">",
"       \"Patient information: Delirium (confusion) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/57/11155?source=see_link\">",
"       \"Patient information: Delirium (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9728621\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delirium is an acute confusional state characterized by an alteration of consciousness with reduced ability to focus, sustain, or shift attention.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk factors for delirium include advanced age and underlying neurodegenerative disease, particularly dementia. Delirium is also common in the setting of underlying malignancy, in the postoperative time period, and acute and chronic pain. Sensory deprivation and sleep disruption also place patients at risk. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors and causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Delirium may be caused by drugs, systemic or central nervous system infections, metabolic disturbances (",
"      <a class=\"graphic graphic_table graphicRef56098 \" href=\"UTD.htm?8/33/8733\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef70449 \" href=\"UTD.htm?1/11/1214\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Effective measures to prevent delirium include avoiding where possible, those factors known to cause or aggravate delirium, orientation protocols, environmental modification and nonpharmacologic sleep aids, early mobilization and minimizing use of physical restraints, and visual and hearing aids. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prevention strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prophylactic medications (cholinesterase inhibitors, antipsychotic agents) do NOT appear to be useful to prevent delirium. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prevention strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thiamine supplementation should be considered in all patients with delirium. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment of the underlying acute illness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the underlying acute illness responsible for delirium is identified, specific therapy is directed toward that condition as the most effective means of reversing the delirium. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment of the underlying acute illness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical restraints should be used only as a last resort, if at all, as they frequently increase agitation and create additional problems, such as loss of mobility, pressure ulcers, aspiration, and prolonged delirium.",
"     </li>",
"     <li>",
"      Frequent reassurance, touch, and verbal orientation from familiar persons lessen disruptive behaviors.",
"     </li>",
"     <li>",
"      A cautious trial of psychotropic medication is warranted for treatment of severe agitation or psychosis with the potential for harm. In this setting, we suggest using low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      (0.5 to 1.0 mg po or IM) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       Haloperidol",
"      </a>",
"      is associated with a low frequency of sedation and hypotension and should be avoided in patients with underlying parkinsonism, for whom atypical antipsychotics are preferred. Short term use of antipsychotic agents is advised.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benzodiazepines should be avoided in patients with or at risk for delirium, except in cases of sedative drug and alcohol withdrawal or when neuroleptic medications are contraindicated. Cholinesterase inhibitors are not effective in preventing or treating the symptoms of delirium, and often create undesirable side effects. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Delirium may require weeks or months to fully resolve. Episodes of delirium may adversely affect the course of the disease in patients with Alzheimer disease. Mortality associated with delirium is high in both the short and long term. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/1\">",
"      Elie M, Cole MG, Primeau FJ, Bellavance F. Delirium risk factors in elderly hospitalized patients. J Gen Intern Med 1998; 13:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/2\">",
"      Dasgupta M, Dumbrell AC. Preoperative risk assessment for delirium after noncardiac surgery: a systematic review. J Am Geriatr Soc 2006; 54:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/3\">",
"      Inouye SK, Zhang Y, Jones RN, et al. Risk factors for delirium at discharge: development and validation of a predictive model. Arch Intern Med 2007; 167:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/4\">",
"      Pisani MA, Murphy TE, Van Ness PH, et al. Characteristics associated with delirium in older patients in a medical intensive care unit. Arch Intern Med 2007; 167:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/5\">",
"      Rudolph JL, Jones RN, Rasmussen LS, et al. Independent vascular and cognitive risk factors for postoperative delirium. Am J Med 2007; 120:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/6\">",
"      McCusker J, Cole M, Abrahamowicz M, et al. Environmental risk factors for delirium in hospitalized older people. J Am Geriatr Soc 2001; 49:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/7\">",
"      Lawlor PG, Gagnon B, Mancini IL, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer: a prospective study. Arch Intern Med 2000; 160:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/8\">",
"      Robinson TN, Raeburn CD, Tran ZV, et al. Postoperative delirium in the elderly: risk factors and outcomes. Ann Surg 2009; 249:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/9\">",
"      Brouquet A, Cudennec T, Benoist S, et al. Impaired mobility, ASA status and administration of tramadol are risk factors for postoperative delirium in patients aged 75 years or more after major abdominal surgery. Ann Surg 2010; 251:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/10\">",
"      Rudolph JL, Jones RN, Levkoff SE, et al. Derivation and validation of a preoperative prediction rule for delirium after cardiac surgery. Circulation 2009; 119:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/11\">",
"      Marcantonio ER, Goldman L, Orav EJ, et al. The association of intraoperative factors with the development of postoperative delirium. Am J Med 1998; 105:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/12\">",
"      Williams-Russo P, Sharrock NE, Mattis S, et al. Cognitive effects after epidural vs general anesthesia in older adults. A randomized trial. JAMA 1995; 274:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/13\">",
"      Sieber FE, Zakriya KJ, Gottschalk A, et al. Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair. Mayo Clin Proc 2010; 85:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/14\">",
"      Lynch EP, Lazor MA, Gellis JE, et al. The impact of postoperative pain on the development of postoperative delirium. Anesth Analg 1998; 86:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/15\">",
"      Duggleby W, Lander J. Cognitive status and postoperative pain: older adults. J Pain Symptom Manage 1994; 9:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/16\">",
"      Morrison RS, Magaziner J, Gilbert M, et al. Relationship between pain and opioid analgesics on the development of delirium following hip fracture. J Gerontol A Biol Sci Med Sci 2003; 58:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/17\">",
"      Milisen K, Foreman MD, Abraham IL, et al. A nurse-led interdisciplinary intervention program for delirium in elderly hip-fracture patients. J Am Geriatr Soc 2001; 49:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/18\">",
"      Schor JD, Levkoff SE, Lipsitz LA, et al. Risk factors for delirium in hospitalized elderly. JAMA 1992; 267:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/19\">",
"      Inouye SK, Charpentier PA. Precipitating factors for delirium in hospitalized elderly persons. Predictive model and interrelationship with baseline vulnerability. JAMA 1996; 275:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/20\">",
"      Dubois MJ, Bergeron N, Dumont M, et al. Delirium in an intensive care unit: a study of risk factors. Intensive Care Med 2001; 27:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/21\">",
"      Pisani MA, Murphy TE, Araujo KL, et al. Benzodiazepine and opioid use and the duration of intensive care unit delirium in an older population. Crit Care Med 2009; 37:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/22\">",
"      Gaudreau JD, Gagnon P, Roy MA, et al. Opioid medications and longitudinal risk of delirium in hospitalized cancer patients. Cancer 2007; 109:2365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/23\">",
"      Coyle N, Breitbart W, Weaver S, Portenoy R. Delirium as a contributing factor to \"crescendo\" pain: three case reports. J Pain Symptom Manage 1994; 9:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/24\">",
"      Adunsky A, Levy R, Heim M, et al. Meperidine analgesia and delirium in aged hip fracture patients. Arch Gerontol Geriatr 2002; 35:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/25\">",
"      Marcantonio ER, Juarez G, Goldman L, et al. The relationship of postoperative delirium with psychoactive medications. JAMA 1994; 272:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/26\">",
"      Moryl N, Kogan M, Comfort C, Obbens E. Methadone in the treatment of pain and terminal delirum in advanced cancer patients. Palliat Support Care 2005; 3:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/27\">",
"      Inouye SK, Bogardus ST Jr, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med 1999; 340:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/28\">",
"      Inouye SK, Baker DI, Fugal P, et al. Dissemination of the hospital elder life program: implementation, adaptation, and successes. J Am Geriatr Soc 2006; 54:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/29\">",
"      Marcantonio ER, Flacker JM, Wright RJ, Resnick NM. Reducing delirium after hip fracture: a randomized trial. J Am Geriatr Soc 2001; 49:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/30\">",
"      Flinn DR, Diehl KM, Seyfried LS, Malani PN. Prevention, diagnosis, and management of postoperative delirium in older adults. J Am Coll Surg 2009; 209:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/31\">",
"      Oldenbeuving AW, de Kort PL, Jansen BP, et al. A pilot study of rivastigmine in the treatment of delirium after stroke: a safe alternative. BMC Neurol 2008; 8:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/32\">",
"      Gamberini M, Bolliger D, Lurati Buse GA, et al. Rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgery--a randomized controlled trial. Crit Care Med 2009; 37:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/33\">",
"      Overshott R, Karim S, Burns A. Cholinesterase inhibitors for delirium. Cochrane Database Syst Rev 2008; :CD005317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/34\">",
"      Sampson EL, Raven PR, Ndhlovu PN, et al. A randomized, double-blind, placebo-controlled trial of donepezil hydrochloride (Aricept) for reducing the incidence of postoperative delirium after elective total hip replacement. Int J Geriatr Psychiatry 2007; 22:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/35\">",
"      Marcantonio ER, Palihnich K, Appleton P, Davis RB. Pilot randomized trial of donepezil hydrochloride for delirium after hip fracture. J Am Geriatr Soc 2011; 59 Suppl 2:S282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/36\">",
"      Kalisvaart KJ, de Jonghe JF, Bogaards MJ, et al. Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: a randomized placebo-controlled study. J Am Geriatr Soc 2005; 53:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/37\">",
"      Prakanrattana U, Prapaitrakool S. Efficacy of risperidone for prevention of postoperative delirium in cardiac surgery. Anaesth Intensive Care 2007; 35:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/38\">",
"      Wang W, Li HL, Wang DX, et al. Haloperidol prophylaxis decreases delirium incidence in elderly patients after noncardiac surgery: a randomized controlled trial*. Crit Care Med 2012; 40:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/39\">",
"      Leung JM, Sands LP, Rico M, et al. Pilot clinical trial of gabapentin to decrease postoperative delirium in older patients. Neurology 2006; 67:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/40\">",
"      Francis J, Martin D, Kapoor WN. A prospective study of delirium in hospitalized elderly. JAMA 1990; 263:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/41\">",
"      Francis J. Drug-induced delirium: Diagnosis and treatment. CNS Drugs 1996; 5:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/42\">",
"      O'Keeffe ST, Tormey WP, Glasgow R, Lavan JN. Thiamine deficiency in hospitalized elderly patients. Gerontology 1994; 40:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/43\">",
"      Hersh D, Kranzler HR, Meyer RE. Persistent delirium following cessation of heavy alcohol consumption: diagnostic and treatment implications. Am J Psychiatry 1997; 154:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/44\">",
"      Barbaro G, Di Lorenzo G, Soldini M, et al. Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study. Hepatology 1998; 28:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/45\">",
"      Cole MG, McCusker J, Bellavance F, et al. Systematic detection and multidisciplinary care of delirium in older medical inpatients: a randomized trial. CMAJ 2002; 167:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/46\">",
"      Pitk&auml;l&auml; KH, Laurila JV, Strandberg TE, Tilvis RS. Multicomponent geriatric intervention for elderly inpatients with delirium: a randomized, controlled trial. J Gerontol A Biol Sci Med Sci 2006; 61:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/47\">",
"      Flaherty JH, Tariq SH, Raghavan S, et al. A model for managing delirious older inpatients. J Am Geriatr Soc 2003; 51:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/48\">",
"      Bergmann MA, Murphy KM, Kiely DK, et al. A model for management of delirious postacute care patients. J Am Geriatr Soc 2005; 53:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/49\">",
"      Boockvar KS, Fridman B, Marturano C. Ineffective communication of mental status information during care transfer of older adults. J Gen Intern Med 2005; 20:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/50\">",
"      Peterson JF, Pun BT, Dittus RS, et al. Delirium and its motoric subtypes: a study of 614 critically ill patients. J Am Geriatr Soc 2006; 54:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/51\">",
"      Landefeld CS, Palmer RM, Kresevic DM, et al. A randomized trial of care in a hospital medical unit especially designed to improve the functional outcomes of acutely ill older patients. N Engl J Med 1995; 332:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/52\">",
"      Flaherty JH, Gonzales JP, Dong B. Antipsychotics in the treatment of delirium in older hospitalized adults: a systematic review. J Am Geriatr Soc 2011; 59 Suppl 2:S269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/53\">",
"      Parellada E, Baeza I, de Pablo J, Mart&iacute;nez G. Risperidone in the treatment of patients with delirium. J Clin Psychiatry 2004; 65:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/54\">",
"      Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med 2004; 30:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/55\">",
"      Lonergan E, Britton AM, Luxenberg J, Wyller T. Antipsychotics for delirium. Cochrane Database Syst Rev 2007; :CD005594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/56\">",
"      Devlin JW, Roberts RJ, Fong JJ, et al. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med 2010; 38:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/57\">",
"      Girard TD, Pandharipande PP, Carson SS, et al. Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial. Crit Care Med 2010; 38:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/58\">",
"      Campbell N, Boustani MA, Ayub A, et al. Pharmacological management of delirium in hospitalized adults--a systematic evidence review. J Gen Intern Med 2009; 24:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/59\">",
"      Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/60\">",
"      Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/61\">",
"      Pandharipande P, Shintani A, Peterson J, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology 2006; 104:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/62\">",
"      Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA 2009; 301:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/63\">",
"      Lonergan E, Luxenberg J, Areosa Sastre A, Wyller TB. Benzodiazepines for delirium. Cochrane Database Syst Rev 2009; :CD006379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/64\">",
"      Carnes M, Howell T, Rosenberg M, et al. Physicians vary in approaches to the clinical management of delirium. J Am Geriatr Soc 2003; 51:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/65\">",
"      van Eijk MM, Roes KC, Honing ML, et al. Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. Lancet 2010; 376:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/66\">",
"      Fogel BS, Mills MJ, Landen JE. Legal aspects of the treatment of delirium. Hosp Community Psychiatry 1986; 37:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/67\">",
"      Auerswald KB, Charpentier PA, Inouye SK. The informed consent process in older patients who developed delirium: a clinical epidemiologic study. Am J Med 1997; 103:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/68\">",
"      Bostwick JM, Masterson BJ. Psychopharmacological treatment of delirium to restore mental capacity. Psychosomatics 1998; 39:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/69\">",
"      Inouye SK, Rushing JT, Foreman MD, et al. Does delirium contribute to poor hospital outcomes? A three-site epidemiologic study. J Gen Intern Med 1998; 13:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/70\">",
"      McAvay GJ, Van Ness PH, Bogardus ST Jr, et al. Older adults discharged from the hospital with delirium: 1-year outcomes. J Am Geriatr Soc 2006; 54:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/71\">",
"      Witlox J, Eurelings LS, de Jonghe JF, et al. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis. JAMA 2010; 304:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/72\">",
"      Girard TD, Jackson JC, Pandharipande PP, et al. Delirium as a predictor of long-term cognitive impairment in survivors of critical illness. Crit Care Med 2010; 38:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/73\">",
"      McCusker J, Cole M, Dendukuri N, et al. The course of delirium in older medical inpatients: a prospective study. J Gen Intern Med 2003; 18:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/74\">",
"      Francis J, Kapoor WN. Prognosis after hospital discharge of older medical patients with delirium. J Am Geriatr Soc 1992; 40:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/75\">",
"      Cole MG, Primeau FJ. Prognosis of delirium in elderly hospital patients. CMAJ 1993; 149:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/76\">",
"      Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 2004; 291:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/77\">",
"      McCusker J, Cole M, Abrahamowicz M, et al. Delirium predicts 12-month mortality. Arch Intern Med 2002; 162:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/78\">",
"      Leslie DL, Zhang Y, Holford TR, et al. Premature death associated with delirium at 1-year follow-up. Arch Intern Med 2005; 165:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/79\">",
"      Kiely DK, Marcantonio ER, Inouye SK, et al. Persistent delirium predicts greater mortality. J Am Geriatr Soc 2009; 57:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/80\">",
"      Pisani MA, Kong SY, Kasl SV, et al. Days of delirium are associated with 1-year mortality in an older intensive care unit population. Am J Respir Crit Care Med 2009; 180:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/81\">",
"      Shehabi Y, Riker RR, Bokesch PM, et al. Delirium duration and mortality in lightly sedated, mechanically ventilated intensive care patients. Crit Care Med 2010; 38:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/82\">",
"      Fong TG, Jones RN, Shi P, et al. Delirium accelerates cognitive decline in Alzheimer disease. Neurology 2009; 72:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28185/abstract/83\">",
"      van den Boogaard M, Schoonhoven L, Evers AW, et al. Delirium in critically ill patients: impact on long-term health-related quality of life and cognitive functioning. Crit Care Med 2012; 40:112.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4823 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-E4A1FE5218-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_33_28185=[""].join("\n");
var outline_f27_33_28185=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9728621\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25688416\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BASIC PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS AND CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Age and neurodegenerative disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Polypharmacy and multiple medical conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Postoperative setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREVENTION STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT OF THE UNDERLYING ACUTE ILLNESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGING BEHAVIORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7363389\">",
"      Neuroleptic medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7363396\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7363403\">",
"      Cholinesterase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ETHICAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9728621\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4823\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4823|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?9/29/9682\" title=\"algorithm 1\">",
"      Assessment and Rx of delirium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4823|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/33/8733\" title=\"table 1\">",
"      American Society of Anesthesiologists physical status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/11/1214\" title=\"table 2\">",
"      Drugs that cause or prolong delirium",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=related_link\">",
"      Anticholinergic poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/15/4346?source=related_link\">",
"      Hepatic encephalopathy in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21784?source=related_link\">",
"      Management of comorbid problems associated with Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/57/11155?source=related_link\">",
"      Patient information: Delirium (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/54/8034?source=related_link\">",
"      Patient information: Delirium (confusion) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/34/21031?source=related_link\">",
"      Prognosis and treatment of dementia with Lewy bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/29/15833?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Selection, initiation, maintenance, and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=related_link\">",
"      Treatment of behavioral symptoms related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10217?source=related_link\">",
"      Wernicke's encephalopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_33_28186="Bacterial arthritis: Treatment and outcome in infants and children";
var content_f27_33_28186=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bacterial arthritis: Treatment and outcome in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/33/28186/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28186/contributors\">",
"     Paul Krogstad, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/33/28186/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28186/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28186/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28186/contributors\">",
"     Thomas JA Lehman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/33/28186/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/33/28186/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/33/28186/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections of the joints may be caused by bacteria, fungi, and viruses. Bacterial joint infections are most common. The term septic arthritis encompasses bacterial arthritis, pyogenic arthritis, suppurative arthritis, purulent arthritis, and pyarthrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment and outcome of bacterial arthritis in infants and children will be reviewed here. The epidemiology, pathogenesis, microbiology, clinical features, and diagnosis of bacterial arthritis in infants and children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40423?source=see_link\">",
"     \"Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=see_link\">",
"     \"Bacterial arthritis: Clinical features and diagnosis in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of arthritis due to Lyme disease is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of Lyme disease\", section on 'Arthritis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial arthritis requires prompt recognition and management. Delays in treatment are often associated with long-term sequelae. These sequelae can have major lifelong impact if a major weight-bearing joint is involved, particularly when the hip joint is involved in infants.",
"   </p>",
"   <p>",
"    The goals of treatment include sterilization and decompression of the joint space and removal of inflammatory debris to relieve pain and prevent deformity or functional sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Surgical drainage and antimicrobial therapy are the cornerstones of therapy.",
"   </p>",
"   <p>",
"    Clinical decision making in the management of the child with bacterial arthritis includes the following questions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      How should the joint be drained and irrigated?",
"     </li>",
"     <li>",
"      Which antibiotics should be administered?",
"     </li>",
"     <li>",
"      What is the optimal duration of antimicrobial therapy?",
"     </li>",
"     <li>",
"      When is it safe to switch from parenteral to oral therapy?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although drainage and antimicrobial therapy are well-established cornerstones of therapy for bacterial arthritis, there is little evidence from controlled trials to guide decisions about the optimal procedure for drainage or the choice, route, or duration of antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because delayed therapy has been associated with long-term sequelae, treatment of infants and children with suspected bacterial arthritis should begin immediately after blood and synovial fluid cultures are obtained. The synovial fluid white blood cell (WBC) count is used in conjunction with clinical findings to make decisions regarding the need for therapeutic drainage and initiation antimicrobial therapy while awaiting culture results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=see_link&amp;anchor=H28#H28\">",
"     \"Bacterial arthritis: Clinical features and diagnosis in infants and children\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After appropriate cultures have been obtained, empiric antimicrobial therapy should be initiated for infants and children with characteristic clinical and laboratory features of bacterial arthritis, which may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In newborns and young infants: clinical manifestations of sepsis (eg, irritability, poor feeding), pseudoparalysis, evidence of discomfort when being handled, or fever without a focus",
"     </li>",
"     <li>",
"      In older infants and children: fever and monoarticular pain, swelling, and limited range of motion (in older infants and children); clinical manifestations of sepsis (eg, irritability, poor feeding), pseudoparalysis, evidence of pain when being handled, or fever without a focus (in young infants)",
"     </li>",
"     <li>",
"      Elevated peripheral WBC count, erythrocyte sedimentation rate (ESR)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      C-reactive protein (CRP)",
"     </li>",
"     <li>",
"      Elevated synovial fluid WBC (&gt;20,000",
"      <span class=\"nowrap\">",
"       cells/microL)with",
"      </span>",
"      a predominance of neutrophils",
"     </li>",
"     <li>",
"      Organism identified on Gram stain of synovial fluid",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differential diagnosis also must be carefully considered to identify disorders with clinical features similar to bacterial arthritis that do not require joint drainage or prolonged antibiotic therapy (eg, transient synovitis, Lyme arthritis, systemic-onset juvenile idiopathic arthritis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=see_link&amp;anchor=H29#H29\">",
"     \"Bacterial arthritis: Clinical features and diagnosis in infants and children\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with bacterial arthritis should be managed in conjunction with an orthopedic surgeon who is experienced in treating children. Aspiration of the joint should occur as soon as possible when bacterial arthritis is suspected. Joint aspiration provides synovial fluid for analysis and culture and decompresses the joint [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Drainage'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=see_link\">",
"     \"Bacterial arthritis: Clinical features and diagnosis in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systemic antimicrobial therapy should be administered as soon as possible after joint aspiration. Adequate antibiotic levels in the joint are essential. All antibiotics that have been studied readily enter the joint fluid after systemic administration; intraarticular injection of antibiotics (which may be painful) is unnecessary. The joint fluid concentration averages 30 percent of the serum concentration at the time of peak serum concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. In addition, because the efflux of antibiotic from the joint fluid is slow, the joint fluid concentration may exceed serum concentration immediately before the next dose.",
"   </p>",
"   <p>",
"    Consultation with an expert in infectious diseases is suggested for children with postoperative infection, chronic joint infection, penetrating injury, unusual pathogens, or antimicrobial allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/11\">",
"     11",
"    </a>",
"    ]. Most children can be treated with sequential antibiotic therapy (parenteral therapy followed by oral therapy) to minimize the length of hospital stay and complications from prolonged vascular access. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Antibiotic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Adjunctive therapies may include pain control and physical therapy. Some experts recommend routine nonsteroidal antiinflammatory agents that decrease reactive synovitis associated with bacterial arthritis. Administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    for the first four days of therapy also has been explored as a possible adjunctive measure, but adjunctive dexamethasone therapy remains investigational [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Adjunctive therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Septic arthritis of the hip",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants and children with bacterial arthritis of the hip require prompt surgical drainage and irrigation of the hip in addition to diagnostic aspiration. Delayed drainage increases the likelihood of adverse outcome. Increased intraarticular pressure can compromise the blood supply to the femoral head, resulting in avascular necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Additional indications for open surgical drainage versus needle aspiration (or recurrent needle aspiration) are discussed below. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Arthrotomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Home care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of antimicrobial therapy for bacterial arthritis is dependent upon the organism isolated or suspected. For",
"    <em>",
"     Staphylococcus aureus",
"    </em>",
"    , treatment is for at least three weeks. Many children receive a portion of this therapy at home. While they are being cared for at home, children with bacterial arthritis may require nursing visits for wound care, physical therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a wheelchair or walker [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/11\">",
"     11",
"    </a>",
"    ]. During outpatient therapy, follow-up should occur at least every one to two weeks. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Route'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H33\">",
"     'Follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DRAINAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;No studies have compared drainage with no drainage in human patients with bacterial arthritis. In animal models, antimicrobial treatment without drainage does not prevent joint destruction unless antimicrobial therapy is administered very early in the disease course (within 48 to 72 hours) of inoculation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. This time frame is almost never achieved in children with bacterial arthritis in whom the clinical presentation is often delayed.",
"   </p>",
"   <p>",
"    At the time of presentation, joint infections are essentially closed abscesses. Drainage and lavage are necessary to decompress the joint space and to remove inflammatory debris in order to preserve synovium and collagen matrix [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/16,18\">",
"     16,18",
"    </a>",
"    ]. Drainage can be accomplished through open surgery (arthrotomy), arthroscopy, or needle aspiration (single or multiple) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/1,4,19-21\">",
"     1,4,19-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Arthrotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthrotomy (open surgical drainage) facilitates thorough debridement of infected tissue, breakdown of loculations, and irrigation of the joint space [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/18,22,23\">",
"     18,22,23",
"    </a>",
"    ]. However, arthrotomy requires general anesthesia and is more invasive than arthroscopy or needle aspiration.",
"   </p>",
"   <p>",
"    We suggest open surgical drainage for bacterial arthritis of the hip in infants and children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/14,24-26\">",
"     14,24-26",
"    </a>",
"    ]. There are case reports of successful treatment with arthroscopic drainage, but these reports are few in number and generally involved older children or children whose infections involved methicillin-susceptible",
"    <em>",
"     S. aureus",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/27-32\">",
"     27-32",
"    </a>",
"    ]. Although some authors have reported successful management of bacterial arthritis of the hip in older children with needle aspiration if the duration of symptoms is less than four days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/33\">",
"     33",
"    </a>",
"    ], we do not advocate this approach.",
"   </p>",
"   <p>",
"    Decisions regarding the optimal drainage procedure for joints other than the hip should be made on a case-by-case basis. Factors to be considered include the site and extent of joint involvement, duration of symptoms, and the suspected organism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. Based on clinical reports, arthrotomy is the preferred procedure for bacterial arthritis of the shoulder in infants and children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other indications for arthrotomy in children with bacterial arthritis may include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/3,35-38\">",
"     3,35-38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exclusion of radiolucent foreign body in children with penetrating injury",
"     </li>",
"     <li>",
"      Large amount of fibrin debris or loculations",
"     </li>",
"     <li>",
"      Debridement in patients with concomitant osteomyelitis",
"     </li>",
"     <li>",
"      Lack of clinical improvement after 48 hours of antibiotic therapy or persistent positive cultures despite appropriate antimicrobial therapy and multiple needle aspirations",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Arthroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arthroscopy is an alternative surgical procedure for drainage of bacterial arthritis, particularly for bacterial arthritis of the knee [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/39\">",
"     39",
"    </a>",
"    ]. As noted above, successful arthroscopic drainage of the hip also has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/27-29\">",
"     27-29",
"    </a>",
"    ], but the number of cases successfully managed is small and largely involves older children. Successful management of septic arthritis of the shoulder joint of infants has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/40\">",
"     40",
"    </a>",
"    ]. When arthroscopic drainage is performed, the surgeon must obtain a full view of the interior of the joint to ensure that no loculated pockets of purulent material remain after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Needle aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;For joints other than the hip, needle aspiration (single or multiple) is an alternative to surgical drainage (arthrotomy or arthroscopy) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/20,23,41,42\">",
"     20,23,41,42",
"    </a>",
"    ]. However, the discomfort and fear associated with repeated needle aspiration in childhood must be considered.",
"   </p>",
"   <p>",
"    If the joint is thoroughly drained during diagnostic aspiration, a single aspiration may suffice [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/42\">",
"     42",
"    </a>",
"    ]. Repeat aspiration may be necessary if fluid reaccumulates. In observational studies in adult patients, the outcome of bacterial arthritis in patients treated with repeated needle aspiration was better than in those treated with surgical drainage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/21,41\">",
"     21,41",
"    </a>",
"    ]. Good outcome was defined by restoration of joint function with minimal or no residual pain.",
"   </p>",
"   <p>",
"    Aspiration has minimal morbidity and, in the older child, may not require general anesthesia [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/23\">",
"     23",
"    </a>",
"    ]. However, it may provide less satisfactory drainage than arthrotomy or arthroscopy. Because of the frequent need for repeated procedures, this technique is not favored for younger children, who may be difficult to assess and be distressed by repeated aspiration procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial therapy is essential to the treatment of bacterial arthritis. Antibiotics should be administered as soon as possible after blood and synovial fluid cultures have been obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=see_link\">",
"     \"Bacterial arthritis: Clinical features and diagnosis in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few randomized controlled trials evaluating antibiotic therapy for bacterial arthritis. However, in the preantibiotic era, complications of bacterial arthritis were frequent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/1\">",
"     1",
"    </a>",
"    ]. In one series of 113 cases, only seven patients (6 percent) had a normal joint after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/44\">",
"     44",
"    </a>",
"    ]. In the antibiotic era, complications are less frequent (10 to 25 percent) and appear to be related to the duration of symptoms before diagnosis and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/1,23\">",
"     1,23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Empiric therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few randomized controlled studies have evaluated antibiotic regimens for bacterial arthritis. The empiric antimicrobial regimen should target the most common pathogens based on age (",
"    <a class=\"graphic graphic_table graphicRef53150 \" href=\"UTD.htm?2/41/2716\">",
"     table 1",
"    </a>",
"    ), clinical features (",
"    <a class=\"graphic graphic_table graphicRef75192 \" href=\"UTD.htm?14/50/15149\">",
"     table 2",
"    </a>",
"    ), Gram stain, and local bacterial susceptibility patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/1,3,35,45\">",
"     1,3,35,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40423?source=see_link&amp;anchor=H5#H5\">",
"     \"Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Commonly used drugs are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef51833 \" href=\"UTD.htm?10/10/10413\">",
"     table 3",
"    </a>",
"    )&nbsp;. Empiric therapy can be altered when the susceptibility pattern of the causative bacterium is known.",
"   </p>",
"   <p>",
"    We recommend that empiric therapy for bacterial arthritis in children of all ages include coverage for",
"    <em>",
"     S. aureus",
"    </em>",
"    . Depending upon the child's age, Gram stain, and particular clinical circumstances, coverage for additional pathogens may be necessary (",
"    <a class=\"graphic graphic_table graphicRef53150 \" href=\"UTD.htm?2/41/2716\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75192 \" href=\"UTD.htm?14/50/15149\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Birth to three months",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric therapy for bacterial arthritis in neonates and young infants from birth to three months of age should be directed against",
"    <em>",
"     Staphylococcus",
"    </em>",
"    , group B streptococcus, and gram-negative bacilli. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40423?source=see_link&amp;anchor=H5#H5\">",
"     \"Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential regimens include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An antistaphylococcal agent (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/57/26519?source=see_link\">",
"       nafcillin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/59/950?source=see_link\">",
"       oxacillin",
"      </a>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      ), PLUS",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"       Gentamicin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     Vancomycin",
"    </a>",
"    (rather than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/57/26519?source=see_link\">",
"     nafcillin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/59/950?source=see_link\">",
"     oxacillin",
"    </a>",
"    ) should be included in the regimen for neonates who have been in the intensive care unit for more than one week because of the risk of nosocomial infection with methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (MRSA) or coagulase-negative staphylococci. Drug doses are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef51833 \" href=\"UTD.htm?10/10/10413\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Older than three months",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric therapy for bacterial arthritis in children older than three months should be directed toward",
"    <em>",
"     S. aureus",
"    </em>",
"    and other gram-positive organisms (eg, group A streptococci,",
"    <em>",
"     Streptococcus pneumoniae",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/3,46-48\">",
"     3,46-48",
"    </a>",
"    ]. Additional coverage for other pathogens (eg,",
"    <em>",
"     Kingella kingae",
"    </em>",
"    ,",
"    <em>",
"     Haemophilus influenzae",
"    </em>",
"    type b [Hib],",
"    <em>",
"     Neisseria gonorrhoeae",
"    </em>",
"    ) may be necessary in select populations. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Special situations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Agents that provide antistaphylococcal and antistreptococcal coverage include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/57/26519?source=see_link\">",
"       Nafcillin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"       Clindamycin",
"      </a>",
"      (also covers MRSA and many penicillin-nonresistant",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      , although a large proportion of serotype 19A isolates are resistant to multiple drugs, including clindamycin)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       Vancomycin",
"      </a>",
"      (also covers MRSA and penicillin-nonresistant",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/36/9797?source=see_link\">",
"       Cefazolin",
"      </a>",
"      (also may provide coverage for",
"      <em>",
"       K. kingae",
"      </em>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Drug doses are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef51833 \" href=\"UTD.htm?10/10/10413\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the only study comparing antimicrobial agents for osteoarticular infections, outcomes were similar among 169 Finnish children with culture-proven acute osteoarticular infections who were treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    versus first generation cephalosporins [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/49\">",
"     49",
"    </a>",
"    ]. In this study, all cases resulted from infection with methicillin susceptible",
"    <em>",
"     S. aureus",
"    </em>",
"    (84 percent),",
"    <em>",
"     S. pyogenes",
"    </em>",
"    (9 percent), or",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    (5 percent).",
"   </p>",
"   <p>",
"    The specific choice of antistaphylococcal agent depends on the local prevalence of community-associated methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    (CA-MRSA) and the susceptibility of these isolates to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37159?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of Staphylococcus aureus bacteremia in children\", section on 'Empiric therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/57/26519?source=see_link\">",
"       nafcillin",
"      </a>",
"      if &lt;10 percent of the community",
"      <em>",
"       S. aureus",
"      </em>",
"      isolates are methicillin resistant.",
"     </li>",
"     <li>",
"      We suggest using either",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      when &ge;10 percent of community",
"      <em>",
"       S. aureus",
"      </em>",
"      isolates are methicillin resistant [",
"      <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/2,50,51\">",
"       2,50,51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      for life-threatening infections; we suggest vancomycin when &ge;10 percent of MRSA isolates in the community also are resistant to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17495?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of antibacterial susceptibility testing\", section on 'D test'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      for children who lack signs of sepsis (if clindamycin resistance not a concern, based on local patterns of antimicrobial drug resistance).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Special situations",
"    </span>",
"    &nbsp;&mdash;&nbsp;It may be necessary to add empiric coverage for pathogens other than",
"    <em>",
"     S. aureus",
"    </em>",
"    when clinical or laboratory factors suggest a specific pathogen (",
"    <a class=\"graphic graphic_table graphicRef75192 \" href=\"UTD.htm?14/50/15149\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40423?source=see_link&amp;anchor=H5#H5\">",
"     \"Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If gram-negative organisms (ie, suspicious for",
"      <em>",
"       K. kingae",
"      </em>",
"      ) are viewed on Gram stain, coverage for gram-negative organisms (eg, a second- or third-generation cephalosporin) should be added to empiric antistaphylococcal therapy. Empiric antistaphylococcal therapy should be continued because Gram stain results are subject to observer misinterpretation.",
"     </li>",
"     <li>",
"      Polymicrobial and anaerobic infections must be considered in children with direct inoculation or a history of penetrating trauma to the affected joint. Therapy should include agents directed against all organisms recovered.",
"     </li>",
"     <li>",
"      <em>",
"       K. kingae",
"      </em>",
"      is a consideration in children &lt;3 years of age. A second- or third-generation cephalosporin provides coverage for",
"      <em>",
"       K. kingae",
"      </em>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/52,53\">",
"       52,53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hib is a consideration in children &lt;2 years who have not been fully immunized against Hib. Coverage for Hib (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/61/31701?source=see_link\">",
"       cefuroxime",
"      </a>",
"      ) should be added to the empiric regimen for children incompletely immunized against Hib in areas where Hib immunization rates are low, but is not necessary for those in areas with high Hib immunization rates.",
"     </li>",
"     <li>",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      is a consideration in children with underlying medical problems (",
"      <a class=\"graphic graphic_table graphicRef68655 \" href=\"UTD.htm?6/13/6364\">",
"       table 4",
"      </a>",
"      ). Penicillin-nonsusceptible",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      is a consideration in children who received antibiotics within four weeks of diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/54\">",
"       54",
"      </a>",
"      ].",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       Ceftriaxone",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      , and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      have been used successfully to treat penicillin-nonsusceptible bone and joint infections due to",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      .",
"     </li>",
"     <li>",
"      <em>",
"       N. gonorrhoeae",
"      </em>",
"      is a consideration in neonates or sexually active adolescents and is treated with a third-generation cephalosporin (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/3,6,55\">",
"       3,6,55",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3976?source=see_link\">",
"       \"Disseminated gonococcal infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/34/39462?source=see_link\">",
"       \"Gonococcal infection in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <em>",
"       Salmonella",
"      </em>",
"      is often the cause of septic arthritis in children with sickle cell disease, and they should receive empiric therapy with a third-generation cephalosporin as part of their initial antibacterial therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link\">",
"       \"Overview of the management of sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Enteric gram-negative organisms are a consideration in patients with recent gastrointestinal surgery or complex urinary tract anatomy. Empiric gram-negative arthritis may be treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=see_link\">",
"       ceftazidime",
"      </a>",
"      (if concern for Pseudomonas), PLUS an aminoglycoside.",
"     </li>",
"     <li>",
"      Organisms that cause infection among injecting drug users (IDU) vary markedly between different communities.",
"      <em>",
"       Pseudomonas aeruginosa",
"      </em>",
"      has been frequently reported among IDUs with bacterial arthritis. If",
"      <em>",
"       P. aeruginosa",
"      </em>",
"      arthritis is a consideration, the combination of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/4/14405?source=see_link\">",
"       ceftazidime",
"      </a>",
"      plus either",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/57/26519?source=see_link\">",
"       nafcillin",
"      </a>",
"      (or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/59/950?source=see_link\">",
"       oxacillin",
"      </a>",
"      ) or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      is suggested; this combination also covers other gram-negative bacilli and",
"      <em>",
"       S. aureus",
"      </em>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43142?source=see_link\">",
"       \"Pseudomonas aeruginosa skin, soft tissue, and bone infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39528?source=see_link\">",
"       \"Treatment of Pseudomonas aeruginosa infections\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Specific therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific therapy is based upon culture and susceptibility results. Suggested regimens for the most commonly isolated pathogens are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef71347 \" href=\"UTD.htm?13/38/13933\">",
"     table 5",
"    </a>",
"    ). Consultation with an expert in infectious diseases is suggested for children with an inadequate response to therapy, unusual organisms,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drug allergies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Negative cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;No organism is identified in 30 to 50 percent of children with clinical bacterial arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/9,56-58\">",
"     9,56-58",
"    </a>",
"    ]. Factors to be considered in the antimicrobial management of such children include age, clinical presentation, and response to empiric therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who demonstrate clinical and laboratory improvement with empiric therapy, the initial empiric therapy is continued. Patients who are immunocompetent and fully immunized against Hib and",
"      <em>",
"       S. pneumoniae",
"      </em>",
"      may be switched to oral therapy if the oral regimen provides the same spectrum of coverage as the initial parenteral empiric regimen. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Oral therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In patients who do not demonstrate clinical and laboratory improvement with empiric therapy, additional infectious agents and diagnoses other than bacterial arthritis must be considered. An aggressive attempt must be made to isolate unusual pathogens and fastidious organisms, such as",
"      <em>",
"       Kingella kingae",
"      </em>",
"      . An aspirate of any involved soft tissue or bone biopsy also should be obtained for histopathologic staining and culture for bacteria. In addition, appropriate serologic testing and tuberculin skin testing should be performed when exposure to",
"      <em>",
"       Coccidioides",
"      </em>",
"      or",
"      <em>",
"       Brucella",
"      </em>",
"      species, or to",
"      <em>",
"       Mycobacterium tuberculosis",
"      </em>",
"      , is suspected. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Treatment failure'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=see_link&amp;anchor=H29#H29\">",
"       \"Bacterial arthritis: Clinical features and diagnosis in infants and children\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Total duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial arthritis is usually treated for a total of three weeks for",
"    <em>",
"     S. aureus",
"    </em>",
"    arthritis, and two to three weeks for",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    ,",
"    <em>",
"     K. kingae",
"    </em>",
"    , or",
"    <em>",
"     N. meningitidis",
"    </em>",
"    arthritis. Antimicrobial therapy may be discontinued if the ESR",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CRP have returned to normal by these time points and there is no radiographic evidence of unsuspected osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/52,59\">",
"     52,59",
"    </a>",
"    ]. Longer courses may be necessary for bacterial arthritis of the hip, and for arthritis caused by",
"    <em>",
"     Enterobacteriaceae",
"    </em>",
"    or other unusual organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These treatment durations were based on studies performed in the 1970s. A multicenter open-label non-inferiority trial examined the possibility of using a shorter duration (10 days) of therapy for select patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The trial was conducted in Finland between 1983 and 2005; 130 children (aged 3 months to 15 years) with culture-positive bacterial arthritis (without adjacent osteomyelitis) were randomly assigned to 10 or 30 days of antimicrobial therapy (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    or first-generation cephalosporin;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    was added for children aged zero to four years until the causative agent was identified) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/42\">",
"     42",
"    </a>",
"    ]. Antimicrobial therapy was administered IV for the first two to four days; the remainder of the course was completed orally. Criteria for discontinuation of antimicrobial therapy included clinical improvement and CRP &lt;2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/L),",
"    </span>",
"    or, for patients who did not meet these criteria at the intended end of therapy, two normal CRP levels. Monitoring included serial CRP and ESR, plain radiographs at admission and on days 10 and 19, and clinical evaluation at two weeks, three months, and &ge;1 year after hospitalization. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Percutaneous aspiration was performed in 110 patients; seven of these received needle lavage.",
"     </li>",
"     <li>",
"      Surgical arthrotomy was only performed in 7 of the 48 cases of hip joint arthritis.",
"     </li>",
"     <li>",
"      Seven of 48 cases (15 percent) of hip joint infection required therapy to be extended beyond the planned duration due to slow resolution of clinical or laboratory abnormalities.",
"     </li>",
"     <li>",
"      Five of 63 patients (8 percent) assigned to short-term therapy required continuation of antibiotics for up to 21 days (four with hip involvement, one with knee involvement) due to slow resolution of clinical or laboratory abnormalities.",
"     </li>",
"     <li>",
"      One child in the long-term treatment group had two late-onset osteoarticular infections. No other patients experienced relapse, recrudescence, residual dysfunction, growth disturbance, or other clinically significant sequelae.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted by an editorialist [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/61\">",
"     61",
"    </a>",
"    ], there was a marked difference in the microbiology of these cases and those currently seen in the United States. The distribution of pathogens was as follows: methicillin-sensitive",
"    <em>",
"     S. aureus",
"    </em>",
"    (MSSA, 58 percent), Hib (18 percent),",
"    <em>",
"     S. pyogenes",
"    </em>",
"    (12 percent),",
"    <em>",
"     S. pneumoniae",
"    </em>",
"    (8 percent), other pathogens (3 percent). There were no cases of MRSA.",
"   </p>",
"   <p>",
"    In view of the relatively high failure rate of the randomized therapy in septic arthritis of the hip, the absence of cases of MRSA, and the paucity of data from infants (in whom septic arthritis of the hip is frequently associated with sequelae), we do not recommend the use of the short-term regimen described by these authors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Route",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial antimicrobial therapy for bacterial arthritis is usually administered parenterally. In neonates (&lt;1 month), we suggest that the entire course of antimicrobial therapy be administered parenterally. Although successful oral therapy for bacterial arthritis in neonates has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/6\">",
"     6",
"    </a>",
"    ], the gastrointestinal absorption of oral antibiotics in neonates is unpredictable [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In infants and children older than one month, parenteral therapy is continued at least until clinical and laboratory improvement have been demonstrated, after which the balance of antibiotic therapy can be administered orally [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Response to therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22\">",
"     'Oral therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Antibiotic therapy can be completed on an outpatient basis in patients with unequivocal clinical improvement. Clear improvement usually is established 5 to 10 days after initiation of antibiotic therapy. It is indicated by achievement of each of the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The patient has been afebrile for 48 to 72 hours",
"     </li>",
"     <li>",
"      Local signs and symptoms of infection are reduced considerably",
"     </li>",
"     <li>",
"      WBC has normalized",
"     </li>",
"     <li>",
"      CRP",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ESR has decreased",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Intravenous therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outpatient parenteral antimicrobial therapy (OPAT) may be necessary if any of the following apply:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The patient's isolate is not susceptible to oral antibiotics",
"     </li>",
"     <li>",
"      Adherence to an oral regimen appears unlikely",
"     </li>",
"     <li>",
"      The patient cannot tolerate the oral agent needed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OPAT also may be necessary for patients with negative cultures if there is not an oral regimen with a spectrum similar to the parenteral regimen that resulted in improvement.",
"   </p>",
"   <p>",
"    Insertion of a percutaneously inserted central catheter (PICC) facilitates prolonged administration of parenteral antibiotics and can be used for outpatient therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/11\">",
"     11",
"    </a>",
"    ]. However, catheter-related complications occur in 30 to 40 percent of children with osteoarticular infections who are treated with OPAT [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. The risks and benefits of prolonged outpatient antimicrobial therapy must be carefully weighed when considering this option [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Oral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral antibiotics may be used to complete the course of therapy for bacterial arthritis in infants and children older than one month. As long as the patient has demonstrated unequivocal improvement, successful treatment does not require a minimum duration of parenteral therapy. In randomized and observational studies, treatment of bacterial arthritis with IV antibiotics for short periods (approximately seven days) followed by oral therapy, was as successful as longer courses of parenteral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/67-69\">",
"     67-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent oral therapy may be substituted for parenteral treatment provided that certain criteria are met [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/11,59,68-71\">",
"     11,59,68-71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clear demonstration of clinical and laboratory improvement (ie, swelling, tenderness, and erythema, reduction of C-reactive protein)",
"     </li>",
"     <li>",
"      Decreasing or absent fever",
"     </li>",
"     <li>",
"      An oral agent with appropriate coverage is available in a formulation that the child can swallow",
"     </li>",
"     <li>",
"      Adherence to the antibiotic and monitoring regimen are assured",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H331165020\">",
"    <span class=\"h4\">",
"     Choice of oral agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of agent(s) for oral therapy depends upon whether an organism was isolated from the synovial fluid, blood, or other culture. If an organism is isolated, the susceptibility pattern can be used to determine an appropriate oral drug. Additional considerations include the bioavailability and palatability of the oral medication.",
"   </p>",
"   <p>",
"    When an organism is not isolated, oral therapy should be directed toward the most likely pathogen(s) given the child's age and clinical presentation (",
"    <a class=\"graphic graphic_table graphicRef53150 \" href=\"UTD.htm?2/41/2716\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75192 \" href=\"UTD.htm?14/50/15149\">",
"     table 2",
"    </a>",
"    ). The chosen regimen should have a spectrum similar to that provided by the parenteral therapy that was associated with improvement. As examples, a child who improved on",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/36/9797?source=see_link\">",
"     cefazolin",
"    </a>",
"    may be switched to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/5/30804?source=see_link\">",
"     cephalexin",
"    </a>",
"    ; a child who improved on parenteral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    could be switched to oral clindamycin. Consultation with an expert in infectious diseases may be helpful in choosing the optimal oral agent, particularly if the child has an unusual pathogen or allergy to antibiotics.",
"   </p>",
"   <p>",
"    Antibiotics administered orally for bacterial arthritis are generally given in higher doses than those used for treatment of other infections and recommended in package inserts (",
"    <a class=\"graphic graphic_table graphicRef58533 \" href=\"UTD.htm?42/47/43771\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. To achieve adequate serum levels, doses of beta-lactams (penicillins and cephalosporins other than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/32/38404?source=see_link\">",
"     cefixime",
"    </a>",
"    ) often can be increased to 200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day without serious adverse side effects. Diarrhea, a frequent complication of high-dose oral beta-lactam therapy, can be mitigated by using the doses indicated in the table (",
"    <a class=\"graphic graphic_table graphicRef58533 \" href=\"UTD.htm?42/47/43771\">",
"     table 6",
"    </a>",
"    ) and adding",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11382?source=see_link\">",
"     probenecid",
"    </a>",
"    for children older than two years of age (40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in 4 divided doses, maximum of 2 grams per day). (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Drug monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The initial doses of oral therapy should be administered while the child is in the hospital to ensure that the drug is tolerated. The child may be discharged home when he or she is able to tolerate oral antibiotics and it is clear that the caregiver can administer oral therapy as prescribed. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Drug monitoring",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Adequacy of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expert opinion differs regarding the routine use of drug monitoring for patients on oral therapy for bacterial arthritis. Some have suggested monitoring of serum bactericidal titers [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/67,74\">",
"     67,74",
"    </a>",
"    ]. However, others suggest that if high-dose therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    or cephalosporin is used, obtaining drug levels is not necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/11,75\">",
"     11,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibiotic levels &ndash; Antibiotic levels in children taking oral medications can be used to ensure that the child is able to absorb the medication enterally. Assays are available for most of the antibiotics that are used routinely to treat bacterial arthritis (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/5/30804?source=see_link\">",
"       cephalexin",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/61/17363?source=see_link\">",
"       dicloxacillin",
"      </a>",
"      ). Antibiotic levels may be helpful in select patients if there is a concern regarding adequate absorption or adherence to the treatment regimen.",
"     </li>",
"     <li>",
"      Serum bactericidal titer &ndash; The SBT is the highest dilution of the patient's serum that will, after 18 hours of incubation, kill 99.9 percent of an inoculum of the infecting organism. In view of the high concentrations of antimicrobial agents that are generally achieved in joint fluid, we do not suggest using SBT to monitor drug therapy in children being transitioned to oral therapy for septic arthritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who are being treated with oral or parenteral antibiotic therapy for bacterial arthritis require monitoring for potential adverse effects. Adverse effects of high-dose antibiotic therapy may include pancytopenia, leukopenia, impaired liver or renal function, antibiotic-associated diarrhea, and pseudomembranous enterocolitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The monitoring schedule varies depending upon the drug, dose, and route of therapy. We obtain ESR, CRP, complete blood count (CBC), and biochemical profile, including serum aminotransferases weekly initially, while the patient is receiving beta-lactam antibiotics. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Follow-up'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive therapies for bacterial arthritis in children may include analgesia and physical therapy. Adjunctive therapy with glucocorticoids remains investigational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain management is an important aspect of therapy for bacterial arthritis. Opioid therapy (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32230?source=see_link\">",
"     codeine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    ) may be necessary; consultation with the pain management service may be helpful. Once they are discharged home, children may receive",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    for pain control [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Physical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention must be paid to joint position and rapid mobilization to prevent contractures and promote optimal nutrition to the articular cartilage. Physical therapy may be helpful in children who are reluctant to use the joint [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/37\">",
"     37",
"    </a>",
"    ]. Once discharged home, the child may require a wheelchair or walker and continued physical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Antiinflammatory agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inflammatory response is an important component of the pathogenesis of bacterial arthritis and accounts for at least a portion of the long-term morbidity. Some experts recommend routine nonsteroidal antiinflammatory agents, which decrease reactive synovitis associated with bacterial arthritis.",
"   </p>",
"   <p>",
"    The use of adjunctive glucocorticoid therapy to decrease inflammation in bacterial arthritis has been evaluated in animal models and in randomized trials in children, as illustrated below [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/4,12,76,77\">",
"     4,12,76,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an experimental model, mice that received glucocorticoid and antistaphylococcal antibiotic three days after inoculation with",
"      <em>",
"       S. aureus",
"      </em>",
"      had a decreased incidence and severity of",
"      <em>",
"       S. aureus",
"      </em>",
"      arthritis compared with those that received antistaphylococcal antibiotic alone [",
"      <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a randomized trial in 123 children (average age of five years) with suspected hematogenous bacterial arthritis, adjunctive",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      during the first four days of antimicrobial therapy appeared to decrease the risk of residual dysfunction 12 months after treatment (2 versus 26 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/12\">",
"       12",
"      </a>",
"      ]. About 85 percent of the children had hip or knee infection;",
"      <em>",
"       H. influenzae",
"      </em>",
"      infection accounted for about 10 percent of cases in both the experimental and control groups.",
"     </li>",
"     <li>",
"      In another randomized trial in 49 children (average age of 33 months) with septic arthritis, adjunctive",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      during the first four days of antimicrobial therapy was associated with decreased duration of fever (1.7 versus 2.8 days), pain (7.2 versus 10.8 days), and parenteral antibiotics (9.9 versus 12.6 days), but no difference in long-term outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/77\">",
"       77",
"      </a>",
"      ]. About 85 percent of children had hip or knee infection. Bacteria were isolated in synovial fluid samples from 17 patients;",
"      <em>",
"       K. kingae",
"      </em>",
"      and methicillin-susceptible",
"      <em>",
"       S. aureus",
"      </em>",
"      were most common (in seven and three patients, respectively). Limitations that prevent generalizability of these findings include the relatively decreased frequency of",
"      <em>",
"       S. aureus",
"      </em>",
"      and the relatively prolonged duration of parenteral antibiotics. Moreover, the effects of dexamethasone were not compared with those of nonsteroidal antiinflammatory agents, which are recommended as adjunctive therapy by some experts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these findings are encouraging, adjunctive glucocorticoid therapy remains controversial, and data are limited about its risk and benefits in cases of methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    infection. We do not suggest its routine use in septic arthritis in childhood. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     RESPONSE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical and laboratory improvement is indicated by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Resolution of fever",
"     </li>",
"     <li>",
"      Decreased joint pain, swelling, and erythema",
"     </li>",
"     <li>",
"      Increased joint mobility",
"     </li>",
"     <li>",
"      Decrease in peripheral WBC count and synovial fluid WBC (if repeated aspirations are performed or a drain is left in place after surgical drainage)",
"     </li>",
"     <li>",
"      Decrease in ESR",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      CRP",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Monitoring response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to therapy can be assessed by serial clinical examination (fever, pain, range of motion), peripheral WBC, ESR",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CRP, and synovial fluid WBC and culture.",
"   </p>",
"   <p>",
"    Improvement in joint symptoms usually occurs within two days of drainage and initiation of antimicrobial therapy. Fever usually resolves within three to five days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/11,67\">",
"     11,67",
"    </a>",
"    ]. The time required for resolution of symptoms and sterilization of the joint fluid are proportional to the duration of symptoms before initiation of appropriate therapy and the synovial fluid WBC at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/78-80\">",
"     78-80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CRP is more useful than ESR for monitoring acute response to treatment. Even with appropriate treatment, the ESR may continue to rise for three to five days, whereas CRP peaks within 36 to 50 hours of onset of infection and quickly falls to normal with appropriate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/18,81\">",
"     18,81",
"    </a>",
"    ]. ESR remains useful for determining the duration of therapy since it normalizes as inflammation resolves.",
"   </p>",
"   <p>",
"    In joints that initially were drained with needle aspiration, synovial fluid may reaccumulate, requiring repeated drainage. Infected knees, in particular, may continue to accumulate fluid for 7 to 10 days. When available (from repeat aspiration or a surgical drain), serial synovial fluid analyses should demonstrate sterilization and a decreasing WBC count. If repeat synovial fluid WBC count remains elevated and the culture remains positive, more definitive joint drainage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an alteration in the antimicrobial regimen are warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Treatment failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment failure may be indicated by: lack of clinical improvement; ESR that continues to rise three to five days after initiation of therapy; persistently elevated ESR, CRP, peripheral WBC, or synovial fluid WBC; or failure to sterilize the synovial fluid in the expected period of one to two days if repeat cultures are obtained.",
"   </p>",
"   <p>",
"    Patients who do not respond to treatment as expected require reevaluation, adjustment of antimicrobial therapy, and definitive surgical drainage.",
"   </p>",
"   <p>",
"    Reevaluation may include magnetic resonance imaging for evidence of osteomyelitis with abscess, and review of the history for exposure to unusual organisms (eg,",
"    <em>",
"     Brucella",
"    </em>",
"    ,",
"    <em>",
"     M. tuberculosis",
"    </em>",
"    ) or mechanism for direct inoculation, and reconsideration or other conditions in the differential diagnosis. Organisms not covered by the initial empiric regimen (eg,",
"    <em>",
"     K. kingae",
"    </em>",
"    in patients initially treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/57/26519?source=see_link\">",
"     nafcillin",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/59/950?source=see_link\">",
"     oxacillin",
"    </a>",
"    ) also must be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=see_link&amp;anchor=H29#H29\">",
"     \"Bacterial arthritis: Clinical features and diagnosis in infants and children\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40423?source=see_link&amp;anchor=H5#H5\">",
"     \"Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children\", section on 'Microbiology'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H7\">",
"     'Drainage'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     During therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients and families who can comply with the oral regimen and close follow-up may be discharged from the hospital and managed as outpatients once a clear clinical response has been established. Children being treated as outpatients for bacterial arthritis should be seen for follow-up approximately one week after discharge from the hospital, and at one- to two-week intervals thereafter.",
"   </p>",
"   <p>",
"    The follow-up visit should include monitoring for continued clinical improvement (including the need to initiate or continue physical therapy) and for complications related to high-dose antibiotic therapy, such as cytopenia, antibiotic associated diarrhea, and pseudomembranous colitis. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Adverse effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We suggest that a CBC, ESR, CRP, and biochemical profile, including serum aminotransferases, be obtained at each visit. If patients are not improving as expected after being transitioned to oral therapy, it may be advisable to revert to intravenous therapy. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Adequacy of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographs should be obtained two to three weeks into the course of treatment for bacterial arthritis to look for bone changes indicative of occult osteomyelitis or osteomyelitis of the epiphysis or metaphysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic findings suggestive of osteomyelitis include lytic lesions (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51834 \" href=\"UTD.htm?14/6/14434\">",
"     image 1",
"    </a>",
"    ) and periosteal elevation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71349 \" href=\"UTD.htm?33/52/34638\">",
"     image 2",
"    </a>",
"    ), thickening, or new bone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/6\">",
"     6",
"    </a>",
"    ]. Osteomyelitis may require surgical intervention or prolonged antibiotic therapy. Bacterial arthritis with concomitant osteomyelitis is associated with a worse prognosis than bacterial arthritis alone [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=see_link&amp;anchor=H6#H6\">",
"     \"Evaluation and diagnosis of hematogenous osteomyelitis in children\", section on 'Imaging'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H39\">",
"     'Prognostic factors'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24730?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of hematogenous osteomyelitis in children\", section on 'Overview of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Long-term follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term follow-up after treatment for bacterial arthritis in infants and children includes monitoring of joint dysfunction and limb-length discrepancy. Severely affected patients should undergo regular imaging after six years of age if progressive limb-length discrepancy occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential complications of bacterial arthritis include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/1,6,13,34,83-85\">",
"     1,6,13,34,83-85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Joint laxity, subluxation, or dislocation",
"     </li>",
"     <li>",
"      Joint restriction",
"     </li>",
"     <li>",
"      Limb-length discrepancy (if the growth plate is involved)",
"     </li>",
"     <li>",
"      Avascular necrosis",
"     </li>",
"     <li>",
"      Enlargement of the femoral head (coxa magna) in bacterial arthritis of the hip",
"     </li>",
"     <li>",
"      Pathologic fractures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The reported complication rates vary depending upon the patient population, the involved joint, and the duration of follow-up; prolonged follow-up may be necessary to determine the true extent of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/6,57,86\">",
"     6,57,86",
"    </a>",
"    ]. The estimated rate of residual dysfunction is 10 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/23\">",
"     23",
"    </a>",
"    ]. Even with appropriate management, approximately 40 percent of patients with hip involvement and 10 percent of patients with knee involvement develop significant complications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/19,37,38\">",
"     19,37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors related to poor outcome have been identified in observational studies. They include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/33/28186/abstract/25,56,57,60,87-91\">",
"     25,56,57,60,87-91",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duration of symptoms before treatment, particularly if &gt;4 to 7 days",
"     </li>",
"     <li>",
"      Involvement of the hip",
"     </li>",
"     <li>",
"      Involvement of the hip or shoulder with concomitant osteomyelitis",
"     </li>",
"     <li>",
"      Young age (ie, less than one year)",
"     </li>",
"     <li>",
"      The causative organism (",
"      <em>",
"       Enterobacteriaceae",
"      </em>",
"      and",
"      <em>",
"       S. aureus",
"      </em>",
"      are associated with more frequent sequelae)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factors that do not appear to be related to outcome include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The mode of drainage, provided that adequate drainage is obtained",
"     </li>",
"     <li>",
"      The choice of antibiotic, provided that it is effective against the infecting organism",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/63/17393?source=see_link\">",
"       \"Patient information: Septic arthritis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial arthritis requires prompt recognition and management. Delays in treatment are associated with long-term sequelae. This is especially true when the hip is involved. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goals of treatment include sterilization and decompression of the joint space and removal of inflammatory debris to relieve pain and prevent deformity or functional sequelae. Drainage of joint fluid and antimicrobial therapy are the cornerstones of therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because delayed therapy is associated with long-term sequelae, treatment of infants and children with suspected bacterial arthritis should begin immediately after blood and synovial fluid cultures are obtained. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Drainage of joint fluid",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend drainage of the joint space in all patients with bacterial arthritis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Drainage and lavage are necessary to decompress the joint space and to remove inflammatory debris. Drainage can be accomplished through open surgery (arthrotomy), arthroscopy, or needle aspiration. Decisions regarding the optimal drainage procedure for an individual patient should be made on a case-by-case basis, depending upon the site and extent of involvement, duration of symptoms, and the suspected organism. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Drainage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend surgical drainage (arthrotomy or arthroscopy) for bacterial arthritis of the hip in infants and children (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We suggest arthrotomy as the procedure of choice (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Drainage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional indications for arthrotomy in children with bacterial arthritis may include suspected radiolucent foreign body in children with penetrating injury; large amount of fibrin debris or loculations; debridement in patients with concomitant osteomyelitis; and lack of clinical improvement or persistent positive cultures despite appropriate antimicrobial therapy and multiple needle aspirations. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Arthrotomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For joints other than the hip, needle aspiration is an alternative to surgical drainage. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Needle aspiration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antibiotic therapy is necessary to sterilize the joint fluid. Antibiotics should be administered as soon as possible after blood and synovial fluid cultures have been obtained. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial antimicrobial therapy for bacterial arthritis is administered parenterally. The empiric regimen should target the most common pathogens in a particular patient. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Empiric therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that empiric therapy include coverage for",
"      <em>",
"       Staphylococcus aureus",
"      </em>",
"      in all infants and children (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Depending upon the child's age (",
"      <a class=\"graphic graphic_table graphicRef53150 \" href=\"UTD.htm?2/41/2716\">",
"       table 1",
"      </a>",
"      ), Gram stain, and particular clinical circumstances (",
"      <a class=\"graphic graphic_table graphicRef75192 \" href=\"UTD.htm?14/50/15149\">",
"       table 2",
"      </a>",
"      ), empiric coverage for additional pathogens may be necessary. As an example, the combination of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"       vancomycin",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/36/9797?source=see_link\">",
"       cefazolin",
"      </a>",
"      may be advisable for a child between 3 months and 3 years of age with indolent disease in a geographic area with a high prevalence of methicillin-resistant",
"      <em>",
"       S. aureus",
"      </em>",
"      . Doses for commonly used drugs are listed in the Table (",
"      <a class=\"graphic graphic_table graphicRef51833 \" href=\"UTD.htm?10/10/10413\">",
"       table 3",
"      </a>",
"      ). Empiric therapy can be altered when the susceptibility pattern of the causative bacterium is known. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Empiric therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific therapy is based upon culture and susceptibility results. Suggested agents for the most commonly isolated pathogens are provided in the table (",
"      <a class=\"graphic graphic_table graphicRef71347 \" href=\"UTD.htm?13/38/13933\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Specific therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacterial arthritis is usually treated for a total of three weeks for",
"      <em>",
"       S. aureus",
"      </em>",
"      arthritis, and two weeks for",
"      <em>",
"       Streptococcus pneumoniae",
"      </em>",
"      or",
"      <em>",
"       Neisseria meningitidis",
"      </em>",
"      arthritis. Antimicrobial therapy may be discontinued if the erythrocyte sedimentation rate (ESR)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      C-reactive protein (CRP) have returned to normal by these time points and there is no radiographic evidence of unsuspected osteomyelitis. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Total duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In neonates (&lt;1 month), we suggest that the entire course of antimicrobial therapy be administered parenterally (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In infants and children older than one month, parenteral therapy is continued at least until clinical and laboratory improvement have been demonstrated, after which the balance of antibiotic therapy can be administered orally. In infants and children older than one month, oral therapy may be initiated if the following criteria are met:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Clear demonstration of clinical and laboratory improvement",
"     </li>",
"     <li>",
"      Decreasing or absent fever",
"     </li>",
"     <li>",
"      An oral agent with appropriate coverage is available in a formulation that the child can swallow",
"     </li>",
"     <li>",
"      Adherence to the antibiotic and monitoring regimen is assured",
"      <br/>",
"      <br/>",
"      Doses for commonly used oral drugs are listed in the table (",
"      <a class=\"graphic graphic_table graphicRef58533 \" href=\"UTD.htm?42/47/43771\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Route'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Oral therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Treatment response",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The adequacy of antibiotic therapy can be assessed by serial clinical examination (fever, pain, range of motion), peripheral white blood cell (WBC) count, ESR",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      CRP, and synovial fluid WBC count and culture. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Monitoring response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who do not respond to treatment as expected require reevaluation, adjustment of antimicrobial therapy, and definitive surgical drainage. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Treatment failure'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Follow-up and outcome",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children being treated as outpatients for bacterial arthritis should be seen for follow-up approximately one week after discharge from the hospital, and at one- to two-week intervals thereafter. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'During therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The follow-up visit should include monitoring for continued clinical improvement and for complications related to high-dose antibiotic therapy. We suggest that a complete blood count, ESR, CRP, and biochemical profile, including serum aminotransferases, be obtained at each visit. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'During therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radiographs should be obtained two to three weeks into the course of treatment to look for bone changes indicative of occult osteomyelitis or osteomyelitis of the epiphysis or metaphysis. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Radiographs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The estimated rate of residual joint dysfunction is 10 to 25 percent; even with appropriate treatment, approximately 40 percent of patients with hip involvement and 10 percent of patients with knee involvement develop significant complications. Factors related to poor outcome include: duration of symptoms before treatment; involvement of the hip: involvement of the hip or shoulder with concomitant osteomyelitis; and age younger than one year. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/1\">",
"      Nade S. Septic arthritis. Best Pract Res Clin Rheumatol 2003; 17:183.",
"     </a>",
"    </li>",
"    <li>",
"     Krogstad P. Septic arthitis. In: Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GL, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.742.",
"    </li>",
"    <li>",
"     Gutierrez K. Infectious and inflammatory arthritis. In: Principles and Practice of Pediatric Infectious Diseases, 4th, Long SS, Pickering LK, Prober CG.  (Eds), Elsevier Saunders, Edinburgh 2012. p.477.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/4\">",
"      Mathews CJ, Coakley G. Septic arthritis: current diagnostic and therapeutic algorithm. Curr Opin Rheumatol 2008; 20:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/5\">",
"      Kang SN, Sanghera T, Mangwani J, et al. The management of septic arthritis in children: systematic review of the English language literature. J Bone Joint Surg Br 2009; 91:1127.",
"     </a>",
"    </li>",
"    <li>",
"     Krogstad P. Septic arthritis. In: Current Pediatric Therapy, 18th ed, Burg FD, Ingelfinger JR, Polin RA, Gershon AA (Eds), Saunders, Philadelphia 2006. p.665.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/7\">",
"      Baciocco EA, Iles RL. Ampicillin and kanamycin concentrations in joint fluid. Clin Pharmacol Ther 1971; 12:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/8\">",
"      Balboni V, Shapiro IM, Kydd DM. The penetration of penicillin into joint fluid following intramuscular administration. Am J Med Sci 1945; 210:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/9\">",
"      Nelson JD. The bacterial etiology and antibiotic management of septic arthritis in infants and children. Pediatrics 1972; 50:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/10\">",
"      Plott MA, Roth H. Penetration of clindamycin into synovial fluid. Clin Pharmacol Ther 1970; 11:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/11\">",
"      Kocher MS, Mandiga R, Murphy JM, et al. A clinical practice guideline for treatment of septic arthritis in children: efficacy in improving process of care and effect on outcome of septic arthritis of the hip. J Bone Joint Surg Am 2003; 85-A:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/12\">",
"      Odio CM, Ramirez T, Arias G, et al. Double blind, randomized, placebo-controlled study of dexamethasone therapy for hematogenous septic arthritis in children. Pediatr Infect Dis J 2003; 22:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/13\">",
"      Wenger DR. Childhood hip sepsis: improving the yield of good results. Instr Course Lect 1985; 34:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/14\">",
"      Fabry G, Meire E. Septic arthritis of the hip in children: poor results after late and inadequate treatment. J Pediatr Orthop 1983; 3:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/15\">",
"      Riegels-Nielsen P, Frimodt-M&oslash;ller N, S&oslash;rensen M, Jensen JS. Antibiotic treatment insufficient for established septic arthritis. Staphylococcus aureus experiments in rabbits. Acta Orthop Scand 1989; 60:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/16\">",
"      Smith RL, Schurman DJ. Bacterial arthritis. A staphylococcal proteoglycan-releasing factor. Arthritis Rheum 1986; 29:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/17\">",
"      Nord KD, Dore DD, Deeney VF, et al. Evaluation of treatment modalities for septic arthritis with histological grading and analysis of levels of uronic acid, neutral protease, and interleukin-1. J Bone Joint Surg Am 1995; 77:258.",
"     </a>",
"    </li>",
"    <li>",
"     Stans AA. Osteomyelitis and septic arthritis. In: Lovell and Winter's Pediatric Orthopaedics, 6th ed, Morrissy RT, Weinstein SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.440.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/19\">",
"      Morrey BF, Bianco AJ Jr, Rhodes KH. Septic arthritis in children. Orthop Clin North Am 1975; 6:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/20\">",
"      Herndon WA, Knauer S, Sullivan JA, Gross RH. Management of septic arthritis in children. J Pediatr Orthop 1986; 6:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/21\">",
"      Goldenberg DL, Brandt KD, Cohen AS, Cathcart ES. Treatment of septic arthritis: comparison of needle aspiration and surgery as initial modes of joint drainage. Arthritis Rheum 1975; 18:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/22\">",
"      Daniel D, Akeson W, Amiel D, et al. Lavage of septic joints in rabbits: effects of chondrolysis. J Bone Joint Surg Am 1976; 58:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/23\">",
"      Smith SP, Thyoka M, Lavy CB, Pitani A. Septic arthritis of the shoulder in children in Malawi. A randomised, prospective study of aspiration versus arthrotomy and washout. J Bone Joint Surg Br 2002; 84:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/24\">",
"      OBLETZ BE. Suppurative arthritis of the hip joint in infants. Clin Orthop 1962; 22:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/25\">",
"      Morrey BF, Bianco AJ, Rhodes KH. Suppurative arthritis of the hip in children. J Bone Joint Surg Am 1976; 58:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/26\">",
"      Paterson DC. Acute suppurative arthritis in infancy and childhood. J Bone Joint Surg Br 1970; 52:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/27\">",
"      Kim SJ, Choi NH, Ko SH, et al. Arthroscopic treatment of septic arthritis of the hip. Clin Orthop Relat Res 2003; :211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/28\">",
"      Nusem I, Jabur MK, Playford EG. Arthroscopic treatment of septic arthritis of the hip. Arthroscopy 2006; 22:902.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/29\">",
"      Chung WK, Slater GL, Bates EH. Treatment of septic arthritis of the hip by arthroscopic lavage. J Pediatr Orthop 1993; 13:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/30\">",
"      P&auml;&auml;kk&ouml;nen M, Kallio MJ, Peltola H, Kallio PE. Pediatric septic hip with or without arthrotomy: retrospective analysis of 62 consecutive nonneonatal culture-positive cases. J Pediatr Orthop B 2010; 19:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/31\">",
"      Givon U, Liberman B, Schindler A, et al. Treatment of septic arthritis of the hip joint by repeated ultrasound-guided aspirations. J Pediatr Orthop 2004; 24:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/32\">",
"      Griffet J, Oborocianu I, Rubio A, et al. Percutaneous aspiration irrigation drainage technique in the management of septic arthritis in children. J Trauma 2011; 70:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/33\">",
"      Wilson NI, Di Paola M. Acute septic arthritis in infancy and childhood. 10 years' experience. J Bone Joint Surg Br 1986; 68:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/34\">",
"      Belthur MV, Palazzi DL, Miller JA, et al. A clinical analysis of shoulder and hip joint infections in children. J Pediatr Orthop 2009; 29:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/35\">",
"      Pioro MH, Mandell BF. Septic arthritis. Rheum Dis Clin North Am 1997; 23:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/36\">",
"      Gordon JE, Wolff A, Luhmann SJ, et al. Primary and delayed closure after open irrigation and debridement of septic arthritis in children. J Pediatr Orthop B 2005; 14:101.",
"     </a>",
"    </li>",
"    <li>",
"     Frank G, Eppes SC. Bone, joint, and soft tissue infections. In: Comprehensive Pediatric Hospital Medicine, Zaoutis LB, Chiang WV (Eds), Mosby, Philadelphia 2007. p.414.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/38\">",
"      Betz RR, Cooperman DR, Wopperer JM, et al. Late sequelae of septic arthritis of the hip in infancy and childhood. J Pediatr Orthop 1990; 10:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/39\">",
"      Stanitski CL, Harvell JC, Fu FH. Arthroscopy in acute septic knees. Management in pediatric patients. Clin Orthop Relat Res 1989; :209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/40\">",
"      Forward DP, Hunter JB. Arthroscopic washout of the shoulder for septic arthritis in infants. A new technique. J Bone Joint Surg Br 2002; 84:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/41\">",
"      Broy SB, Schmid FR. A comparison of medical drainage (needle aspiration) and surgical drainage (arthrotomy or arthroscopy) in the initial treatment of infected joints. Clin Rheum Dis 1986; 12:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/42\">",
"      Peltola H, P&auml;&auml;kk&ouml;nen M, Kallio P, et al. Prospective, randomized trial of 10 days versus 30 days of antimicrobial treatment, including a short-term course of parenteral therapy, for childhood septic arthritis. Clin Infect Dis 2009; 48:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/43\">",
"      Nade S. Acute septic arthritis in infancy and childhood. J Bone Joint Surg Br 1983; 65:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/44\">",
"      Badgley CE, Yglesias L, Perham WS, Snyder CH. Study of the end results in 113 cases of septic hips. J Bone Joint Surg Br 1936; 18:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/45\">",
"      Fink CW, Nelson JD. Septic arthritis and osteomyelitis in children. Clin Rheum Dis 1986; 12:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/46\">",
"      Bowerman SG, Green NE, Mencio GA. Decline of bone and joint infections attributable to haemophilus influenzae type b. Clin Orthop Relat Res 1997; :128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/47\">",
"      Luhmann JD, Luhmann SJ. Etiology of septic arthritis in children: an update for the 1990s. Pediatr Emerg Care 1999; 15:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/48\">",
"      Nelson JD. Antibiotic concentrations in septic joint effusions. N Engl J Med 1971; 284:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/49\">",
"      Peltola H, P&auml;&auml;kk&ouml;nen M, Kallio P, et al. Clindamycin vs. first-generation cephalosporins for acute osteoarticular infections of childhood--a prospective quasi-randomized controlled trial. Clin Microbiol Infect 2012; 18:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/50\">",
"      Kaplan SL. Osteomyelitis in children. Infect Dis Clin North Am 2005; 19:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/51\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/52\">",
"      Yagupsky P. Kingella kingae: from medical rarity to an emerging paediatric pathogen. Lancet Infect Dis 2004; 4:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/53\">",
"      Yagupsky P. Antibiotic susceptibility of Kingella kingae isolates from children with skeletal system infections. Pediatr Infect Dis J 2012; 31:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/54\">",
"      Bradley JS, Kaplan SL, Tan TQ, et al. Pediatric pneumococcal bone and joint infections. The Pediatric Multicenter Pneumococcal Surveillance Study Group (PMPSSG). Pediatrics 1998; 102:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/55\">",
"      Brewer GF, Davis JR, Grossman M. Gonococcal arthritis in an adolescent girl. Am J Dis Child 1971; 122:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/56\">",
"      Barton LL, Dunkle LM, Habib FH. Septic arthritis in childhood. A 13-year review. Am J Dis Child 1987; 141:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/57\">",
"      Welkon CJ, Long SS, Fisher MC, Alburger PD. Pyogenic arthritis in infants and children: a review of 95 cases. Pediatr Infect Dis 1986; 5:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/58\">",
"      Wiley JJ, Fraser GA. Septic arthritis in childhood. Can J Surg 1979; 22:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/59\">",
"      Tetzlaff TR, McCracken GH Jr, Nelson JD. Oral antibiotic therapy for skeletal infections of children. II. Therapy of osteomyelitis and suppurative arthritis. J Pediatr 1978; 92:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/60\">",
"      Bennett OM, Namnyak SS. Acute septic arthritis of the hip joint in infancy and childhood. Clin Orthop Relat Res 1992; :123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/61\">",
"      Bradley JS. What is the appropriate treatment course for bacterial arthritis in children? Clin Infect Dis 2009; 48:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/62\">",
"      Perkins MD, Edwards KM, Heller RM, Green NE. Neonatal group B streptococcal osteomyelitis and suppurative arthritis. Outpatient therapy. Clin Pediatr (Phila) 1989; 28:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/63\">",
"      Schwartz GJ, Hegyi T, Spitzer A. Subtherapeutic dicloxacillin levels in a neonate: possible mechanisms. J Pediatr 1976; 89:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/64\">",
"      Ballock RT, Newton PO, Evans SJ, et al. A comparison of early versus late conversion from intravenous to oral therapy in the treatment of septic arthritis. J Pediatr Orthop 2009; 29:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/65\">",
"      Maraqa NF, Gomez MM, Rathore MH. Outpatient parenteral antimicrobial therapy in osteoarticular infections in children. J Pediatr Orthop 2002; 22:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/66\">",
"      Ruebner R, Keren R, Coffin S, et al. Complications of central venous catheters used for the treatment of acute hematogenous osteomyelitis. Pediatrics 2006; 117:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/67\">",
"      Newton PO, Ballock RT, Bradley JS. Oral antibiotic therapy of bacterial arthritis. Pediatr Infect Dis J 1999; 18:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/68\">",
"      Jaberi FM, Shahcheraghi GH, Ahadzadeh M. Short-term intravenous antibiotic treatment of acute hematogenous bone and joint infection in children: a prospective randomized trial. J Pediatr Orthop 2002; 22:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/69\">",
"      Kim HK, Alman B, Cole WG. A shortened course of parenteral antibiotic therapy in the management of acute septic arthritis of the hip. J Pediatr Orthop 2000; 20:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/70\">",
"      Kolyvas E, Ahronheim G, Marks MI, et al. Oral antibiotic therapy of skeletal infections in children. Pediatrics 1980; 65:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/71\">",
"      Arnold JC, Cannavino CR, Ross MK, et al. Acute bacterial osteoarticular infections: eight-year analysis of C-reactive protein for oral step-down therapy. Pediatrics 2012; 130:e821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/72\">",
"      Nelson JD, Bucholz RW, Kusmiesz H, Shelton S. Benefits and risks of sequential parenteral--oral cephalosporin therapy for suppurative bone and joint infections. J Pediatr Orthop 1982; 2:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/73\">",
"      Mart&iacute;nez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003; 22:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/74\">",
"      Benjamin B, Khan MR. Hip involvement in childhood brucellosis. J Bone Joint Surg Br 1994; 76:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/75\">",
"      Peltola H, Unkila-Kallio L, Kallio MJ. Simplified treatment of acute staphylococcal osteomyelitis of childhood. The Finnish Study Group. Pediatrics 1997; 99:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/76\">",
"      Sakiniene E, Bremell T, Tarkowski A. Addition of corticosteroids to antibiotic treatment ameliorates the course of experimental Staphylococcus aureus arthritis. Arthritis Rheum 1996; 39:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/77\">",
"      Harel L, Prais D, Bar-On E, et al. Dexamethasone therapy for septic arthritis in children: results of a randomized double-blind placebo-controlled study. J Pediatr Orthop 2011; 31:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/78\">",
"      Ho G Jr, Su EY. Therapy for septic arthritis. JAMA 1982; 247:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/79\">",
"      WARD J, COHEN AS, BAUER W. The diagnosis and therapy of acute suppurative arthritis. Arthritis Rheum 1960; 3:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/80\">",
"      Goldenberg DL, Brandt KD, Cathcart ES, Cohen AS. Acute arthritis caused by gram-negative bacilli: a clinical characterization. Medicine (Baltimore) 1974; 53:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/81\">",
"      P&auml;&auml;kk&ouml;nen M, Kallio MJ, Kallio PE, Peltola H. Sensitivity of erythrocyte sedimentation rate and C-reactive protein in childhood bone and joint infections. Clin Orthop Relat Res 2010; 468:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/82\">",
"      Jackson MA, Burry VF, Olson LC. Pyogenic arthritis associated with adjacent osteomyelitis: identification of the sequela-prone child. Pediatr Infect Dis J 1992; 11:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/83\">",
"      EYRE-BROOK AL. Septic arthritis of the hip and osteomyelitis of the upper end of the femur in infants. J Bone Joint Surg Br 1960; 42-B:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/84\">",
"      Singer JI. The cause of gait disturbance in 425 pediatric patients. Pediatr Emerg Care 1985; 1:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/85\">",
"      Bos CF, Mol LJ, Obermann WR, Tjin a Ton ER. Late sequelae of neonatal septic arthritis of the shoulder. J Bone Joint Surg Br 1998; 80:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/86\">",
"      Yuan HC, Wu KG, Chen CJ, et al. Characteristics and outcome of septic arthritis in children. J Microbiol Immunol Infect 2006; 39:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/87\">",
"      SAMILSON RL, WATKINS MB, WINTERS DM. Acute suppurative arthritis. J Bone Joint Surg Am 1956; 38-A:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/88\">",
"      OBLETZ BE. Acute suppurative arthritis of the hip in the neonatal period. J Bone Joint Surg Am 1960; 42-A:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/89\">",
"      Lunseth PA, Heiple KG. Prognosis in septic arthritis of the hip in children. Clin Orthop Relat Res 1979; :81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/90\">",
"      Goldenberg DL, Cohen AS. Acute infectious arthritis. A review of patients with nongonococcal joint infections (with emphasis on therapy and prognosis). Am J Med 1976; 60:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/33/28186/abstract/91\">",
"      Newman JH. Review of septic arthritis throughout the antibiotic era. Ann Rheum Dis 1976; 35:198.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6033 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-B63444C5D6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_33_28186=[""].join("\n");
var outline_f27_33_28186=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Septic arthritis of the hip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Home care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DRAINAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Arthrotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Arthroscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Needle aspiration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ANTIBIOTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Empiric therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Birth to three months",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Older than three months",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Special situations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Specific therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Negative cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Total duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Route",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Intravenous therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Oral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H331165020\">",
"      Choice of oral agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Drug monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Adequacy of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ADJUNCTIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Physical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Antiinflammatory agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Monitoring response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Treatment failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      During therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Long-term follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Drainage of joint fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Treatment response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Follow-up and outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6033\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6033|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/6/14434\" title=\"diagnostic image 1\">",
"      Osteomyelitis limp fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/52/34638\" title=\"diagnostic image 2\">",
"      Osteomyelitis periosteal elevation plain radiograph",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6033|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/41/2716\" title=\"table 1\">",
"      Etiology of septic arthritis by age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/50/15149\" title=\"table 2\">",
"      Clues to the etiology of septic arthritis in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/10/10413\" title=\"table 3\">",
"      Doses of IV antibiotics for bacterial arthritis in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/13/6364\" title=\"table 4\">",
"      High risk conditions for invasive pneumococcal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/38/13933\" title=\"table 5\">",
"      Specific treatment for bacterial arthritis in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/47/43771\" title=\"table 6\">",
"      Bact arthritis child PO Rx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/30/14826?source=related_link\">",
"      Bacterial arthritis: Clinical features and diagnosis in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40423?source=related_link\">",
"      Bacterial arthritis: Epidemiology, pathogenesis, and microbiology in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/56/3976?source=related_link\">",
"      Disseminated gonococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33289?source=related_link\">",
"      Evaluation and diagnosis of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/34/39462?source=related_link\">",
"      Gonococcal infection in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17495?source=related_link\">",
"      Overview of antibacterial susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/63/17393?source=related_link\">",
"      Patient information: Septic arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43142?source=related_link\">",
"      Pseudomonas aeruginosa skin, soft tissue, and bone infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=related_link\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39528?source=related_link\">",
"      Treatment of Pseudomonas aeruginosa infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/18/37159?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24730?source=related_link\">",
"      Treatment of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_33_28187="Principles of prevention for exertional heat illness";
var content_f27_33_28187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Principles of prevention for exertional heat illness",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Ensure that appropriate medical care and equipment, including a cold water immersion tub or other effective tools for rapid cooling, are available at practices and games.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Review and update emergency plans for exertional heat illness (EHI) annually with athletic directors, coaches, athletes, and medical personnel.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Educate the medical staff, emergency personnel, athletes, coaches, and parents about EHI and proper acclimatization and hydration strategies.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Include questions about EHI on pre-participation questionnaires and during examinations to identify \"high-risk\" individuals.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Establish and follow heat acclimatization guidelines: These should allow individuals to acclimatize over the course of 10-14 days, progressively increasing the intensity and duration of activity and the amount of equipment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Establish and follow hot and humid weather activity guidelines that incorporate Wet Bulb Globe Temperature (WBGT) readings, time of day for activity, intensity and duration of activity, equipment, and rest and water breaks.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Establish and follow clear policies to ensure proper hydration: Use appropriate rest to work ratios, weigh-ins before and after activity, and encourage drinking both water and sodium-containing fluids during activity.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_33_28187=[""].join("\n");
var outline_f27_33_28187=null;
var title_f27_33_28188="Antimicrobial prophylaxis for cardiac surgery";
var content_f27_33_28188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76499&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial prophylaxis for cardiac surgery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Nature of operation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common pathogens",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommended antimicrobials",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual adult dosage*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Cardiac surgery",
"       </td>",
"       <td rowspan=\"3\">",
"        Staphylococcus aureus, S. epidermidis",
"       </td>",
"       <td>",
"        Cefazolin",
"       </td>",
"       <td>",
"        <p>",
"         &lt;80 kg: 1 g IV",
"        </p>",
"        &ge;80 kg: 2 g IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        cefuroxime",
"       </td>",
"       <td>",
"        1.5 g IV",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         OR",
"        </strong>",
"        vancomycin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        1 g IV",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Parenteral prophylactic antimicrobials can be given as a single IV dose begun within 60 minutes before the procedure. For prolonged procedures (&gt;3 hours) or those with major blood loss, or in patients with extensive burns, additional intraoperative doses should be given at intervals one to two times the half-life of the drug (ampicillin-sulbactam every 2 hours, cefazolin every 4 hours, cefuroxime every 4 hours, cefoxitin every 2 hours, clindamycin every 6 hours, vancomycin every 12 hours) for the duration of the procedure in patients with normal renal function. If vancomycin or a fluoroquinolone is used, the infusion should be started within 60 to 120 minutes before the initial incision to have adequate tissue levels at the time of incision and to minimize the possibility of an infusion reaction close to the time of induction of anesthesia.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Some experts recommend an additional dose when patients are removed from bypass during open-heart surgery.",
"     <br/>",
"     &Delta; Vancomycin can be used in hospitals in which methicillin-resistant S. aureus and S. epidermidis are a frequent cause of postoperative wound infection, in patients previously colonized with MRSA, or for those who are allergic to penicillins or cephalosporins. Rapid IV administration may cause hypotension, which could be especially dangerous during induction of anesthesia. Even when the drug is given over 60 minutes, hypotension may occur; treatment with diphenhydramine and further slowing of the infusion rate may be helpful. Some experts would give 15 mg/kg of vancomycin to patients weighing more than 75 kg, up to a maximum of 1.5 g, with a slower infusion rate (90 minutes for 1.5 g). For procedures in which enteric gram-negative bacilli are common pathogens, many experts would add another drug such as an aminoglycoside (gentamicin, tobramycin, or amikacin), aztreonam, or a fluoroquinolone.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with special permission from: Treatment Guidelines from The Medical Letter, October 2012; Vol. 10 (122):73.",
"     <a href=\"file://www.medicalletter.org\" target=\"_blank\">",
"      www.medicalletter.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_33_28188=[""].join("\n");
var outline_f27_33_28188=null;
var title_f27_33_28189="FEV1 and age in males";
var content_f27_33_28189=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    FEV1 and age in healthy men",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 298px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Growth and decline of lung function in healthy males. Actual values are shown in the top panel and growth velocity in the bottom panel.",
"    <div class=\"footnotes\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     : forced expiratory volume in one second.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Sherrill DL, Camilli A, Lebowitz MD. Am Rev Respir Dis 1989; 140:638.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_33_28189=[""].join("\n");
var outline_f27_33_28189=null;
var title_f27_33_28190="Treatment algorithm for victims after extrication";
var content_f27_33_28190=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F83616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F83616&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Algorithm for fluid administration for crush victims after extrication",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 400px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Algorithm for fluid resuscitation to prevent crush-related AKI in entrapped victims of mass disasters early after extrication.",
"    <div class=\"footnotes\">",
"     IV: intravenous; L: liters.",
"     <br/>",
"     * IV fluid: Isotonic saline is the first choice.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sever MS, Vanholder R, and the Workgroup on Recommendations for the Management of Crush Victims in Mass Disasters. Recommendations for the management of crush victims in mass disasters. Nephrol Dial Transplant 2012; 27: Supplement 1, i1-i67. Published by Oxford University Press on behalf of ERA-EDTA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_33_28190=[""].join("\n");
var outline_f27_33_28190=null;
var title_f27_33_28191="Flow rate and work";
var content_f27_33_28191=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F74214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F74214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Flow rate and work",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 226px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flow and airway pressure (Paw) during assist-control ventilation at an inspiratory flow rate of 60 L/min (panel A) and 30 L/min (panel B). In panel A, the small negative phase, smooth rise, and convex appearance of the Paw waveform indicate that the patient is making a slight inspiratory effort to breathe. In panel B, the more pronounced negative phase and excessive scalloping of the Paw waveform indicate that the patient is making a strenuous effort to breathe due to inadequate flow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jubran, A, Tobin, MJ. In: Principles and Practice of Mechanical Ventilation. Tobin, MJ (Ed), McGraw Hill, Inc. New York 2006. Copyright &copy;2006 McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_33_28191=[""].join("\n");
var outline_f27_33_28191=null;
